An introduction to G protein-coupled receptors
==============================================

G protein-coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular N-terminus, an intracellular C-terminus and seven hydrophobic transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). About 800 GPCRs have been identified in man, of which about half have sensory functions, mediating olfaction (∼400), taste (33), light perception (10) and pheromone signalling (5)(Mombaerts, 2004). The remaining ∼350 non-sensory GPCRs mediate intercellular signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage (Overington *et al*., 2006; Rask-Andersen *et al*., 2011), although only a minority of these receptors are exploited therapeutically. The first classification scheme to be proposed for GPCRs (Kolakowski, 1994) divided them, on the basis of sequence homology, into six classes. These classes and their prototype members were as follows: **Class A** (rhodopsin-like), **Class B** (secretin receptor family), **Class C** (metabotropic glutamate), **Class D** (fungal mating pheromone receptors), **Class E** (cyclic AMP receptors) and **Class F** (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classification scheme "GRAFS" (Schioth & Fredriksson, 2005) divides vertebrate GPCRs into five classes, overlapping with the A-F nomenclature, *viz*:

**Glutamate family (class C)**, which includes metabotropic glutamate receptors, a calcium-sensing receptor and GABA~B~ receptors, as well as three taste type 1 receptors (Page 1468) and a family of pheromone receptors (V2 receptors) that are abundant in rodents but absent in man (Mombaerts, 2004).

**Rhodopsin family (class A),** which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2 receptors (Page 1469) and five pheromone receptors (V1 receptors).

**Adhesion family** GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N-termini that are autoproteolytically cleaved from their 7TM domains at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (∼320 residue) "GPCR autoproteolysis-inducing" (GAIN) domain, an evolutionarily ancient motif also found in polycystic kidney disease 1 (PKD1)-like proteins, which has been suggested to be both required and sufficient for autoproteolysis (Promel *et al*., 2013).

**Frizzled family** consists of 10 Frizzled proteins (FZD(1-10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).

**Secretin family,** encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27-141 amino-acid residues; nine of the mammalian receptors respond to ligands that are structurally related to one another (glucagon, glucagon-like peptides (GLP-1, GLP-2), glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP) and growth-hormone-releasing hormone (GHRH)) (Harmar, 2001).

GPCR families
=============

  ------------------------------ ------------------------------------------------------ -------------------- ----------------------------------- -------------------------------- ----------
  Family                         Class A (Rhodopsin)                                    Class B (Secretin)   Class C (Glutamate)                 Adhesion                         Frizzled
  Receptors with known ligands   197[a](#fn1){ref-type="fn"}                            15                   12                                  0                                11
  Orphans                        87 (54)[a](#fn1){ref-type="fn"}                        --                   8 (1)[a](#fn1){ref-type="fn"}       26 (6)[a](#fn1){ref-type="fn"}   0
  Sensory (olfaction)            390[b](#fn2){ref-type="fn"},[c](#fn3){ref-type="fn"}   --                   --                                  --                               --
  Sensory (vision)               10[d](#fn4){ref-type="fn"} opsins                      --                   --                                  --                               --
  Sensory (taste)                30[c](#fn3){ref-type="fn"} taste 2                     --                   3[c](#fn3){ref-type="fn"} taste 1   --                               --
  Sensory (pheromone)            5[c](#fn3){ref-type="fn"} vomeronasal 1                --                   --                                  --                               --
  Total                          719                                                    15                   22                                  33                               11
  ------------------------------ ------------------------------------------------------ -------------------- ----------------------------------- -------------------------------- ----------

Numbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see Davenport *et al*. (2013)
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Orphan GPCRs
============

Class A Orphans
---------------

### Overview

Table [1](#tbl1){ref-type="table"} lists a number of putative GPCRs identified by IUPHAR [@b24], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential link to a disease, or disorder. The GPCRs in Table [1](#tbl1){ref-type="table"} are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table [1](#tbl1){ref-type="table"} are putative GPCRs with as-yet unidentified endogenous ligands.

###### 

Class A orphan GPCRs with putative endogenous ligands

  Nomenclature   HGNC, UniProt     Principal transduction   Endogenous agonists (p*K*~i~)                                                                                                                                                                                                                                            Radioligands (*K*~d~)                              Selective agonists (p*K*~i~)                                                                                                                                                                                                                               Comment
  -------------- ----------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GPR1           GPR1, P46091      --                       chemerin (RARRES2, Q99969) (pK~d~ 8.28) [@b2]                                                                                                                                                                                                                            --                                                 --                                                                                                                                                                                                                                                         Reported to act as a co-receptor for HIV [@b86].
  GPR3           GPR3, P46089      G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         sphingosine 1-phosphate was reported to be an endogenous agonist [@b97], but this finding was not replicated in subsequent studies [@b106]. Reported to activate adenylyl cyclase constitutively through G~s~ [@b21]. Gene disruption results in premature ovarian aging [@b55], reduced β-amyloid deposition [@b96] and hypersensitivity to thermal pain [@b81] in mice.
  GPR4           GPR4, P46093      G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         An initial report suggesting activation by lysophosphatidylcholine and sphingosylphosphorylcholine [@b111] has been retracted [@b112]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as protein-sensing receptors detecting acidic pH [@b17],[@b85]. Gene disruption is associated with increased perinatal mortality and impaired vascular proliferation [@b113].
  GPR6           GPR6, P46095      G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         An initial report that sphingosine 1-phosphate (S1P) was a high-affinity ligand (EC~50~ value of 39nM) [@b36],[@b97] was not repeated by β-arrestin PathHunter\[TM\] assays [@b90],[@b106]. Reported to activate adenylyl cyclase constitutively through G~s~ and to be located intracellularly [@b75]. Gpr6-deficient mice showed reduced striatal cyclic AMP production *in vitro* and selected alterations in instrumental conditioning *in vitro*. [@b62].
  GPR12          GPR12, P47775     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Reports that sphingosine 1-phosphate was a ligand of GPR12 [@b35],[@b97] have not been replicated in β-arrestin-based assays [@b90],[@b106]. Gene disruption results in dyslipidemia and obesity [@b6].
  GPR15          GPR15, P49685     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Reported to act as a co-receptor for HIV [@b19]. In an infection-induced colitis model, Gpr15 knockout mice were more prone to tissue damage and inflammatory cytokine expression [@b47].
  GPR17          GPR17, Q13304     --                       LTC4 (pEC~50~ 7.83 -- 9.48) [@b16], LTD4 (pEC~50~ 8.14 -- 8.36) [@b16], UDP-glucose (pEC~50~ 5.92 -- 9.52) [@b5],[@b16], UDP-galactose (pEC~50~ 5.96 -- 8.92) [@b5],[@b16], UDP (pEC~50~ 5.97 -- 8.8) [@b5],[@b16]                                                       --                                                 --                                                                                                                                                                                                                                                         Reported to be a dual leukotriene and UDP receptor [@b16]. Another group instead proposed that GPR17 functions as a negative regulator of the CysLT~1~ receptor response to leukotriene D~4~ (LTD4). For further discussion, see [@b17]. Reported to antagonize CysLT~1~ receptor signalling in vivo and *in vitro* [@b65].
  GPR20          GPR20, Q99678     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Reported to inhibit adenylyl cyclase constitutively through G~i/o~ [@b30]. GPR20 deficient mice exhibit hyperactivity characterised by increased total distance travelled in an open field test [@b8].
  GPR22          GPR22, Q99680     G~i/o~                   --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Gene disruption results in increased severity of functional decompensation following aortic banding [@b1]. Identified as a susceptibility locus for osteoarthritis [@b23],[@b46],[@b98].
  GPR26          GPR26, Q8NDV2     G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Has been reported to activate adenylyl cyclase constitutively through G~s~ [@b40]. Gpr26 knockout mice show increased levels of anxiety and depression-like behaviours [@b108].
  GPR31          GPR31, O00270     --                       12S-HETE (Selective) (pEC~50~ 9.55 - Mouse) [@b27]                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         --
  GPR32          GPR32, O75388     Not yet established      resolvin D1 (Selective) (pEC~50~ 11.06) [@b51], LXA4 (Selective) (pEC~50~ 9.7) [@b51]                                                                                                                                                                                    \[3H\]resolvin D1 (Agonist) (2x10^-10^ M) [@b51]   --                                                                                                                                                                                                                                                         resolvin D1 (more potently than LxA4) has been demonstrated to activate GPR32 in two publications [@b15],[@b51]. The pairing was not replicated in a recent study based on β-arrestin recruitment [@b90]. GPR32 is a pseudogene in mice and rats.
  GPR34          GPR34, Q9UPC5     G~i~/G~o~                lysophosphatidylserine (Selective) (pEC~50~ 6.57 -- 6.89) [@b48],[@b91]                                                                                                                                                                                                  --                                                 --                                                                                                                                                                                                                                                         Lysophosphatidylserine has been reported to be a ligand of GPR34 in several publications, but the pairing was not replicated in a recent study based on β-arrestin recruitment [@b90]. Fails to respond to a variety of lipid-derived agents [@b106]. Gene disruption results in an enhanced immune response [@b59].
  GPR35          GPR35, Q9HC97     --                       2-oleoyl-LPA (pEC~50~ 7.3 -- 7.52) [@b73], kynurenic acid (pEC~50~ 3.9 -- 4.41) [@b90],[@b99]                                                                                                                                                                            --                                                 --                                                                                                                                                                                                                                                         Several studies have shown that kynurenic acid is an agonist of GPR35 but it remains controversial whether the proposed endogenous ligand reaches sufficient tissue concentrations to activate the receptor [@b53]. 2-oleoyl-LPA has also been proposed as an endogenous ligand [@b73] but these results were not replicated in in a recent β-arrestin assay [@b90]. The phosphodiesterase inhibitor zaprinast [@b95] has become widely used as a surrogate agonist to investigate GPR35 pharmacology and signaliing [@b95]. GPR35 is also activated by the pharmaceutical adjunct pamoic acid [@b110].
  GPR37          GPR37, O15354     G~i~/G~o~                --                                                                                                                                                                                                                                                                       --                                                 neuropeptide head activator (pEC~50~ 7.96 -- 8.48) [@b78]                                                                                                                                                                                                  Reported to associate and regulate the dopamine transporter [@b68] and to be a substrate for parkin [@b66]. Gene disruption results in altered striatal signalling [@b67].
  GPR39          GPR39, O43194     G~q~/G~11~               Zn2+ [@b33]                                                                                                                                                                                                                                                              --                                                 --                                                                                                                                                                                                                                                         Zn^2+^ has been reported to be a potent and efficacious agonist of human, mouse and rat GPR39 [@b105]. obestatin (GHRL, Q9UBU3), a fragment from the ghrelin precursor, was reported initially as an endogenous ligand, but subsequent studies failed to reproduce these findings. Has been reported to be down-regulated in adipose tissue in obesity-related diabetes [@b10]. Gene disruption results in obesity and altered adipocyte metabolism [@b77].
  GPR50          GPR50, Q13585     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         GPR50 is structurally related to MT~1~ and MT~2~ melatonin receptors, with which it heterodimerises constitutively and specifically [@b57]. GPR50 knockout mice display abnormal thermoregulation and are much more likely than wild-type mice to enter fasting-induced torpor [@b3].
  GPR61          GPR61, Q9BZJ8     G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         GPR61 deficient mice exhibit obesity associated with hyperphagia [@b70]. Although no endogenous ligands have been identified, 5-(nonyloxy)tryptamine has been reported to be a low affinity inverse agonist [@b94].
  GPR63          GPR63, Q9BZJ6     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         sphingosine 1-phosphate and dioleoylphosphatidic acid have been reported to be low affinity agonists for GPR63 [@b72] but this finding was not replicated in a β-arrestin-based assay [@b106].
  GPR65          GPR65, Q8IYL9     G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         GPR4, GPR65, GPR68 and GPR132 are now thought to function as proton-sensing receptors detecting acidic pH [@b17],[@b85]. Reported to activate adenylyl cyclase; gene disruption leads to reduced eosinophlia in models of allergic airway disease [@b50].
  GPR68          GPR68, Q15743     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Gpr68 was previously identified as a receptor for sphingosylphosphorylcholine (SPC) [@b103], but the original publication has been retracted [@b104]. GPR4, GPR65, GPR68 and GPR132 are now thought to function as protein-sensing receptors detecting acidic pH [@b17],[@b85]. A family of 3,5-disubstituted isoxazoles were identified as agonists of GPR68 [@b82].
  GPR75          GPR75, O95800     G~q~/G~11~               --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         CCL5 (CCL5, P13501) was reported to be an agonist of GPR75 [@b37], but the pairing could not be repeated in a recent β-arrestin assay [@b90].
  GPR84          GPR84, Q9NQS5     G~i~/G~o~                --                                                                                                                                                                                                                                                                       --                                                 decanoic acid (pEC~50~ 5.0 -- 5.4) [@b90],[@b100], undecanoic acid (pEC~50~ 5.1) [@b100], lauric acid (pEC~50~ 5.05) [@b100]                                                                                                                               Medium chain free fatty acids with carbon chain lengths of 9-14 activate GPR84 [@b92],[@b100]. A surrogate ligand for GPR84, 6-n-octylaminouracil has also been proposed [@b92].
  GPR87          GPR87, Q9BY21     --                       LPA (pEC~50~ 7.44) [@b69],[@b93]                                                                                                                                                                                                                                         --                                                 --                                                                                                                                                                                                                                                         --
  GPR88          GPR88, Q9GZN0     --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Gene disruption results in altered striatal signalling [@b63].
  GPR132         GPR132, Q9UNW8    G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         GPR4, GPR65, GPR68 and GPR132 are now thought to function as protein-sensing receptors detecting acidic pH [@b17],[@b85]. Reported to respond to lysophosphatidylcholine [@b41], but later retracted [@b102].
  GPR149         GPR149, Q86SP6    --                       --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         Gpr149 knockout mice displayed increased fertility and enhanced ovulation, with increased levels of FSH receptor and cyclin D2 mRNA levels [@b20].
  GPR183         GPR183, P32249    --                       7α,25-dihydroxycholesterol (Selective) (pEC~50~ 8.1 -- 9.85) [@b28],[@b60], 7α,27-dihydroxycholesterol (Selective) (pEC~50~ 8.89) [@b60], 7β, 25-dihydroxycholesterol (Selective) (pEC~50~ 8.68) [@b60], 7β, 27-dihydroxycholesterol (Selective) (pEC~50~ 7.29) [@b60]   --                                                 --                                                                                                                                                                                                                                                         Two independent publications have shown that 7α,25-dihydroxycholesterol is an agonist of GPR183 and have demonstrated by mass spectrometry that this oxysterol is present endogenously in tissues [@b28],[@b60]. Gpr183-deficient mice show reduction in the early antibody response to a T-dependent antigen. GPR183-deficient B cells fail to migrate to the outer follicle and instead stay in the follicle centre [@b44],[@b76].
  LGR4           LGR4, Q9BXB1      --                       R-spondin-2 (RSPO2, Q6UXX9) (Selective) (pEC~50~ 12.52) [@b9], R-spondin-1 (RSPO1, Q2MKA7) (Selective) (pEC~50~ 10.7) [@b9], R-spondin-3 (RSPO3, Q9BXY4) (Selective) (pEC~50~ 10.7) [@b9], R-spondin-4 (RSPO4, Q2I0M5) (Selective) (pEC~50~ 10.05) [@b9]                 --                                                 R-spondin-2 (RSPO2, Q6UXX9) (Selective) (pEC~50~ 12.52) [@b9], R-spondin-1 (RSPO1, Q2MKA7) (Selective) (pEC~50~ 10.7) [@b9], R-spondin-3 (RSPO3, Q9BXY4) (Selective) (pEC~50~ 10.7) [@b9], R-spondin-4 (RSPO4, Q2I0M5) (Selective) (pEC~50~ 10.05) [@b9]   LGR4 does not couple to heterotrimeric G proteins or to β-arrestin when stimulated by the R-spondins, indicating a unique mechanism of action. R-spondins bind to LGR4, which specifically associates with Frizzled and LRPs---proteins that are activated by the extracellular Wnt molecules and then trigger canonical Wnt signalling to increase gene expression [@b9],[@b18],[@b80]. Gene disruption leads to multiple developmental disorders [@b39],[@b64],[@b89],[@b101].
  LGR5           LGR5, O75473      --                       R-spondin-2 (RSPO2, Q6UXX9) (Selective) (pEC~50~ 12.0) [@b9], R-spondin-1 (RSPO1, Q2MKA7) (Selective) (pEC~50~ 11.1) [@b9], R-spondin-3 (RSPO3, Q9BXY4) (Selective) (pEC~50~ 11.0) [@b9], R-spondin-4 (RSPO4, Q2I0M5) (Selective) (pEC~50~ 9.4) [@b9]                    --                                                 R-spondin-2 (RSPO2, Q6UXX9) (Selective) (pEC~50~ 12.0) [@b9], R-spondin-1 (RSPO1, Q2MKA7) (Selective) (pEC~50~ 11.1) [@b9], R-spondin-3 (RSPO3, Q9BXY4) (Selective) (pEC~50~ 11.0) [@b9], R-spondin-4 (RSPO4, Q2I0M5) (Selective) (pEC~50~ 9.4) [@b9]      The four R-spondins can bind to LGR4, LGR5, and LGR6, which specifically associate with Frizzled and LRPs---proteins that are activated by extracellular Wnt molecules- and then trigger canonical Wnt signalling to increase gene expression [@b9],[@b18].
  LGR6           LGR6, Q9HBX8      --                       R-spondin-1 (RSPO1, Q2MKA7) (Selective) [@b9],[@b18], R-spondin-2 (RSPO2, Q6UXX9) (Selective) [@b9],[@b18], R-spondin-3 (RSPO3, Q9BXY4) (Selective) [@b9],[@b18], R-spondin-4 (RSPO4, Q2I0M5) (Selective) [@b9],[@b18]                                                   --                                                 --                                                                                                                                                                                                                                                         --
  MAS1           MAS1, P04201      G~q~/G~11~               angiotensin-(1-7) (AGT, P01019) (Selective) [@b84]                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         --
  MRGPRD         MRGPRD, Q8TDS7    G~i~/G~o~                β-alanine (pEC~50~ 4.8) [@b87],[@b90]                                                                                                                                                                                                                                    --                                                 --                                                                                                                                                                                                                                                         An endogenous peptide with a high degree of sequence similarity to angiotensin-(1-7) (AGT, P01019), alamandine, was shown to promote NO release in MrgD-transfected cells. The binding of alamandine to MRGPRD to was shown to be blocked by D-Pro^7^-angiotensin-(1--7), β-alanine and PD123319 [@b54]. Genetic ablation of MRGPRD+ neurons of adult mice decreased behavioural sensitivity to mechanical stimuli but not to thermal stimuli [@b11].
  MRGPRX1        MRGPRX1, Q96LB2   G~q~/G~11~               BAM8-22 (PENK, P01210) (Selective) (pEC~50~ 5.3 -- 7.8) [@b13],[@b56],[@b90]                                                                                                                                                                                             --                                                 --                                                                                                                                                                                                                                                         Reported to mediate the sensation of itch [@b61],[@b88]. Reports that BAM8-22 (PENK, P01210) was the most potent of a series of proenkephalin A--derived peptides as an agonist of MRGPRX1 in assays of calcium mobilisation and radioligand binding [@b56] were replicated in an independent study using a β-arrestin recruitment assay [@b90].
  MRGPRX2        MRGPRX2, Q96LB1   --                       PAMP-20 (ADM, P35318) (Selective) [@b42]                                                                                                                                                                                                                                 --                                                 PAMP-12 (human) (pEC~50~ 7.24 -- 7.68) [@b42], CST-14 {Sp: Mouse, Rat} (pEC~50~ 6.9 -- 7.6) [@b42],[@b79],[@b90]                                                                                                                                           A diverse range of substances has been reported to be agonists of MRGPRX2, with cortistatin 14 the highest potency agonist in assays of calcium mobilisation [@b79], also confirmed in an independent study using a β-arrestin recruitment assay [@b90].
  P2RY10         P2RY10, O00398    --                       sphingosine 1-phosphate (Selective) (pEC~50~ 7.3) [@b69], LPA (Selective) (pEC~50~ 6.9) [@b69]                                                                                                                                                                           --                                                 --                                                                                                                                                                                                                                                         --
  TAAR2          TAAR2, Q9P1P5     G~s~                     --                                                                                                                                                                                                                                                                       --                                                 --                                                                                                                                                                                                                                                         β-phenylethylamine \> tryptamine [@b7] probable pseudogene in 10--15% of Asians due to a polymorphism (rs8192646) producing a premature stop codon at amino acid 168 [@b17] see Page 139.

In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together (see page 1519).

###### 

Class A Orphan GPCR with limited pharmacological or phenotypic profiles

  Nomenclature   HGNC, UniProt     Principal transduction   Comment
  -------------- ----------------- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GPR19          GPR19, Q15760     --                       --
  GPR21          GPR21, Q99679     G~q/11~                  Gpr21 knockout mice were resistant to diet-induced obesity, exhibiting an increase in glucose tolerance and insulin sensitivity and a modest lean phenotype [@b74].
  GPR25          GPR25, O00155     --                       --
  GPR27          GPR27, Q9NS67     G~q~/G~11~               Knockdown of Gpr27 reduces endogenous mouse insulin promotor activity and glucose stimulated insulin secretion [@b52].
  GPR33          GPR33, Q49SQ1     G~i~/G~o~                GPR33 is a pseudogene in most individuals, containing a premature stop codon within the coding sequence of the second intracellular loop [@b83].
  GPR37L1        GPR37L1, O60883   G~i~/G~o~                --
  GPR45          GPR45, Q9Y5Y3     --                       --
  GPR52          GPR52, Q9Y2T5     --                       --
  GPR62          GPR62, Q9BZJ7     --                       --
  GPR78          GPR78, Q96P69     G~s~                     GPR78 has been reported to be constitutively active, coupled to elevated cAMP production [@b40].
  GPR82          GPR82, Q96P67     --                       Mice with Gpr82 knockout have a lower body weight and body fat content associated with reduced food intake, decreased serum triglyceride levels, higher insulin sensitivity and glucose tolerance [@b22].
  GPR83          GPR83, Q9NYM4     --                       One isoform has been implicated in the induction of CD4(+)CD25(+) regulatory T cells (Tregs) during inflammatory immune responses [@b29].
  GPR85          GPR85, P60893     --                       Proposed to regulate of hippocampal adult neurogenesis and neurogenesis-dependent learning and memory [@b14].
  GPR135         GPR135, Q8IZ08    --                       --
  GPR139         GPR139, Q6DWJ6    G~q~/G~11~               --
  GPR141         GPR141, Q7Z602    --                       --
  GPR142         GPR142, Q7Z601    --                       --
  GPR146         GPR146, Q96CH1    --                       Yosten et al. demonstrated inhibition of proinsulin C-peptide (INS, P01308)-induced stimulation of cFos expression folllowing knockdown of GPR146 in KATOIII cells, suggesting proinsulin C-peptide as an endogenous ligand of the receptor [@b107].
  GPR148         GPR148, Q8TDV2    --                       --
  GPR150         GPR150, Q8NGU9    --                       --
  GPR151         GPR151, Q8TDV0    --                       GPR151 responded to galanin with an EC~50~ value of 2 μM, suggesting that the endogenous ligand shares structural features with galanin (GAL, P22466) [@b34].
  GPR152         GPR152, Q8TDT2    --                       --
  GPR153         GPR153, Q6NV75    --                       --
  GPR160         GPR160, Q9UJ42    --                       --
  GPR162         GPR162, Q16538    --                       --
  GPR171         GPR171, O14626    --                       GPR171 has been shown to be activated by endogenous peptide BigLEN. This receptor-peptide interaction is believed to be involved in regulating feeding and metabolism responses [@b26].
  GPR173         GPR173, Q9NS66    --                       --
  GPR174         GPR174, Q9BXC1    G~s~                     Reported to respond to lysophosphatidylserine (pEC~50~ 7.1) [@b38].
  GPR176         GPR176, Q14439    --                       --
  GPR182         GPR182, O15218    --                       Rat GPR182 was first proposed as adrenomedullin receptor [@b43]. However, it was later reported that rat and human GPR182 did not respond to adrenomedullin [@b45] and GPR182 is not currently considered to be a genuine adrenomedullin receptor [@b31].
  MAS1L          MAS1L, P35410     --                       --
  MRGPRX3        MRGPRX3, Q96LB0   G~q~/G~11~               --
  MRGPRX4        MRGPRX4, Q96LA9   G~q~/G~11~               --
  MRGPRE         MRGPRE, Q86SM8    --                       --
  MRGPRF         MRGPRF, Q96AM1    --                       MRGPRF has been reported to respond to stimulation by angiotensin metabolites [@b25].
  MRGPRG         MRGPRG, Q86SM5    --                       --
  OPN3           OPN3, Q9H1Y3      --                       --
  OPN5           OPN5, Q6U736      G~i~/G~o~                Evidence indicates OPN5 triggers a UV-sensitive G~i~-mediated signalling pathway in mammalian tissues [@b49].
  P2RY8          P2RY8, Q86VZ1     --                       --

###### 

Class C Orphans

  Nomenclature   HGNC, UniProt
  -------------- ----------------
  GPR156         GPR156, Q8NFN8
  GPR158         GPR158, Q5T848
  GPR179         GPR179, Q6PRD1
  GPRC5A         GPRC5A, Q8NFJ5
  GPRC5B         GPRC5B, Q9NZH0
  GPRC5C         GPRC5C, Q9NQ84
  GPRC5D         GPRC5D, Q9NZD1

Taste 1 receptors
=================

Overview
--------

Whilst the taste of acid and salty foods appear to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R and T2R, which are similar in sequence and structure to Class C and Class A GPCR, respectively. Activation of taste receptors appears to involve gustducin- (Gαt3) and Gα14-mediated signalling, although the precise mechanisms remain obscure. Gene disruption studies suggest the involvement of PLCβ2 [@b109], TRPM5 [@b109] and IP3 [@b32] receptors in post-receptor signalling of taste receptors. Although predominantly associated with the oral cavity, taste receptors are also located elsewhere, including further down the gastrointestinal system, in the lungs and in the brain.

### Sweet/Umami

T1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3 heterodimers respond to L-glutamic acid and may be positively allosterically modulated by 5′-nucleoside monophosphates, such as 5\'-GMP [@b58]. T1R2/T1R3 heterodimers respond to sugars, such as sucrose, and artificial sweeteners, such as saccharin [@b71].

  ------------------------ ---------------- ---------------- ----------------
  Nomenclature             TAS1R1           TAS1R2           TAS1R3
  HGNC, UniProt            TAS1R1, Q7RTX1   TAS1R2, Q8TE23   TAS1R3, Q7RTX0
  Principal transduction   --               --               --
  ------------------------ ---------------- ---------------- ----------------

Taste 2 receptors
=================

Overview
--------

Whilst the taste of acid and salty foods appear to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R and T2R, which are similar in sequence and structure to Class C and Class A GPCR, respectively. Activation of taste receptors appears to involve gustducin- (Gαt3) and Gα14-mediated signalling, although the precise mechanisms remain obscure. Gene disruption studies suggest the involvement of PLCβ2 [@b109], TRPM5 [@b109] and IP3 [@b32] receptors in post-receptor signalling of taste receptors. Although predominantly associated with the oral cavity, taste receptors are also located elsewhere, including further down the gastrointestinal system, in the lungs and in the brain.

### Bitter

The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand specificity or much broader responsiveness. For example, T2R5 responded to cycloheximide, but not 10 other bitter compounds [@b12], while T2R14 responded to at least eight different bitter tastants, including (-)-α-thujone and picrotoxinin [@b4].

  -------------- -----------------
  Nomenclature   HGNC, UniProt
  TAS2R1         TAS2R1, Q9NYW7
  TAS2R3         TAS2R3, Q9NYW6
  TAS2R4         TAS2R4, Q9NYW5
  TAS2R5         TAS2R5, Q9NYW4
  TAS2R7         TAS2R7, Q9NYW3
  TAS2R8         TAS2R8, Q9NYW2
  TAS2R8         TAS2R8, Q9NYW2
  TAS2R9         TAS2R9, Q9NYW1
  TAS2R10        TAS2R10, Q9NYW0
  TAS2R13        TAS2R13, Q9NYV9
  TAS2R14        TAS2R14, Q9NYV8
  TAS2R16        TAS2R16, Q9NYV7
  TAS2R19        TAS2R19, P59542
  TAS2R20        TAS2R20, P59543
  TAS2R42        TAS2R42, Q7RTR8
  TAS2R30        TAS2R30, P59541
  TAS2R31        TAS2R31, P59538
  TAS2R39        TAS2R39, P59534
  TAS2R40        TAS2R40, P59535
  TAS2R50        TAS2R50, P59544
  TAS2R43        TAS2R43, P59537
  TAS2R46        TAS2R46, P59540
  TAS2R41        TAS2R41, P59536
  TAS2R60        TAS2R60, P59551
  TAS2R38        TAS2R38, P59533
  -------------- -----------------

Other 7TM proteins
==================

  -------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    Comment
  GPR157         GPR157, Q5UAW9   GPR157 has ambiguous sequence similarities to several different GPCR families (class A, class B and the slime mould cyclic AMP receptor). Because of its distant relationship to other GPCRs, it cannot be readily classified.
  -------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5-Hydroxytryptamine receptors
=============================

Overview
--------

5-HT receptors \[nomenclature as agreed by NC-IUPHAR Subcommittee on 5-HT receptors [@b158] and subsequently revised [@b153] \] are, with the exception of the ionotropic 5-HT~3~ class, GPCR receptors where the endogenous agonist is 5-HT. The diversity of metabotropic 5-HT receptors is increased by alternative splicing that produces isoforms of the 5-HT~2A~ (non-functional), 5-HT~2C~ (non-functional), 5-HT~4~, 5-HT~6~ (non-functional) and 5-HT~7~ receptors. Unique amongst the GPCRs, RNA editing produces 5-HT~2C~ receptor isoforms that differ in function, such as efficiency and specificity of coupling to G~q/11~ and also pharmacology [@b124],[@b216]. Most 5-HT receptors (except 5-ht~1e~ and 5-ht~5a/5b~) play specific roles mediating functional responses in different tissues (reviewed by [@b197],[@b211].

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      5-HT1A receptor                                                                                                                                                                                                                                                                                                            5-HT1B receptor                                                                                                                                                                                                                                                                                                                                                                                                                          5-HT1D receptor                                                                                                                                                                                                                                                                                                          5-ht1e receptor                                                                     5-HT1F receptor
  HGNC, UniProt                     HTR1A, P08908                                                                                                                                                                                                                                                                                                              HTR1B, P28222                                                                                                                                                                                                                                                                                                                                                                                                                            HTR1D, P28221                                                                                                                                                                                                                                                                                                            HTR1E, P28566                                                                       HTR1F, P30939
  Principal transduction            G~i/o~                                                                                                                                                                                                                                                                                                                     G~i/o~                                                                                                                                                                                                                                                                                                                                                                                                                                   G~i/o~                                                                                                                                                                                                                                                                                                                   G~i/o~                                                                              G~i/o~
  Selective agonists (p*K*~i~)      U92016A (9.7) [@b178], 8-OH-DPAT (8.4 -- 9.4) [@b140],[@b151],[@b170],[@b183],[@b189],[@b191],[@b192], F15599 (8.6) [@b190]                                                                                                                                                                                                L-694,247 (9.2) [@b149], CP94253 (8.7) [@b167], eletriptan (8.0) [@b184], sumatriptan (Partial agonist) (6.5 -- 8.1) [@b149],[@b172],[@b183],[@b184],[@b187],[@b194],[@b215]                                                                                                                                                                                                                                                             PNU109291 (9.1 - Gorilla) [@b143], L-694,247 (9.0) [@b217], eletriptan (8.9) [@b184], sumatriptan (8.0 -- 8.7) [@b150],[@b172],[@b183],[@b184],[@b215]                                                                                                                                                                   BRL-54443 (8.7) [@b136]                                                             BRL-54443 (8.9) [@b136], LY334370 (8.7) [@b213], LY573144 (8.7) [@b186], LY344864 (8.2) [@b195], eletriptan (8.0) [@b184], sumatriptan (7.2 -- 7.9) [@b114],[@b115],[@b184],[@b213]
  Selective antagonists (p*K*~i~)   NAD 299 (9.2) [@b161], WAY-100635 (7.9 -- 9.2) [@b189],[@b191], (S)-UH 301 (7.9) [@b189]                                                                                                                                                                                                                                   GR-55562 (p*K*~B~ 7.4) [@b159], SB 224289 (Inverse agonist) (8.2 -- 8.6) [@b146],[@b187],[@b203], SB236057 (Inverse agonist) (8.2) [@b182]                                                                                                                                                                                                                                                                                               SB 714786 (9.1) [@b214], BRL-15572 (7.9) [@b196]                                                                                                                                                                                                                                                                         --                                                                                  --
  Radioligands (*K*~d~)             p-\[18F\]MPPF, \[11C\]WAY100635 (Antagonist), \[3H\]NAD 299 (Antagonist) (1.58x10^-10^ M) [@b160], \[3H\]WAY100635 (Antagonist) (3x10^-10^ M) [@b164], \[3H\]F13640 (Agonist, Full agonist) (1.4x10^-9^ M) [@b155], \[3H\]8-OH-DPAT (Agonist, Full agonist) (3.98x10^-10^ -- 1x10^-6^ M) [@b122],[@b162],[@b188],[@b191]   \[11C\]AZ10419369, \[3H\]N-methyl-AZ10419369 (Antagonist) (3.7x10^-10^ M) [@b175], \[125I\]GTI (Agonist) (1.3x10^-9^ M - Rat) [@b130], \[3H\]GR 125,743 (Antagonist) (2.6x10^-9^ -- 7.1x10^-10^ M) [@b149],[@b218], \[3H\]alniditan (Agonist, Full agonist) (1x10^-9^ -- 2.51x10^-9^ M) [@b171], \[3H\]eletriptan (Agonist, Partial agonist) (3x10^-9^ M) [@b184], \[3H\]sumatriptan (Agonist, Partial agonist) (1.1x10^-8^ M) [@b184]   \[3H\]eletriptan (Agonist, Full agonist) (9x10^-10^ M) [@b184], \[125I\]GTI (Agonist) (1.3x10^-9^ M - Rat) [@b130], \[3H\]alniditan (Agonist, Full agonist) (1.2x10^-9^ -- 1.4x10^-9^ M) [@b171], \[3H\]GR 125,743 (Antagonist) (2.8x10^-9^ M) [@b218], \[3H\]sumatriptan (Agonist, Full agonist) (7x10^-9^ M) [@b184]   \[3H\]5-HT (Agonist, Full agonist) (6.31x10^-9^ -- 7.94x10^-9^ M) [@b177],[@b194]   \[3H\]LY334370 (Agonist, Full agonist) (3.98x10^-10^ M) [@b213], \[125I\]LSD (Agonist) (9.8x10^-10^ M - Mouse) [@b116]
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      5-HT2A receptor                                                                                                                                                                         5-HT2B receptor                                                                                                                                                                                               5-HT2C receptor
  HGNC, UniProt                     HTR2A, P28223                                                                                                                                                                           HTR2B, P41595                                                                                                                                                                                                 HTR2C, P28335
  Principal transduction            G~q/11~                                                                                                                                                                                 G~q/11~                                                                                                                                                                                                       G~q/11~
  Selective agonists (p*K*~i~)      DOI (7.4 -- 9.2) [@b131],[@b185],[@b205]                                                                                                                                                Ro 60-0175 (8.3) [@b166], BW723C86 (7.3 -- 8.6) [@b119],[@b166],[@b201], DOI (7.6 -- 7.7) [@b169],[@b185],[@b201],                                                                                            Ro 60-0175 (7.7 -- 8.2) [@b165],[@b166], DOI (7.2 -- 8.6) [@b142],[@b185],[@b201], lorcaserin (7.8) [@b209], WAY-163909 (6.7 -- 8.0) [@b141]
  Selective antagonists (p*K*~i~)   ketanserin (8.1 -- 9.7) [@b137],[@b166],[@b198], MDL-100,907 (pIC~50~ 6.5 -- 9.3) [@b166],[@b173],[@b199]                                                                               RS-127445 (9.0 -- 9.5) [@b128],[@b166], EGIS-7625 (9.0) [@b168]                                                                                                                                               FR260010 (9.0) [@b152], SB 242084 (8.2 -- 9.0) [@b163],[@b166], RS-102221 (8.3 -- 8.4) [@b129],[@b166]
  Radioligands (*K*~d~)             \[11C\]MDL100907, \[18F\]altanserin (Antagonist), \[3H\]RP62203 (Antagonist) (1.3x10^-10^ M - Rat) [@b176], \[3H\]ketanserin (Antagonist) (2x10^-10^ -- 2.9x10^-9^ M) [@b166],[@b198]   \[3H\]LSD (Agonist, Full agonist) (2.1x10^-9^ M) [@b198], \[3H\]mesulergine (5x10^-9^ -- 1x10^-8^ M), \[3H\]5-HT (Agonist, Full agonist) (8x10^-9^ M - Rat) [@b212], \[125I\]DOI (2x10^-8^ -- 2.5x10^-8^ M)   \[3H\]LSD (Agonist), \[3H\]mesulergine (Antagonist, Inverse agonist) (5x10^-10^ -- 2.2x10^-9^ M) [@b144],[@b198], \[125I\]DOI (6x10^-9^ -- 2.5x10^-8^ M)
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      5-HT4 receptor                                                                                                                                                                                                                                               5-ht5a receptor                                                                                                        5-ht5b receptor           5-HT6 receptor                                                                                                                                                                         5-HT7 receptor
  HGNC, UniProt                     HTR4, Q13639                                                                                                                                                                                                                                                 HTR5A, P47898                                                                                                          HTR5BP, P31387            HTR6, P50406                                                                                                                                                                           HTR7, P34969
  Principal transduction            G~s~                                                                                                                                                                                                                                                         G~i~/G~o~                                                                                                              None identified           G~s~                                                                                                                                                                                   G~s~
  Selective agonists (p*K*~i~)      ML 10302 (Partial agonist) (7.9 -- 9.0) [@b121],[@b123],[@b179]--[@b181], BIMU 8 (7.3) [@b138], RS67506 (pEC~50~ 8.8 - Rat) [@b154]                                                                                                                          --                                                                                                                     --                        E-6801 (Partial agonist) (8.7) [@b157], WAY-181187 (8.7) [@b202]                                                                                                                       E55888 (8.6) [@b132]
  Selective antagonists (p*K*~i~)   RS 100235 (8.7 -- 12.2) [@b138],[@b200], SB 204070 (9.8 -- 10.4) [@b120],[@b179],[@b180],[@b210], GR 113808 (9.3 -- 10.3) [@b117],[@b120],[@b123],[@b138],[@b180],[@b200],[@b210]                                                                            SB 699551 (8.2) [@b139]                                                                                                --                        SB399885 (9.0) [@b156], SB 271046 (8.9) [@b133], SB357134 (8.5) [@b134], Ro 63-0563 (7.9 -- 8.4) [@b126],[@b204]                                                                       SB269970 (8.6 -- 8.9) [@b207], SB656104 (8.7) [@b145], SB 258719 (Inverse agonist) (7.5) [@b208]
  Radioligands (*K*~d~)             \[123I\]SB 207710 (8.6x10^-11^ M - Pig) [@b135], \[3H\]GR 113808 (Antagonist) (5x10^-11^ -- 2x10^-10^ M) [@b117],[@b120],[@b181],[@b210], \[3H\]RS 57639 (Agonist) (2x10^-10^ M - Guinea pig) [@b127], \[11C\]SB207145 (Antagonist) (2.8x10^-9^ M) [@b174]   \[125I\]LSD (Agonist, Full agonist) (2x10^-10^ M) [@b148], \[3H\]5-CT (Agonist, Full agonist) (2.5x10^-9^ M) [@b148]   \[125I\]LSD, \[3H\]5-CT   \[3H\]5-CT (Agonist), \[125I\]SB258585 (Antagonist) (1x10^-9^ M) [@b156], \[3H\]LSD (Agonist, Full agonist) (2x10^-9^ M) [@b125], \[3H\]Ro 63-0563 (Antagonist) (5x10^-9^ M) [@b126]   \[3H\]5-CT (Agonist) (4x10^-10^ M) [@b207], \[3H\]SB269970 (Antagonist) (1.2x10^-9^ M) [@b207], \[3H\]5-HT (Agonist, Full agonist) (1x10^-9^ -- 7.94x10^-9^ M) [@b118],[@b206], \[3H\]LSD (Agonist, Full agonist) (2.51x10^-9^ -- 3.16x10^-9^ M) [@b206]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Tabulated *pK*~i~ and *K*~D~ values refer to binding to human 5-HT receptors unless indicated otherwise. Unreferenced values are extracted from the **NC-IUPHAR database** (www.iuphar-db.org). The nomenclature of 5-HT~1B~/5-HT~1D~ receptors has been revised [@b153]. Only the non-rodent form of the receptor was previously called 5-HT~1D;~: the human 5-HT~1B~ receptor (tabulated) displays a different pharmacology to the rodent forms of the receptor due to Thr335 of the human sequence being replaced by Asn in rodent receptors. NAS181 is a selective antagonist of the rodent 5-HT~1B~ receptor. fananserin and ketanserin bind with high affinity to dopamine D4 and histamine H~1~ receptors respectively, and ketanserin is a potent α1 adrenoceptor antagonist, in addition to blocking 5-HT~2A~ receptors. The human 5-ht~5A~ receptor has been claimed to couple to several signal transduction pathways when stably expressed in C6 glioma cells [@b193]. The human orthologue of the mouse 5-ht~5b~ receptor is non-functional due to interruption of the gene by stop codons. The 5-ht~1e~ receptor appears not to have been cloned from mouse, or rat, impeding definition of its function. In addition to the receptors listed in the table, an \'orphan\' receptor, unofficially termed 5-HT~1P~, has been described [@b147].

Acetylcholine receptors (muscarinic)
====================================

Overview
--------

Muscarinic acetylcholine receptors (nomenclature as agreed by NC-IUPHAR sub-committee on Muscarinic Acetylcholine Receptors, [@b224]) are GPCR of the Class A, rhodopsin-like family where the endogenous agonist is acetylcholine. In addition to the agents listed in the table, AC-42, its structural analogues AC-260584 and 77-LH-28-1, N-desmethylclozapine, TBPB and LuAE51090 have been described as functionally selective agonists of the M~1~ receptor subtype *via* binding in a mode distinct from that utilized by non-selective agonists [@b220],[@b235],[@b237],[@b238],[@b246],[@b253],[@b256],[@b257],[@b259]. There are two pharmacologically characterised allosteric sites on muscarinic receptors, one defined by it binding gallamine, strychnine and brucine, and the other binds KT 5720, WIN 62,577, WIN 51,708 and staurosporine [@b240],[@b241].

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      M1 receptor                                                                                                                                                                                                                                                                                                                                                    M2 receptor                                                                                                                                                                                                             M3 receptor                                                                                                                                                                                                                                M4 receptor                                                                                                                                                                                                                M5 receptor
  HGNC, UniProt                     CHRM1, P11229                                                                                                                                                                                                                                                                                                                                                  CHRM2, P08172                                                                                                                                                                                                           CHRM3, P20309                                                                                                                                                                                                                              CHRM4, P08173                                                                                                                                                                                                              CHRM5, P08912
  Principal transduction            G~q/11~                                                                                                                                                                                                                                                                                                                                                        G~i/o~                                                                                                                                                                                                                  G~q/11~                                                                                                                                                                                                                                    G~i/o~                                                                                                                                                                                                                     G~q/11~
  Selective antagonists (p*K*~i~)   MT7 (11.0--11.1) [@b249], VU0255035 (7.8) [@b254]                                                                                                                                                                                                                                                                                                              --                                                                                                                                                                                                                      --                                                                                                                                                                                                                                         MT3 (8.7) [@b234],[@b250]                                                                                                                                                                                                  --
  Selective allosteric regulators   BQCA (Positive) [@b244], brucine (Positive) [@b221], KT 5720 (Positive) [@b221], ML169 (Positive) [@b252], VU0029767 (Positive) [@b245], VU0090157 (Positive) [@b245]                                                                                                                                                                                          --                                                                                                                                                                                                                      N-chloromethyl-brucine (Positive) [@b221], WIN 62,577 (Positive) [@b221]                                                                                                                                                                   LY2033298 (Positive) [@b226], thiochrome (Positive) [@b221], VU0152099 (Positive) [@b222], VU0152100 (Positive) [@b222]                                                                                                    VU0238429 (Positive) [@b223]
  Radioligands (*K*~d~)             \[11C\]butylthio-TZTP, \[11C\]xanomeline, \[18F\](R,R)-quinuclidinyl-4-fluoromethyl-benzilate, \[3H\]QNB (Antagonist) (1.58×10^−11^--2.51×10^−11^ M) [@b229],[@b251], \[3H\]N-methyl scopolamine (Antagonist) (5.01×10^−11^--1.58×10^−9^ M) [@b225],[@b228]--[@b230],[@b232]--[@b234],[@b236],[@b239], \[3H\]pirenzepine (Antagonist) (1.4×10^−8^ M) [@b263]   \[18F\]FP-TZTP, \[3H\]QNB (Antagonist) (2.51×10^−11^--7.94×10^−11^ M) [@b251], \[3H\]N-methyl scopolamine (Antagonist) (1.25×10^−10^--5.01×10^−7^ M) [@b225],[@b227],[@b230],[@b232]--[@b234],[@b236],[@b239],[@b262]   \[3H\]QNB (Antagonist) (3.98×10^−11^ M) [@b251], \[3H\]darifenacin (Antagonist) (3.16×10^−10^ M) [@b255], \[3H\]N-methyl scopolamine (Antagonist) (3.98×10^−11^--2.51×10^−9^ M) [@b225],[@b227],[@b230]--[@b232],[@b234],[@b236],[@b239]   \[3H\]QNB (Antagonist) (3.16×10^−11^--2×10^−10^ M) [@b229],[@b251], \[3H\]N-methyl scopolamine (Antagonist) (6.3×10^−11^--1.58×10^−8^ M) [@b225],[@b227],[@b229],[@b230],[@b232],[@b234],[@b236],[@b239],[@b250],[@b262]   \[3H\]QNB (2×10^−11^--6×10^−11^ M), \[3H\]N-methyl scopolamine (Antagonist) (2×10^−10^--7.94×10^−9^ M) [@b225],[@b227],[@b230],[@b234],[@b236],[@b262]
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

LY2033298 and BQCA have also been shown to directly activate the M~4~ and M~1~ receptors, respectively, via an allosteric site [@b242],[@b243],[@b247],[@b248]. The allosteric site for gallamine and strychnine on M~2~ receptors can be labelled by \[3H\]dimethyl-W84 [@b260]. McN-A-343 is a functionally selective partial agonist that appears to interact in a bitopic mode with both the orthosteric and an allosteric site on the M~2~ muscarinic receptor [@b261]. THRX-160209, hybrid 1 and hybrid 2, are multivalent (bitopic) ligands that also achieve selectivity for M~2~ receptors by binding both to the orthosteric and a nearby allosteric site [@b219],[@b258].

Although numerous ligands for muscarinic acetylcholine receptors have been described, relatively few selective antagonists have been described, so it is common to assess the rank order of affinity of a number of antagonists of limited selectivity (e.g. 4-DAMP, darifenacin, pirenzepine) in order to identify the involvement of particular subtypes.

Adenosine receptors
===================

Overview
--------

Adenosine receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Adenosine Receptors; [@b280]) are activated by the endogenous ligand adenosine (potentially inosine also at A~3~ receptors). Crystal structures for the antagonist-bound and agonist-bound A~2A~ adenosine receptors have been described [@b287],[@b323].

  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                  A1 receptor                                                                                                                                                                                        A2A receptor                                                                                                                                                     A2B receptor                                                                                                                                                                                           A3 receptor
  HGNC, UniProt                                 ADORA1, P30542                                                                                                                                                                                     ADORA2A, P29274                                                                                                                                                  ADORA2B, P29275                                                                                                                                                                                        ADORA3, P33765
  Principal transduction                        G~i/o~                                                                                                                                                                                             G~s~                                                                                                                                                             G~s~                                                                                                                                                                                                   G~i/o~
  (Sub)family-selective agonists (p*K*~i~)      NECA (5.3 -- 8.2) [@b283],[@b295],[@b311],[@b317],[@b324]                                                                                                                                          NECA (6.9 -- 8.7) [@b270],[@b276],[@b283],[@b299],[@b303],[@b324]                                                                                                NECA (5.7 -- 6.9) [@b268],[@b270],[@b292],[@b306],[@b314],[@b319],[@b324]                                                                                                                              NECA (7.5 -- 8.4) [@b270],[@b283],[@b289],[@b312],[@b320],[@b324]
  Selective agonists (p*K*~i~)                  5-Cl-5-deoxy-(±)-ENBA (9.29) [@b279], GR79236 (8.51 - Rat) [@b288], cyclopentyladenosine (6.5 -- 9.4) [@b274],[@b275],[@b283],[@b285],[@b288],[@b295],[@b311], CCPA (7.7 -- 8.1) [@b288],[@b308]   apadenoson (9.3) [@b310], CGS 21680 (6.7 -- 8.1) [@b270],[@b276],[@b283],[@b288],[@b299],[@b302],[@b303],[@b308]                                                 Bay60-6583 (8.0 -- 8.52) [@b277]                                                                                                                                                                       IB-MECA (8.7 -- 9.2) [@b278],[@b281],[@b302],[@b320], Cl-IB-MECA (8.0 -- 8.9) [@b271],[@b289],[@b298]
  (Sub)family-selective antagonists (p*K*~i~)   XAC (p*K*~d~ 7.5) [@b279], CGS 15943 (8.46) [@b309]                                                                                                                                                XAC (8.4 -- 9.0) [@b276],[@b302], CGS 15943 (7.7 -- 9.4) [@b276],[@b299],[@b302],[@b309]                                                                         XAC (p*A*~2~ 7.9) [@b265], CGS 15943 (p*A*~2~ 7.8) [@b265], XAC (6.9 -- 8.8) [@b268],[@b292],[@b293],[@b302],[@b306],[@b314], CGS 15943 (6.0 -- 8.1) [@b267],[@b292],[@b293],[@b302],[@b309],[@b314]   CGS 15943 (7.0 -- 7.9) [@b301],[@b302],[@b309],[@b320], XAC (7.0 -- 7.4) [@b302],[@b312],[@b320]
  Selective antagonists (p*K*~i~)               PSB36 (9.9 - Rat) [@b264], SLV320 (9.0) [@b297], DPCPX (7.4 -- 9.2) [@b275],[@b286],[@b308],[@b311],[@b322]                                                                                        SCH442416 (8.4 -- 10.3) [@b313],[@b316], ZM-241385 (8.8 -- 9.1) [@b309], SCH 58261 (8.3 -- 9.2) [@b276],[@b303],[@b309]                                          PSB-0788 (9.4) [@b269], PSB603 (9.26) [@b269], MRS1754 (8.8) [@b292],[@b300], PSB1115 (7.27) [@b284]                                                                                                   MRS1220 (8.2 -- 9.2) [@b289],[@b301],[@b315],[@b325], VUF5574 (8.39) [@b318], MRS1523 (7.7) [@b304], MRS1191 (7.5) [@b289],[@b294],[@b305]
  Radioligands (*K*~d~)                         \[3H\]CCPA (Agonist, Full agonist) (6.31x10^-10^ M) [@b302],[@b311], \[3H\]DPCPX (Antagonist) (6x10^-10^ -- 1.2x10^-9^ M) [@b274],[@b278],[@b302],[@b309],[@b311],[@b317]                          \[3H\]ZM 241385 (Antagonist) (8x10^-10^ -- 1.8x10^-9^ M) [@b266],[@b282], \[3H\]CGS 21680 (Agonist, Full agonist) (1.6x10^-8^ -- 2.2x10^-8^ M) [@b291],[@b321]   \[3H\]MRS1754 (Antagonist) (1.58x10^-10^ M) [@b292]                                                                                                                                                    \[125I\]AB-MECA (Agonist, Full agonist) (6x10^-10^ -- 1x10^-9^ M) [@b309],[@b320]
  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Adenosine inhibits many intracellular ATP-utilising enzymes, including adenylyl cyclase (P-site). A pseudogene exists for the A~2B~ adenosine receptor (ADORA2BP1) with 79% identity to the A~2B~ adenosine receptor cDNA coding sequence, but which is unable to encode a functional receptor [@b290]. DPCPX also exhibits antagonism at A~2B~ receptors (p*K*~i~ ca. 7,[@b265],[@b302]). Antagonists at A~3~ receptors exhibit marked species differences, such that only MRS1523 and MRS1191 are selective at the rat A~3~ receptor. In the absence of other adenosine receptors, \[3H\]DPCPX and \[3H\]ZM 241385 can also be used to label A~2B~ receptors (K~D~ *ca*. 30 and 60 nM respectively). \[125I\]AB-MECA also binds to A~1~ receptors [@b302]. \[3H\]CGS 21680 is relatively selective for A~2A~ receptors, but may also bind to other sites in cerebral cortex [@b273],[@b296]. \[3H\]NECA binds to other non-receptor elements, which also recognise adenosine [@b307]. XAC-BY630 has been described as a fluorescent antagonist for labelling A~1~ adenosine receptors in living cells, although activity at other adenosine receptors was not examined [@b272].

Adhesion Class GPCRs
====================

Overview
--------

Adhesion GPCRs are structurally identified on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a \"stalk\" motif containing a GPCR proteolytic site. The N-terminus often shares structural homology with proteins such as lectins and immunoglobulins, leading to the term adhesion GPCR [@b326],[@b331].

  -------------- ---------------- ----------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    Comment
  BAI1           BAI1, O14514     BAI1 is reported to respond to phosphatidylserine [@b329].
  BAI2           BAI2, O60241     --
  BAI3           BAI3, O60242     --
  CD97           CD97, P48960     --
  CELSR1         CELSR1, Q9NYQ6   --
  CELSR2         CELSR2, Q9HCU4   --
  CELSR3         CELSR3, Q9NYQ7   --
  ELTD1          ELTD1, Q9HBW9    --
  EMR1           EMR1, Q14246     --
  EMR2           EMR2, Q9UHX3     --
  EMR3           EMR3, Q9BY15     --
  EMR4P          EMR4P, Q86SQ3    --
  GPR56          GPR56, Q9Y653    Reported to bind tissue transglutaminase 2 [@b330] and collagen, which activates the G~12/13~ pathway [@b328].
  GPR64          GPR64, Q8IZP9    --
  GPR97          GPR64, Q8IZP9    --
  VLGR1          GPR98, Q8WXG9    Loss-of-function mutations are associated with Usher syndrome, a sensory deficit disorder [@b327].
  GPR110         GPR110, Q5T601   --
  GPR111         GPR111, Q8IZF7   --
  GPR112         GPR112, Q8IZF6   --
  GPR113         GPR113, Q8IZF5   --
  GPR114         GPR114, Q8IZF4   --
  GPR115         GPR115, Q8IZF3   --
  GPR116         GPR116, Q8IZF2   --
  GPR123         GPR123, Q86SQ6   --
  GPR124         GPR124, Q96PE1   --
  GPR125         GPR125, Q8IWK6   --
  GPR126         GPR126, Q86SQ4   --
  GPR128         GPR128, Q96K78   --
  GPR133         GPR133, Q6QNK2   --
  GPR144         GPR144, Q7Z7M1   --
  LPHN1          LPHN1, O94910    --
  LPHN2          LPHN2, O95490    --
  LPHN3          LPHN3, Q9HAR2    --
  -------------- ---------------- ----------------------------------------------------------------------------------------------------------------

Adrenoceptors
=============

Overview
--------

α~1~-Adrenoceptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Adrenoceptors; [@b340]) are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline with equal potency. phenylephrine, methoxamine and cirazoline are agonists selective for α~1~-adrenoceptors relative to α~2~-adrenoceptors, while prazosin (8.5--10.5) and corynanthine (6.5--7.5) are antagonists considered selective for α~1~-adrenoceptors relative to α~2~-adrenoceptors. \[3H\]prazosin (0.25 nM) and \[125I\]HEAT (0.1 nM; also known as BE2254) are relatively selective radioligands. The α~1A~-adrenoceptor antagonist (+)-niguldipine also has high affinity for L-type Ca^2+^ channels. The conotoxin ρ-TIA acts as a negative allosteric modulator at the α~1B~-adrenoceptor [@b396], while the snake toxin ρ-Da1a acts as a selective competitive antagonist at the α~1A~-adrenoceptor [@b386]. Fluorescent derivatives of prazosin (Bodipy PL-prazosin -- QAPB) are increasingly used to examine cellular localisation of α~1~-adrenoceptors. The vasoconstrictor effects of selective α1-adrenoceptor agonists have led to their use as nasal decongestants; antagonists are used to treat hypertension (doxazosin, prazosin) and benign prostatic hyperplasia (alfuzosin, tamsulosin). The combined α~1~- and β~2~-adrenoceptor antagonist carvedilol is widely used to treat congestive heart failure, although the contribution of α~1~-adrenoceptor blockade to the therapeutic effect is unclear. Several anti-depressants and anti-psychotic drugs possess α~1~-adrenoceptor blocking properties that are believed to contribute to side effects such as orthostatic hypotension and extrapyramidal effects.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ -------------------------------------
  Nomenclature                      α1A-adrenoceptor                                                                                                                                                                                             α1B-adrenoceptor   α1D-adrenoceptor
  HGNC, UniProt                     ADRA1A, P35348                                                                                                                                                                                               ADRA1B, P35368     ADRA1D, P25100
  Principal transduction            G~q/11~                                                                                                                                                                                                      G~q/11~            G~q/11~
  Selective agonists (p*K*~i~)      dabuzalgron (7.4) [@b339], A61603 (pIC~50~ 7.8--8.4) [@b355],[@b369]                                                                                                                                         --                 --
  Selective antagonists (p*K*~i~)   silodosin (10.4) [@b397], tamsulosin (10.0--10.7) [@b343],[@b346],[@b355],[@b397],[@b410], (+)-niguldipine (9.1--10.0) [@b355],[@b397], ρ-Da1a (9.22) [@b386], SNAP5089 (8.8--9.4) [@b360],[@b371],[@b409]   --                 BMY-7378 (8.7--9.1) [@b342],[@b413]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ -------------------------------------

Comments
========

Adrenoceptors, α~1~
-------------------

The clone originally called the α~1C~-adrenoceptor corresponds to the pharmacologically defined α~1A~-adrenoceptor [@b361]. Some tissues possess α~1A~-adrenoceptors (termed αα1~L~-adrenoceptors [@b355],[@b381]) that display relatively low affinity in functional and binding assays for prazosin (p*K~i~* \< 9) indicative of different receptor states or locations. α~1A~-adrenoceptor C-terminal splice variants form homo- and heterodimers, but fail to generate a functional α~1L~-adrenoceptor [@b387]. A study suggests that the &alpha~1L~-adenoceptor phenotype may result from the interaction of α~1A~-adrenoceptors with cysteine-rich epidermal growth factor-like domain 1α (CRELD1α) [@b382],[@b383],[@b404]. α~1D~-Adrenoceptors form heterodimers with α~1B~- or β~2~-adrenoceptors that show increased cell-surface expression [@b402]. Heterodimers formed between α~1D~- and α~1B~-adrenoceptors have distinct functional properties [@b359]. Recombinant α~1D~-adrenoceptors have been shown in some heterologous systems to be mainly located intracellularly but cell-surface localization is attained by truncation of the N-terminus, or by co-expression of α1B- or β2-adrenoceptors to form heterodimers [@b359],[@b402]. In smooth muscle of native blood vessels all three α~1~-adrenoceptor subtypes are located on the surface and intracellularly [@b377],[@b378].

Signalling is predominantly via G~q/11~ but α~1~-adrenoceptors also couple to G~i/o~, G~s~ and G~12/13~. Several ligands activating α~1A~-adrenoceptors display ligand directed signalling bias. For example, oxymetazoline is a full agonist for extracellular acidification rate (ECAR) and a partial agonist for Ca2+ release but does not stimulate cAMP production. Phenylephrine is biased toward ECAR versus Ca2+ release or cAMP accumulation but not between Ca2+ release and cAMP accumulation [@b351]. There are also differences between subtypes in coupling efficiency to different pathways -- *e.g.* in some systems coupling efficiency to Ca^2+^ signalling is α~1A~ \> α~1B~ \> α~1D~, but for MAP kinase signalling is α~1D~ \> α~1A~ \> α~1B~. In vascular smooth muscle, potency of agonists is related to the predominant subtype, α~1D~- conveying greater sensitivity than α1A-adrenoceptors [@b354].

Adrenoceptors, α~2~
===================

α~2~-Adrenoceptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Adrenoceptors; [@b340]) are activated by endogenous agonists with a relative potency of (-)-adrenaline \> (-)-noradrenaline. UK14304 (brimonidine) and BHT920 are agonists selective for α~2~-adrenoceptors relative to α~1~-adrenoceptors, rauwolscine (9.0) and yohimbine (9.0) are antagonists selective for α~2~-adrenoceptors relative to α~1~-adrenoceptors. \[3H\]rauwolscine (1 nM), \[3H\]UK14304 (5 nM) and \[3H\]RX821002 (0.5 nM and 0.1 nM at α~2C~) are relatively selective radioligands. There is species variation in the pharmacology of the α~2A~-adrenoceptor; for example, yohimbine, rauwolscine and oxymetazoline have an ∼20-fold lower affinity for rat, mouse and bovine α~2A~-adrenoceptors compared to the human receptor. These α~2A~ orthologues are sometimes referred to as α~2D~-adrenoceptors. Multiple mutations of α~2~-adrenoceptors have been described, some of which are associated with alterations in function. Presynaptic α~2~-adrenoceptors are widespread in the nervous system and regulate many functions, hence the multiplicity of actions. The effects of classical (not subtype selective) α~2~-adrenoceptor agonists such as clonidine, guanabenz and UK14304 (brimonidine) on central baroreflex control (hypotension and bradycardia), hypnotic, analgesic, seizure modulation and platelet aggregation are mediated by α~2A~-adrenoceptors. clonidine has been used as an anti-hypertensive and also to counteract opioid withdrawal. Actions on imidazoline receptors may contribute to the pharmacological effects of clonidine. α~2~-Adrenoceptor agonists such as dexmedetomidine have been widely used as sedatives and analgesics in veterinary medicine (also xylazine) and are now used frequently in humans. α~2~-Adrenoceptor antagonists are relatively little used therapeutically although yohimbine has been used to treat erectile dysfunction and several anti-depressants (cyanopindolol, mirtazepine) that block α~2~-adrenoceptors may work through this mechanism. The roles of α~2B~ and α~2C~-adrenoceptors are less clear but the α~2B~ subtype appears to be involved in neurotransmission in the spinal cord and α~2C~ in regulating catecholamine release from adrenal chromaffin cells.

  --------------------------------- --------------------------------------------------------------------------------- ------------------------------ ------------------------------
  Nomenclature                      α2A-adrenoceptor                                                                  α2B-adrenoceptor               α2C-adrenoceptor
  HGNC, UniProt                     ADRA2A, P08913                                                                    ADRA2B, P18089                 ADRA2C, P18825
  Principal transduction            G~i/o~                                                                            G~i/o~                         G~i/o~
  Selective agonists (p*K*~i~)      oxymetazoline (Partial agonist) (8.0) [@b365],[@b403], guanfacine (7.1) [@b374]   --                             --
  Selective antagonists (p*K*~i~)   BRL 44408 (8.2--8.77) [@b403],[@b414]                                             imiloxan (7.3 - Rat) [@b379]   JP1302 (p*K*~B~ 7.8) [@b392]
  --------------------------------- --------------------------------------------------------------------------------- ------------------------------ ------------------------------

Comments
========

ARC-239 (pKi 8.0) and prazosin (pKi 7.5) show selectivity for α~2B~- and α2~C~-adrenoceptors over α~2A~-adrenoceptors.oxymetazoline is a reduced efficacy agonist and is one of many α~2~-adrenoceptor agonists that are imidazolines or closely related compounds. Other binding sites for imidazolines, distinct from α~2~-adrenoceptors, and structurally distinct from the 7TM adrenoceptors, have been identified and classified as I~1~, I~2~ and I~3~ sites; catecholamines have a low affinity, while rilmenidine and moxonidine are selective ligands for these sites, evoking hypotensive effects *in vivo*. I~1~-imidazoline receptors are involved in central inhibition of sympathetic tone, I~2~-imidazoline receptors are an allosteric binding site on monoamine oxidase B, and I~3~-imidazoline receptors regulate insulin secretion from pancreatic β-cells. α~2A~-adrenoceptor stimulation reduces insulin secretion from β-islets [@b412], with a polymorphism in the 5′-UTR of the ADRA2A gene being associated with increased receptor expression in β-islets and heightened susceptibility to diabetes [@b391].

α~2A~- and α~2c~-adrenoceptors form homodimers [@b398]. Heterodimers between α~2A~- and either the α~2c~-adrenoceptor or μ opioid peptide receptor exhibit altered signalling and trafficking properties compared to the individual receptors [@b398],[@b401],[@b405]. Signalling by α~2~-adrenoceptors is primarily via G~i/o~, however the α~2A~-adrenoceptor also couples to G~s~ [@b350]. Imidazoline compounds display bias at the α~2A~-adrenoceptor when assayed by \[^35^S\] GTPγS binding compared to inhibition of cAMP accumulation [@b384]. The noradrenaline reuptake inhibitor desipramine acts directly on the α~2A~-adrenoceptor, promoting internalisation via recruitment of β-arrestin without activating G proteins [@b345].

Adrenoceptors, β
----------------

β-Adrenoceptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Adrenoceptors, [@b340]) are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. isoprenaline is a synthetic agonist selective for β-adrenoceptors relative to α~1~- and α~2~-adrenoceptors, while propranolol (pK~i~ 8.2--9.2) and cyanopindolol (pK~i~ 10.0--11.0) are relatively selective antagonists. (-)-noradrenaline, xamoterol and (-)-Ro 363 are agonists that show selectivity for β~1~- relative to β~2~-adrenoceptors. Pharmacological differences exist between human and mouse β~3~-adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy at the human β~3~-adrenoceptor whereas CGP 12177 and L 755507 activate human β~3~-adrenoceptors [@b393]. β~3~-Adrenoceptors are relatively resistant to blockade by propranolol (pK~i~ 5.8--7.0), but can be blocked by high concentrations of bupranolol (pK~i~ 8.65,[@b394]). SR59230A has reasonably high affinity at β~3~-adrenoceptors [@b375], but does not discriminate well between the three β-adrenoceptor subtypes [@b341] and has been reported to have lower affinity for the β~3~-adrenoceptor in some circumstances [@b368]. \[^125^I\]-cyanopindolol, \[^125^I\]-hydroxybenzylpindolol and \[^3^H\]-alprenolol are high affinity radioligands widely used to label β~1~- and β~2~-adrenoceptors and β~3~-adrenoceptors can be labelled with higher concentrations (nM) of \[^125^I\]-cyanopindolol in the presence of appropriate concentrations of β~1~- and β~2~-adrenoceptor antagonists. Fluorescent ligands such as BODIPY-TMR-CGP12177 are also increasingly being used to track β-adrenoceptors at the cellular level [@b335]. Somewhat selective β~1~-adrenoceptor selective agonists (denopamine, dobutamine) are used short-term to treat cardiogenic shock but, in the longer term, reduce survival. β~1~-Adrenoceptor-preferring antagonists are used to treat hypertension (atenolol, betaxolol, bisoprolol, metoprolol and nebivolol), cardiac arrhythmias (atenolol, bisoprolol, esmolol) and cardiac failure (metoprolol, nebivolol). Cardiac failure is also succesfully treated with carvedilol which blocks both β~1~- and β~2~-adrenoceptors, as well as α~1~-adrenoceptors. β~2~-Adrenoceptor-selective agonists are powerful bronchodilators widely used to treat respiratory disorders. There are both short (salbutamol, terbutaline) and long acting drugs (formoterol, salmeterol). Although many first generation β-adrenoceptor antagonists (propranolol) block both β~1~- and β~2~-adrenoceptors there are no β~2~-adrenoceptor-selective antagonists used therapeutically. Although potentially useful for the treatment of obesity, there are no β~3~-adrenoceptor-selective agonists used for this purpose currently. Several β~3~-adrenoceptor agonists (mirabegron, amibegron and solabegron) are used to control overactive bladder syndrome.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      β1-adrenoceptor                                                                                                                                                                                                          β2-adrenoceptor                                                                                                                                                                                           β3-adrenoceptor
  HGNC, UniProt                     ADRB1, P08588                                                                                                                                                                                                            ADRB2, P07550                                                                                                                                                                                             ADRB3, P13945
  Principal transduction            G~s~                                                                                                                                                                                                                     G~s~                                                                                                                                                                                                      G~s~
  Rank order of potency             (-)-noradrenaline \> (-)-adrenaline                                                                                                                                                                                      (-)-adrenaline \> (-)-noradrenaline                                                                                                                                                                       (-)-noradrenaline = (-)-adrenaline
  Endogenous agonists (p*K*~i~)     noradrenaline (6.0) [@b356]                                                                                                                                                                                              --                                                                                                                                                                                                        --
  Selective agonists (p*K*~i~)      (-)-Ro 363 (8.0) [@b380], xamoterol (Partial agonist) (7.0) [@b364], denopamine (Partial agonist) (5.8) [@b364],[@b400]                                                                                                  formoterol (pEC~50~ 10.08) [@b334], salmeterol (pEC~50~ 9.9) [@b334], zinterol (pEC~50~ 9.48) [@b334], procaterol (pEC~50~ 8.43) [@b334]                                                                  carazolol (8.7) [@b376], BRL 37344 (6.4--7.0) [@b338],[@b348],[@b362],[@b376], CGP 12177 (Partial agonist) (6.1--7.3) [@b338],[@b373],[@b376],[@b380], CL316243 (5.2) [@b411], L 755507 (pEC~50~ 10.1) [@b334], L742791 (pEC~50~ 8.8) [@b408], SB251023 (pEC~50~ 7.14 - Mouse) [@b363]
  Selective antagonists (p*K*~i~)   CGP 20712A (8.5--9.2) [@b332],[@b341],[@b373], betaxolol (8.8) [@b373], atenolol (6.7--7.6) [@b332],[@b366],[@b373]                                                                                                      ICI 118551 (Inverse agonist) (9.2--9.5) [@b332],[@b335],[@b373]                                                                                                                                           L-748337 (8.4) [@b341], SR59230A (6.9--8.4) [@b341],[@b347],[@b362]
  Radioligands (*K*~d~)             \[125I\]ICYP (Antagonist, it is necessary to use an excess of a β~2~-AR-selective ligand such as ICI 118551 to allow visualisation of β~1~-AR binding in native tissue) (4.99x10^-12^--3.28x10^-11^ M) [@b373],[@b395]   \[125I\]ICYP (Antagonist, it is necessary to use an excess of a β~1~-AR-selective ligand such as CGP20712A to allow visualisation of β~2~-AR binding in native tissues) (7.9x10^-12^ M) [@b373],[@b395]   \[125I\]ICYP (Agonist, Partial agonist) (1.58x10^-10^--6.31x10^-10^ M) [@b373],[@b380],[@b385],[@b395],[@b399]
  Comment                           The agonists indicated have less than two orders of magnitude selectivity [@b334].                                                                                                                                       --                                                                                                                                                                                                        Agonist SB251023 has a pEC~50~ of 6.9 for the splice variant of the mouse β~3~ receptor, β~3b~ [@b363].
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Radioligand binding with \[125I\]ICYP can be used to define β~1~- or β~2~-adrenoceptors when conducted in the presence of a 'saturating' concentration of either a β~1~- or β~2~-adrenoceptor-selective antagonist. \[3H\]CGP12177 or \[3H\]dihydroalprenolol can be used in place of \[125I\]ICYP. Binding of a fluorescent analogue of CGP 12177 to β~2~-adrenoceptors in living cells has been described [@b336]. \[125I\]ICYP at higher (nM) concentrations can be used to label β~3~-adrenoceptors in systems where there are few if any other β-adrenoceptor subtypes.Pharmacological differences exist between human and mouse β~3~-adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy at the human β~3~-adrenoceptor whereas CGP 12177 and L 755507 activate human β3-adrenoceptors [@b394]. The β~3~-adrenoceptor has an intron in the coding region, but splice variants have only been described for the mouse [@b352], where the isoforms display different signalling characteristics [@b363]. There are 3 β-adrenoceptors in turkey (termed the tβ, tβ3c and tβ4c) that have a pharmacology that differs from the human β-adrenoceptors [@b333]. The 'putative β~4~-adrenoceptor' is not a novel receptor but is likely to represent an alternative site of interaction of CGP 12177 and other nonconventional partial agonists at β~1~-adrenoceptors, since 'putative β~4~-adrenoceptor\'-mediated agonist effects of CGP 12177 are absent in mice lacking β~1~-adrenoceptors [@b367],[@b370]. Numerous polymorphisms have been described for the three β-adrenoceptors; some are associated with alterations in agonist-evoked signalling, trafficking, altered diseases susceptibility and/or altered responses to pharmacotherapy.

All β-adrenoceptors couple to G~s~ (activating adenylyl cyclase and elevating cAMP levels), but it is also clear that they activate other G proteins such as G~i~ and many other G protein-independent signalling pathways, including β-arrestins, which may in turn lead to activation of mitogen-activated protein kinases. Many antagonists at β~1~- and β~2~-adrenoceptors are agonists at β~3~-adrenoceptors (CL316243, CGP 12177 and carazolol). Many 'antagonists' that block agonist-stimulated cAMP accumulation, for example carvedilol and bucindolol, are able to activate mitogen-activated protein kinase pathways [@b337],[@b353],[@b357],[@b358],[@b393],[@b394] and thus display 'protean agonism'. bupranolol appears to act as a neutral antagonist in most systems so far examined. Agonists also display biased signalling at the β~2~-adrenoceptor via G~s~ or β-arrestins [@b349].

The X-ray crystal structures have been described of the agonist bound [@b406] and antagonist bound forms of the β~1~- [@b407], agonist-bound [@b344] and antagonist-bound forms of the β~2~-adrenoceptor [@b388],[@b390], as well as a fully active agonist-bound, G~s~ protein-coupled β~2~-adrenoceptor [@b389]. carvedilol and bucindolol bind to an extended site of the β~1~-adrenoceptor involving contacts in TM2, 3, and 7 and extracellular loop 2 that may facilitate coupling to β-arrestins [@b407]. Compounds displaying β-arrestin-biased signalling at the β~2~-adrenoceptor also have a greater effect on the conformation of TM7, whereas full agonists for G~s~ coupling promote movement of TM5 and TM6 [@b372].

Angiotensin receptors
=====================

Overview
--------

The actions of angiotensin II (AGT, P01019) (Ang II) are mediated by AT~1~ and AT~2~ receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on Angiotensin Receptors; [@b424]), which have around 30% sequence similarity. Endogenous ligands are angiotensin II (AGT, P01019) and angiotensin III (AGT, P01019) (Ang III), while angiotensin I (AGT, P01019) is weakly active in some systems.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------
  Nomenclature                      AT1 receptor                                                                                                                                                                                                                                                                                                                                     AT2 receptor
  HGNC, UniProt                     AGTR1, P30556                                                                                                                                                                                                                                                                                                                                    AGTR2, P50052
  Principal transduction            G~q/11~                                                                                                                                                                                                                                                                                                                                          G~i~/G~o~, Tyr & Ser/Thr phosphatases
  Selective agonists (p*K*~i~)      L-162313 (pIC~50~ 7.85--7.92) [@b433]                                                                                                                                                                                                                                                                                                            \[p-aminoPhe6\]ang II (p*K*~d~ 9.1--9.4 - Rat) [@b426],[@b434], CGP42112 (pIC~50~ 9.63) [@b417]
  Selective antagonists (p*K*~i~)   candesartan (pIC~50~ 9.5--9.7) [@b436], irbesartan (pIC~50~ 8.7--8.8) [@b436], valsartan (pIC~50~ 8.61) [@b425], eprosartan (pIC~50~ 8.4--8.8) [@b429], EXP3174 (pIC~50~ 7.4--9.5) [@b435],[@b436], losartan (pIC~50~ 7.4--8.7) [@b426],[@b435]                                                                                                  PD123319 (p*K*~d~ 8.7--9.2) [@b426],[@b427],[@b440], PD123177 (pIC~50~ 8.5--9.5 - Rat) [@b419],[@b422],[@b428]
  Radioligands (*K*~d~)             \[3H\]eprosartan (Antagonist), \[3H\]A81988 (Antagonist) (5.7x10^−10^ M - Rat) [@b430], \[3H\]L158809 (Antagonist) (6.6x10^−10^ M - Rat) [@b421], \[125I\]EXP985 (Antagonist) (1.49x10^−9^ M - Rat) [@b423], \[3H\]losartan (Antagonist) (6.2x10^−9^ M - Rat) [@b420], \[3H\]valsartan (Antagonist) (IC~50~ 1x10^−9^ -- 1.58x10^−9^ M) [@b437]   \[125I\]CGP42112 (Agonist, Full agonist) (2.51x10^−11^ M) [@b426],[@b438],[@b439]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------

Comments
--------

AT~1~ receptors are predominantly coupled to Gq~/11~, however they are also linked to arrestin recruitment and stimulate G protein-independent arrestin signalling [@b431]. Most species express a single *AGTR1* gene, but two related *agtr1a* and a*gtr1b* receptor genes are expressed in rodents. The AT~2~ receptor counteracts several of the growth responses initiated by the AT~1~ receptors. The AT~2~ receptor is much less abundant than the AT~1~ receptor in adult tissues and is upregulated in pathological conditions.

There is also evidence for an AT~4~ receptor that specifically binds angiotensin IV (AGT) and is located in the brain and kidney. An additional putative endogenous ligand for the AT~4~ receptor has been described (LVV-hemorphin (HBB, P68871), a globin decapeptide) [@b432]. The AT~1~ and bradykinin B2 receptors have been proposed to form a heterodimeric complex [@b416]. The antagonist activity of CGP42112 has also been reported [@b415]. AT~1~ receptor antagonists bearing substituted 4-phenylquinoline moieties have been synthesized, which bind to AT~1~ receptors with nanomolar affinity and are slightly more potent than losartan in functional studies [@b418].

Apelin receptor
===============

Overview
--------

The apelin receptor (APJ, nomenclature as agreed by NC-IUPHAR on apelin receptors, [@b449]) responds to apelin, a 36 amino-acid peptide derived initially from bovine stomach. apelin-36 (APLN, Q9ULZ1), apelin-13 (APLN, Q9ULZ1) and \[Pyr1\]apelin-13 (APLN, Q9ULZ1) are the predominant endogenous ligands which are cleaved from a 77 amino-acid precursor peptide (APLN, Q9ULZ1) by a so far unidentified enzymatic pathway [@b450].

  ----------------- --------------- ------------------------ ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature      HGNC, UniProt   Principal transduction   Rank order of potency                                        Endogenous agonists (p*K*~i~)                                                                                                                                                                                                                                                     Radioligands (*K*~d~)
  apelin receptor   APLNR, P35414   G~i/o~                   \[Pyr1\]apelin-13 ≥ apelin-13 \> apelin-36 [@b443],[@b450]   apelin-13 (Selective) (pIC~50~ 8.8 -- 9.5) [@b443],[@b444],[@b448], apelin-17 (Selective) (pIC~50~ 7.9 -- 9.02) [@b442],[@b448], apelin-36 (Selective) (pIC~50~ 8.2 -- 8.6) [@b443],[@b444],[@b446],[@b448], \[Pyr1\]apelin-13 (Selective) (pIC~50~ 7.0 -- 8.8) [@b446],[@b448]   \[125I\]\[Nle75,Tyr77\]apelin-36 (human) (Agonist, Full agonist) (6.3x10^-12^ M) [@b446], \[125I\]\[Glp65Nle75,Tyr77\]apelin-13 (Agonist, Full agonist) (2.23x10^-11^ M) [@b444], \[125I\](Pyr1)apelin-13 (Agonist, Full agonist) (3x10^-10^ M) [@b445], \[125I\]apelin-13 (Agonist, Full agonist) (7x10^-10^ M) [@b443], \[3H\](Pyr1)\[Met(0)11\]-apelin-13 (Agonist, Full agonist) (2.7x10^-9^ M) [@b448]
  ----------------- --------------- ------------------------ ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Potency order determined for heterologously expressed human APJ receptor (p*D*~2~ values range from 9.5 to 8.6). APJ may also act as a co-receptor with CD4 for isolates of human immunodeficiency virus, with apelin blocking this function [@b441]. A modified apelin-13 peptide, apelin-13(F13A) was reported to block the hypotensive response to apelin in rat *in vivo* [@b447], however, this peptide exhibits agonist activity in HEK293 cells stably expressing the recombinant APJ receptor [@b443].

Bile acid receptor
==================

Overview
--------

The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such as type II diabetes, obesity and atherosclerosis.

  --------------- ---------------- ------------------------ -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Nomenclature    HGNC, UniProt    Principal transduction   Rank order of potency                                                                        Selective agonists (p*K*~i~)
  GPBA receptor   GPBAR1, Q8TDU6   G~s~ [@b454]             lithocholic acid \> deoxycholic acid \> chenodeoxycholic acid, cholic acid [@b452],[@b454]   betulinic acid (pEC~50~ 5.98) [@b451], oleanolic acid (pEC~50~ 5.65) [@b455]
  --------------- ---------------- ------------------------ -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------

Comments
========

The triterpenoid natural product betulinic acid has also been reported to inhibit inflammatory signalling through the NFκB pathway [@b456]. Disruption of GPBA expression is reported to protect from cholesterol gallstone formation [@b457]. A new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides have been reported as highly potent agonists [@b453].

Bombesin receptors
==================

Overview
--------

Bombesin receptors (nomenclature recommended by the NC-IUPHAR Subcommittee on bombesin receptors, [@b462]) are activated by the endogenous ligands gastrin-releasing peptide (GRP, P07492) (GRP), NMB (NMB, P08949) (NMB) and GRP-(18--27) (GRP, P07492) (previously named neuromedin C). bombesin is a tetradecapeptide, originally derived from amphibians. These receptors couple primarily to the G~q/11~ family of G proteins (but see also [@b463]). Activation of BB~1~ and BB~2~ receptors causes a wide range of physiological actions, including the stimulation of tissue growth, smooth--muscle contraction, secretion and many central nervous system effects [@b469]. A physiological role for the BB~3~ receptor has yet to be fully defined although receptor knockout experiments suggest a role in energy balance and the control of body weight [@b462].

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Nomenclature                      BB1 receptor                                                                                                                                                                                       BB2 receptor                                                                                                                                                                                  BB3 receptor
  HGNC, UniProt                     NMBR, P28336                                                                                                                                                                                       GRPR, P30550                                                                                                                                                                                  BRS3, P32247
  Principal transduction            G~q/11~                                                                                                                                                                                            G~q/11~                                                                                                                                                                                       G~q/11~
  Endogenous agonists (p*K*~i~)     NMB (Selective) (8.1 -- 10.3) [@b458],[@b468]                                                                                                                                                      gastrin-releasing peptide (Selective) (6.34 -- 8.21) [@b458],[@b468]                                                                                                                          --
  Selective antagonists (p*K*~i~)   dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH2, PD 165929 (p*K*~d~ 8.2) [@b460], PD 168368 (pIC~50~ 9.24 -- 9.6) [@b459], D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2 (pIC~50~ 6.22 -- 6.56) [@b459],[@b468]   \[D-Phe6,Cpa14,ψ13--14\]bombesin-(6--14), JMV594 (pIC~50~ 8.7 - Mouse) [@b464],[@b470], Ac-GRP-(20--26)-methylester (pIC~50~ 8.4 - Mouse) [@b461]                                             --
  Selective agonists (p*K*~i~)      --                                                                                                                                                                                                 --                                                                                                                                                                                            \[D-Tyr6,Apa-4Cl11,Phe13,Nle14\]bombesin-(6--14) (8.1) [@b466]
  Radioligands (*K*~d~)             \[125I\]BH-NMB, \[125I\]\[Tyr4\]bombesin                                                                                                                                                           \[125I\]GRP (human), \[125I\]\[D-Tyr6\]bombesin-(6--13)-methyl ester (Antagonist) (5.3x10^-10^ M - Mouse) [@b465], \[125I\]\[Tyr4\]bombesin (Agonist, Full agonist) (6.31x10^-9^ M) [@b458]   \[125I\]\[D-Tyr6,β-Ala11,Phe13,Nle14\]bombesin-(6--14) (Agonist, Full agonist) (1x10^-8^ -- 3.98x10^-9^ M) [@b467]
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------

Comments
========

All three subtypes may be activated by \[D-Phe6,β-Ala11,Phe13,Nle14\]bombesin-(6--14) [@b467]. \[D-Tyr6,Apa-4Cl11,Phe13,Nle14\]bombesin-(6--14) has more than 200-fold selectivity for BB~3~ receptors over BB~1~ and BB~2~ [@b466].

Bradykinin receptors
====================

Overview
--------

Bradykinin (or kinin) receptors (nomenclature recommended by the NC-IUPHAR subcommittee on bradykinin (kinin) receptors, [@b478]) are activated by the endogenous peptides bradykinin (KNG1, P01042) (BK), \[des-Arg9\]bradykinin (KNG1, P01042), Lys-BK (kallidin (KNG1, P01042)), \[des-Arg10\]kallidin (KNG1, P01042), T-kinin (KNG1, P01042) (Ile-Ser-BK), \[Hyp3\]-BK (KNG1, P01042) and Lys-\[Hyp3\]-bradykinin (KNG1, P01042). The variation in affinity or inactivity of B~2~ receptor antagonists could reflect the existence of species homologues of B~2~ receptors.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      B1 receptor                                                                                                                                               B2 receptor
  HGNC, UniProt                     BDKRB1, P46663                                                                                                                                            BDKRB2, P30411
  Principal transduction            G~q/11~                                                                                                                                                   G~q/11~
  Rank order of potency             \[des-Arg10\]kallidin \> \[des-Arg9\]bradykinin = kallidin \> bradykinin                                                                                  kallidin \> bradykinin \>\> \[des-Arg9\]bradykinin, \[des-Arg10\]kallidin
  Endogenous agonists (p*K*~i~)     \[des-Arg10\]kallidin (KNG1, P01042) (Selective) (9.6 -- 10.0) [@b471],[@b472],[@b477]                                                                    --
  Selective agonists (p*K*~i~)      \[Sar,D-Phe8,des-Arg9\]bradykinin (5.7) [@b477]                                                                                                           \[Hyp3,Tyr(Me)8\]BK, \[Phe8,ψ(CH2-NH)Arg9\]BK
  Selective antagonists (p*K*~i~)   R 914 (p*A*~2~ 8.6) [@b474], R-715 (p*A*~2~ 8.5) [@b475], B-9958 (9.2 -- 10.3) [@b473],[@b480], \[Leu9,des-Arg10\]kallidin (9.1 -- 9.3) [@b471],[@b472]   icatibant (p*A*~2~ 8.4) [@b476], FR173657 (p*A*~2~ 8.2) [@b481], anatibant (8.2) [@b479]
  Radioligands (*K*~d~)             \[3H\]Lys-\[Leu8\]\[des-Arg9\]BK (Antagonist), \[125I\]Hpp-desArg10HOE140 (1x10^-10^ M), \[3H\]Lys-\[des-Arg9\]BK (Agonist, Full agonist) (4x10^-10^ M)   \[125I\]\[Tyr8\]bradykinin, \[3H\]BK (human, mouse, rat) (Agonist, Full agonist) (3.99x10^-10^ M - Mouse) [@b482], \[3H\]NPC17731 (Antagonist) (3.9x10^-10^ -- 7.7x10^-10^ M) [@b483],[@b484]
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Calcitonin receptors
====================

Overview
--------

Calcitonin (CT), amylin (AMY), calcitonin gene-related peptide (CGRP) and adrenomedullin (AM) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on CGRP, AM, AMY, and CT receptors, [@b495],[@b504]) are generated by the genes *CALCR* (which codes for the CT receptor (CTR),) and *CALCRL* (which codes for the calcitonin receptor-like receptor, CLR, previously known as CRLR,). Their function and pharmacology are altered in the presence of RAMPs (receptor activity-modifying protein), which are single TM domain proteins of *ca.* 130 amino acids, identified as a family of three members; RAMP1, RAMP2 and RAMP3. There are splice variants of CTR; these in turn produce variants of the AMY receptor [@b504]. The endogenous agonists are the peptides CT (CALCA, P01258), α-CGRP (CALCA, P06881) (formerly known as CGRP-I), β-CGRP (CALCB, P10092) (formerly known as CGRP-II), AMY (IAPP, P10997) (occasionally called islet-amyloid polypeptide, diabetes-associated polypeptide), AM (ADM, P35318) and AM2/IMD (ADM2, Q7Z4H4) (AM2/IMD). There are species differences in peptide sequences, particularly for the CTs. CTR-stimulating peptide (CRSP) is another member of the family with selectivity for the CTR but it is not expressed in humans [@b497]. BIBN4096BS (also known as olcegepant, *p*Ki∼10.5) and MK-0974 (also known as telcagepant, *p*Ki∼9) are the most selective antagonists available, having a high selectivity for CGRP receptors, with a particular preference for those of primate origin.

CLR by itself binds no known endogenous ligand, but in the presence of RAMPs it gives receptors for CGRP, AM and AM2/IMD.

  --------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------
  Nomenclature                      CGRP receptor                                                                                                     AM1 receptor                                                         AM2 receptor
  Subunits                          RAMP1 (Accessory protein), calcitonin receptor-like receptor                                                      RAMP2 (Accessory protein), calcitonin receptor-like receptor         RAMP3 (Accessory protein), calcitonin receptor-like receptor
  Principal transduction            G~s~                                                                                                              G~s~                                                                 G~s~
  Rank order of potency             α-CGRP \> AM ≥ AM2/IMD \> AMY ≥ CT (salmon)                                                                       AM \> AMY \> α-CGRP, AM2/IMD \> CT (salmon)                          AM ≥ AM2/IMD ≥ α-CGRP \> AMY \> CT (salmon)
  Endogenous agonists (p*K*~i~)     β-CGRP (9.9 -- 11.0) [@b485],[@b501], α-CGRP (9.7 -- 10.0) [@b485],[@b501]                                        AM (8.3 -- 9.2) [@b485],[@b501]                                      AM (8.3 -- 9.0) [@b485],[@b491]
  Selective antagonists (p*K*~i~)   BIBN4096BS (10.2 -- 10.7) [@b489],[@b493],[@b494],[@b500], MK-0974 (9.1) [@b506]                                  AM-(22-52) (human) (7.0 -- 7.8) [@b485],[@b494],[@b501]              --
  Radioligands (*K*~d~)             \[125I\]αCGRP (mouse, rat) (Agonist, Full agonist), \[125I\]αCGRP (human) (Agonist, Full agonist) (1x10^−10^ M)   \[125I\]AM (rat) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)   \[125I\]AM (rat) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)
  --------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------

  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------
  Nomenclature                    CT receptor                                                                                                                       AMY1 receptor                                                                   AMY2 receptor                                                                   AMY3 receptor
  HGNC, UniProt                   CALCR, P30988                                                                                                                     --                                                                              --                                                                              --
  Subunits                        --                                                                                                                                RAMP1 (Accessory protein), CT receptor                                          RAMP2 (Accessory protein), CT receptor                                          RAMP3 (Accessory protein), CT receptor
  Principal transduction          G~s~                                                                                                                              G~s~                                                                            G~s~                                                                            G~s~
  Rank order of potency           CT (salmon) ≥ CT ≥ AMY, α-CGRP \> AM, AM2/IMD                                                                                     CT (salmon) ≥ AMY ≥ α-CGRP \> AM2/IMD ≥ CT \> AM                                Poorly defined                                                                  CT (salmon) ≥ AMY \> α-CGRP ≥ AM2/IMD ≥ CT \> AM
  Endogenous agonists (p*K*~i~)   CT (Selective) (pEC~50~ 9.0 -- 11.2) [@b486],[@b487],[@b492],[@b498],[@b499],[@b503]                                              AMY                                                                             AMY                                                                             AMY
  Radioligands (*K*~d~)           \[125I\]CT (salmon) (Agonist, Full agonist) (1x10^−10^ M), \[125I\]CT (human) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)   \[125I\]BH-AMY (rat, mouse) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)   \[125I\]BH-AMY (rat, mouse) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)   \[125I\]BH-AMY (rat, mouse) (Agonist, Full agonist) (1x10^−10^ -- 1x10^−9^ M)
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------

Comments
========

It is important to note that a complication with the interpretation of pharmacological studies with AMY receptors in transfected cells is that most of this work has likely used a mixed population of receptors, encompassing RAMP-coupled CTR as well as CTR alone. This means that although in binding assays human CT (CALCA, P01258) has low affinity for ^125^I-AMY binding sites, cells transfected with CTR and RAMPs can display potent CT functional responses. Transfection of human CTR with any RAMP can generate receptors with a high affinity for both salmon CT and AMY and varying affinity for different antagonists [@b488],[@b492],[@b493]. The insert negative (and major) human CTR splice variant (hCT~(a)~) with RAMP1 (*i.e.* the AMY~1(a)~ receptor) has a high affinity for CGRP, unlike hCT~(a)~--RAMP3 (*i.e*. AMY~3(a)~ receptor) [@b488],[@b492]. However, the AMY receptor phenotype is RAMP-type, splice variant and cell-line-dependent [@b507]. In particular, CGRP is a more potent agonist than AMY (IAPP, P10997) at increasing cAMP at the delta 47 hCT(a) receptor, when transfected with RAMP1 (to give the corresponding AMY1(a) receptor) in Cos 7 cells [@b505].

The ligands described represent the best available but their selectivity is limited, apart from BIBN4096BS and MK-0974. For example, AM has appreciable affinity for CGRP receptors. CGRP can show significant cross-reactivity at AMY receptors and AM~2~ receptors. AM2/IMD also has high affinity for the AM~2~ receptor [@b496]. CGRP-(8-37) acts as an antagonist of CGRP (*p*K~i~ ∼8) and inhibits some AM and AMY responses (*p*K~i~ ∼6--7). It is weak at CT receptors. Salmon CT-(8-32) is an antagonist at both AMY and CT receptors. AC187, a salmon CT analogue, is also an antagonist at AMY and CT receptors. Human AM-(22-52) has some selectivity towards AM receptors, but with modest potency (*p*K~i~ ∼7), limiting its use [@b494]. AM-(22-52) is slightly more effective at AM~1~ than AM~2~ receptors but this difference is not sufficient for this peptide to be a useful discriminator of the AM receptor subtypes.

Ligand responsiveness at CT and AMY receptors can be affected by receptor splice variation and can depend on the pathway being measured. Particularly for AMY receptors, relative potency can vary with the type and level of RAMP present and can be influenced by other factors such as G proteins [@b502],[@b507].

G~s~ is a prominent route for effector coupling for CLR and CTR but other pathways (*e.g.* Ca^2+^, ERK, Akt), and G proteins can be activated [@b508]. There is evidence that CGRP-RCP (a 148 amino-acid hydrophilic protein, ASL (P04424) is important for the coupling of CLR to adenylyl cyclase [@b490].

\[^125^I\]-Salmon CT is the most common radioligand for CT receptors but it has high affinity for AMY receptors and is also poorly reversible. \[^125^I\]-Tyr^0^-CGRP is widely used as a radioligand for CGRP receptors.

Some early literature distinguished between *CGRP~1~* and *CGRP~2~* receptors. It is now clear that *CLCRL/RAMP1* represents the *CGRP~1~* subtype and is now known simply as the CGRP receptor [@b495]. The *CGRP~2~* receptor is now considered to have arisen from the actions of CGRP at AM~2~ and AMY receptors. This term should not be used [@b495].

Calcium-sensing receptors
=========================

Overview
--------

The calcium-sensing receptor (CaS, provisional nomenclature) responds to extracellular calcium and magnesium in the millimolar range and to gadolinium and some polycations in the micromolar range [@b509]. The sensitivity of CaS to primary agonists can be increased by aromatic L-amino acids [@b511] and also by elevated extracellular pH [@b520] or decreased extracellular ionic strength [@b521].

This receptor bears no sequence or structural relation to the plant calcium receptor, also called CaS.

  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  Nomenclature                       CaS receptor                                                                                                                                                                                                                                                                                                                                                                  GPRC6 receptor
  HGNC, UniProt                      CASR, P41180                                                                                                                                                                                                                                                                                                                                                                  GPRC6A, Q5T6X5
  Principal transduction             G~q/11~, G~i/o~, G~12/13~ [@b523]                                                                                                                                                                                                                                                                                                                                             --
  Amino-acid rank order of potency   L-phenylalanine, L-tryptophan, L-histidine \> L-alanine \> L-serine, L-proline, L-glutamic acid \> L-aspartic acid (not L-lysine, L-arginine, L-leucine and L-isoleucine) [@b511]                                                                                                                                                                                             --
  Cation rank order of potency       Gd3+ \> Ca2+ \> Mg2+ [@b509]                                                                                                                                                                                                                                                                                                                                                  --
  Polyamine rank order of potency    spermine \> spermidine \> putrescine [@b522]                                                                                                                                                                                                                                                                                                                                  --
  Selective allosteric regulators    NPS 89636 (Negative) [@b515], NPS R-568 (Positive) (p*K*~d~ 6.5) [@b517], calindol (Positive) (p*K*~d~ 6.0 -- 6.5) [@b513], AC265347 (Positive) (pEC~50~ 7.6 -- 8.1) [@b514], cinacalcet (Positive) (pEC~50~ 7.3) [@b516], calindol (Positive) (pEC~50~ 6.5) [@b518], NPS 2143 (Negative) (pIC~50~ 7.1 -- 7.4) [@b515],[@b525], calhex 231 (Negative) (pIC~50~ 6.4) [@b519]   --
  Comment                            2-benzylpyrrolidine derivatives of NPS 2143 are also negative allosteric modulators of the calcium sensing receptor [@b525].                                                                                                                                                                                                                                                  GPRC~6~ is a related G~q~-coupled receptor which responds to basic amino acids [@b524][@b525].
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------

Comments
========

Positive allosteric modulators of CaS are termed Type II calcimimetics and can suppress parathyroid hormone (PTH (PTH, P01270)) secretion [@b517]. Negative allosteric modulators are called calcilytics and can act to increase PTH (PTH, P01270) secretion [@b515].

The central role of CaS in the maintenance of extracellular calcium homeostasis is seen most clearly in patients with loss-of-function CaS mutations who develop familial hypocalciuric hypercalcaemia (heterozygous mutation) or neonatal severe hyperparathyroidism (homozygous mutation) and in CaS null mice [@b510],[@b512], which exhibit similar increases in PTH secretion and blood Ca2+ levels. A gain-of-function mutation in the CaS gene is associated with autosomal dominant hypocalcaemia.

Cannabinoid receptors
=====================

Overview
--------

Cannabinoid receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Cannabinoid Receptors; [@b542]) are activated by endogenous ligands that include N-arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [@b526].

  ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                               CB1 receptor                                                                                                                                                                CB2 receptor
  HGNC, UniProt                              CNR1, P21554                                                                                                                                                                CNR2, P34972
  Principal transduction                     G~i/o~                                                                                                                                                                      G~i/o~
  (Sub)family-selective agonists (p*K*~i~)   CP55940 [@b550], Δ9-tetrahydrocannabinol [@b550], HU-210 [@b530], WIN55212-2 [@b550]                                                                                        CP55940 [@b550], Δ9-tetrahydrocannabinol [@b550], HU-210 [@b530], WIN55212-2 [@b550]
  Selective agonists (p*K*~i~)               arachidonyl-2-chloroethylamide (8.9 - Rat) [@b533], arachidonylcyclopropylamide (8.7 - Rat) [@b533], O-1812 (8.5 - Rat) [@b528], R-(+)-methanandamide (7.7 - Rat) [@b537]   JWH-133 (8.5) [@b535],[@b541], AM1241 (8.1) [@b555], L-759,633 (7.7 -- 8.2) [@b531],[@b548], L-759,656 (7.7 -- 7.9) [@b531],[@b548], HU-308 (7.6) [@b532]
  Selective antagonists (p*K*~i~)            rimonabant (7.9 -- 8.7) [@b529],[@b530],[@b545],[@b549],[@b550], AM251 (8.1 - Rat) [@b539], AM281 (7.9 - Rat) [@b538], LY320135 (6.9) [@b529]                               SR144528 (8.3 -- 9.2) [@b546],[@b548], AM630 (7.5) [@b548]
  Radioligands (*K*~d~)                      \[3H\]rimonabant (Antagonist) (1x10^−10^ -- 1.2x10^−9^ M - Rat) [@b527],[@b534],[@b536],[@b543],[@b547],[@b551],[@b554]                                                     --
  ------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Both CB~1~ and CB~2~ receptors may be labelled with \[3H\]CP55940 (0.5 nM; [@b550]) and \[3H\]WIN55212-2 (2--2.4 nM; [@b552],[@b553]). anandamide is also an agonist at vanilloid receptors (TRPV1) and PPARs [@b540],[@b556]. There is evidence for an allosteric site on the CB~1~ receptor [@b544]. All of the compounds listed as antagonists behave as inverse agonists in some bioassay systems [@b542]. For some cannabinoid receptor ligands, additional pharmacological targets that include GPR55 and GPR119 have been identified [@b542]. Moreover, GPR18, GPR55 and GPR119, although showing little structural similarity to CB~1~ and CB~2~ receptors, respond to endogenous agents that are structurally similar to the endogenous cannabinoid ligands [@b542].

Chemerin receptor
=================

Overview
--------

The chemerin receptor is activated by the lipid-derived, anti-inflammatory ligand resolvin E1 (RvE1), which is the result of sequential metabolism of EPA by aspirin-modified cyclooxygenase and lipoxygenase [@b557],[@b558]. In addition, 2 GPCRs for resolvin D1 (RvD1) have been identified, FPR2/ALX, the lipoxin A~4~ receptor, and GPR32, an orphan receptor [@b559].

  ------------------- ---------------- ------------------------ ----------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature        HGNC, UniProt    Principal transduction   Rank order of potency                                                   Selective agonists (p*K*~i~)   Radioligands (*K*~d~)                                        Comment
  chemerin receptor   CMKLR1, Q99788   Not yet established      resolvin E1 \> chemerin C-terminal peptide \> 18R-HEPE \> EPA [@b557]   resolvin E1                    \[3H\]resolvin E1 (Agonist) (1.1x10^−8^ M) [@b557],[@b558]   NC-IUPHAR has issued a recommendation for a formal nomenclature change for this receptor from *CMKLR1* to 'chemerin receptor' based on new pairings with chemerin [@b560]--[@b562].
  ------------------- ---------------- ------------------------ ----------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemokine receptors
===================

Overview
--------

Chemokine receptors (nomenclature agreed by NC-IUPHAR Subcommittee on Chemokine Receptors, [@b600],[@b601]) comprise a large subfamily of 7TM proteins that bind one or more chemokines, a large family of small cytokines typically possessing chemotactic activity for leukocytes. Chemokine receptors can be divided by function into two main groups: G protein-coupled chemokine receptors, which mediate leukocyte trafficking, and "Atypical chemokine receptors", which may signal through non-G protein-coupled mechanisms and act as chemokine scavengers to downregulate inflammation or shape chemokine gradients.

Chemokines in turn can be divided by structure into four subclasses by the number and arrangement of conserved cysteines. CC (also known as β-chemokines; *n* = 28), CXC (also known as *α*-chemokines; *n* = 17) and CX3C (*n* = 1) chemokines all have four conserved cysteines, with zero, one and three amino acids separating the first two cysteines respectively. C chemokines (*n* = 2) have only the second and fourth cysteines found in other chemokines. Chemokines can also be classified by function into homeostatic and inflammatory subgroups. Most chemokine receptors are able to bind multiple high-affinity chemokine ligands, but the ligands for a given receptor are almost always restricted to the same structural subclass. Most chemokines bind to more than one receptor subtype. Receptors for inflammatory chemokines are typically highly promiscuous with regard to ligand specificity, and may lack a selective endogenous ligand. G protein-coupled chemokine receptors are named acccording to the class of chemokines bound, whereas ACKR is the root acronym for atypical chemokine receptors. Listed are those human agonists with EC~50~ values \<50 nM in either Ca^2+^ flux or chemotaxis assays at human recombinant G protein-coupled chemokine receptors expressed in mammalian cell lines. There can be substantial cross-species differences in the sequences of both chemokines and chemokine receptors, and in the pharmacology and biology of chemokine receptors. Endogenous and microbial non-chemokine ligands have also been identified for chemokine receptors. Many chemokine receptors function as HIV co-receptors, but CCR5 is the only one demonstrated to play an essential role in HIV/AIDS pathogenesis. The tables include both standard chemokine receptor names [@b628] and the most commonly used aliases. Numerical data quoted are typically p*K*~i~ or pIC~50~ values from radioligand binding to heterologously expressed receptors.

  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                       CCR1                                                                                                                                                                                                                                      CCR2                                                                                                                                                                                                                                     CCR3                                                                                                                                                                                                                                                                                                                       CCR4                                                                               CCR5
  HGNC, UniProt                      CCR1, P32246                                                                                                                                                                                                                              CCR2, P41597                                                                                                                                                                                                                             CCR3, P51677                                                                                                                                                                                                                                                                                                               CCR4, P51679                                                                       CCR5, P51681
  Principal transduction             G~i/o~                                                                                                                                                                                                                                    G~i/o~                                                                                                                                                                                                                                   G~i/o~                                                                                                                                                                                                                                                                                                                     G~i/o~                                                                             G~i/o~
  Endogenous agonists (p*K*~i~)      CCL13, CCL8, CCL3 (7.8 -- 10.2) [@b571],[@b572],[@b588],[@b630], CCL23 (Selective) (8.9) [@b571], CCL7 (8.1) [@b571],[@b583], CCL5 (6.8 -- 8.2) [@b572],[@b588], CCL14 (7.4) [@b571], CCL15 (Selective) (pIC~50~ 7.9) [@b573]             CCL16, CCL2 (pIC~50~ 9.3 -- 10.2) [@b573],[@b595],[@b598],[@b605],[@b615], CCL13 (pIC~50~ 8.6 -- 8.7) [@b595],[@b615], CCL7 (pIC~50~ 8.4 -- 8.7) [@b573],[@b595],[@b615], CCL11 (Partial agonist) (pIC~50~ 7.1 -- 7.7) [@b595],[@b605]   CCL28, CCL8, CCL7 (8.6 -- 9.2) [@b575], CCL13 (pIC~50~ 8.7 -- 10.3) [@b599],[@b615], CCL11 (Selective) (pIC~50~ 8.7 -- 9.0) [@b577],[@b591],[@b599],[@b610],[@b615], CCL24 (Selective) (pIC~50~ 8.0 -- 9.4) [@b599],[@b605], CCL15 (pIC~50~ 8.6) [@b573], CCL26 (Selective) (pIC~50~ 7.9 -- 8.9) [@b591],[@b599],[@b605]   CCL22 (Selective) (pIC~50~ 9.2) [@b589], CCL17 (Selective) (pIC~50~ 8.7) [@b589]   CCL16, CCL4 (Selective) (9.4 -- 9.6) [@b602],[@b609], CCL5 (9.2 -- 9.7) [@b566],[@b602],[@b609], CCL8 (9.3) [@b609], CCL3 (8.0 -- 8.9) [@b602],[@b609],[@b630], CCL2 (7.5) [@b602], CCL14 (7.2) [@b602], CCL11 (pIC~50~ 7.7) [@b570]
  Selective agonists (p*K*~i~)       --                                                                                                                                                                                                                                        --                                                                                                                                                                                                                                       CCL11 {Sp: Mouse} (9.5 -- 10.0) [@b575]                                                                                                                                                                                                                                                                                    --                                                                                 R5-HIV-1 gp120
  Non-selective agonists (p*K*~i~)   --                                                                                                                                                                                                                                        --                                                                                                                                                                                                                                       --                                                                                                                                                                                                                                                                                                                         vMIP-III                                                                           --
  Endogenous antagonists (p*K*~i~)   CCL4 (Selective) (7.1 -- 7.8) [@b571],[@b572]                                                                                                                                                                                             CCL26 (Selective) (pIC~50~ 8.5) [@b605]                                                                                                                                                                                                  CXCL10 (Selective), CXCL11 (CXCL11, O14625) (Selective), CXCL9 (Selective)                                                                                                                                                                                                                                                 --                                                                                 CCL7 (Selective) (7.5) [@b602]
  Selective antagonists (p*K*~i~)    CP-481,715 (p*K*~d~ 8.0) [@b579], BX 471 (8.2 -- 9.0) [@b593], 2b-1 (pIC~50~ 8.7) [@b603], UCB35625 (pIC~50~ 8.0) [@b610]                                                                                                                 GSK Compound 34 (7.6)                                                                                                                                                                                                                    banyu (I) (Inverse agonist) (8.5) [@b617], SB328437 (8.4), BMS compound 87b (8.1) [@b616]                                                                                                                                                                                                                                  --                                                                                 MRK-1, vicriviroc (9.1) [@b613], aplaviroc (8.5) [@b596], ancriviroc (7.8 -- 8.7) [@b596],[@b604],[@b613], TAK-779 (7.5) [@b596], E913 (pIC~50~ 8.7) [@b597], maraviroc (pIC~50~ 8.1) [@b602]
  Radioligands (*K*~d~)              \[125I\]CCL7 (human) (Agonist, Full agonist) (7x10^-10^ M) [@b568], \[125I\]CCL3 (human) (Agonist, Full agonist) (1.58x10^-9^ -- 1x10^-8^ M) [@b568],[@b580],[@b611], \[125I\]CCL5 (human) (Agonist, Full agonist) (7x10^-9^ M) [@b611]   \[125I\]CCL2 (Agonist, Full agonist), \[125I\]CCL7 (human) (Agonist)                                                                                                                                                                     \[125I\]CCL5 (human) (Agonist), \[125I\]CCL7 (human) (Agonist), \[125I\]CCL11 (human) (Antagonist) (5.01x10^-9^ M) [@b617]                                                                                                                                                                                                 \[125I\]CCL17 (Agonist, Full agonist), \[125I\]CCL27 (Agonist)                     \[125I\]CCL3 (human) (Agonist), \[125I\]CCL5 (human) (Agonist), \[125I\]CCL8 (human) (Agonist), \[125I\]CCL4 (human) (Agonist, Full agonist) (2.51x10^-10^ M) [@b602]
  Comment                            --                                                                                                                                                                                                                                        --                                                                                                                                                                                                                                       --                                                                                                                                                                                                                                                                                                                         Monoclonal antibody mogamulizumab selectively blocks CCR4                          --
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------
  Nomenclature                      CCR6                                                                                                                CCR7                                                                                              CCR8                                                                                          CCR9                                    CCR10
  HGNC, UniProt                     CCR6, P51684                                                                                                        CCR7, P32248                                                                                      CCR8, P51685                                                                                  CCR9, P51686                            CCR10, P46092
  Principal transduction            G~i/o~                                                                                                              G~i/o~                                                                                            G~i/o~                                                                                        G~i/o~                                  G~i/o~
  Endogenous agonists (p*K*~i~)     beta-defensin 4A (DEFB4A, DEFB4B, O15263) (Selective) [@b625], CCL20 (pIC~50~ 7.9 -- 8.5) [@b564],[@b565],[@b606]   CCL21 (Selective) (pIC~50~ 9.3) [@b627], CCL19 (Selective) (pIC~50~ 7.7 -- 9.0) [@b626],[@b627]   CCL8 (Mouse), CCL1 (Selective) (pIC~50~ 8.5 -- 9.8) [@b574],[@b585],[@b590]                   CCL25 (Selective)                       CCL27 (Selective), CCL28 (Selective)
  Selective agonists (p*K*~i~)      --                                                                                                                  --                                                                                                vMIP-I (pIC~50~ 8.9 -- 9.9) [@b574],[@b590]                                                   --                                      --
  Selective antagonists (p*K*~i~)   --                                                                                                                  --                                                                                                vMCC-I (pIC~50~ 9.4) [@b574]                                                                  --                                      --
  Radioligands (*K*~d~)             \[125I\]CCL20 (Agonist, Full agonist) (∼1x10^-10^ M) [@b582]                                                        \[125I\]CCL19 (Agonist, Full agonist), \[125I\]CCL21 (Agonist, Full agonist)                      \[125I\]CCL1 (human) (Agonist, Full agonist) (2.13x10^-10^ -- 1.2x10^-9^ M) [@b590],[@b608]   \[125I\]CCL25 (Agonist, Full agonist)   --
  --------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------

  ---------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------
  Nomenclature                       CXCR1                                                                                          CXCR2                                                                                                                                                                                                                                                                                                                                             CXCR3                                                                                                                                        CXCR4                                                                                                CXCR5                CXCR6
  HGNC, UniProt                      CXCR1, P25024                                                                                  CXCR2, P25025                                                                                                                                                                                                                                                                                                                                     CXCR3, P49682                                                                                                                                CXCR4, P61073                                                                                        CXCR5, P32302        CXCR6, O00574
  Principal transduction             G~i/o~                                                                                         G~i/o~                                                                                                                                                                                                                                                                                                                                            G~i/o~                                                                                                                                       G~i/o~                                                                                               G~i/o~               G~i/o~
  Endogenous agonists (p*K*~i~)      CXCL8 (8.8 -- 9.5) [@b569],[@b584],[@b592],[@b622],[@b623], CXCL6 (7.0) [@b624]                CXCL6 (p*K*~d~ 7.0) [@b624], CXCL8 (8.8 -- 9.5) [@b569],[@b584],[@b592],[@b622],[@b623], CXCL1 (Selective) (8.4 -- 9.7) [@b584],[@b592],[@b623], CXCL3 (Selective) (pIC~50~ 7.8 -- 9.2) [@b563], CXCL2 (Selective) (pIC~50~ 7.0 -- 9.1) [@b563], CXCL5 (Selective) (pIC~50~ 6.9 -- 9.0) [@b563], CXCL7 (Selective) (pIC~50~ 6.3 -- 9.3) [@b563]   CXCL11 (Selective) (10.4 -- 10.5) [@b586], CXCL10 (Selective) (7.8 -- 9.8) [@b586],[@b619], CXCL9 (Selective) (7.3 -- 8.3) [@b586],[@b619]   SDF-1α (Selective) (p*K*~d~ 7.7 -- 8.2) [@b587],[@b594], SDF-1β (Selective) (p*K*~d~ 7.86) [@b587]   CXCL13 (Selective)   CXCL16 (Selective) (p*K*~d~ 9.0) [@b621]
  Endogenous antagonists (p*K*~i~)   --                                                                                             --                                                                                                                                                                                                                                                                                                                                                CCL11 (Selective) (7.2) [@b619], CCL7 (Selective) (6.6) [@b619]                                                                              --                                                                                                   --                   --
  Selective agonists (p*K*~i~)       --                                                                                             --                                                                                                                                                                                                                                                                                                                                                --                                                                                                                                           X4-HIV-1 gp120, ALX40-4C (Partial agonist) (pIC~50~ 6.1) [@b629]                                     --                   --
  Non-selective agonists (p*K*~i~)   --                                                                                             vCXCL-1                                                                                                                                                                                                                                                                                                                                           --                                                                                                                                           --                                                                                                   --                   --
  Selective antagonists (p*K*~i~)    --                                                                                             SB 225002 (pIC~50~ 7.7) [@b620]                                                                                                                                                                                                                                                                                                                   --                                                                                                                                           HIV-Tat, plerixafor (7.0) [@b629], T134 (pIC~50~ 8.4) [@b614]                                        --                   --
  Radioligands (*K*~d~)              \[125I\]CXCL8 (human) (Agonist, Full agonist) (2.51x10^-10^ -- 1.2x10^-9^ M) [@b584],[@b607]   \[125I\]CXCL1 (Agonist, Full agonist), \[125I\]CXCL5 (Agonist, Full agonist), \[125I\]CXCL7 (Agonist, Full agonist), \[125I\]CXCL8 (human) (Agonist, Full agonist) (3.98x10^-10^ -- 1.02x10^-9^ M) [@b584],[@b607]                                                                                                                                \[125I\]CXCL10 (Agonist, Full agonist), \[125I\]CXCL11 (Agonist, Full agonist)                                                               \[125I\]SDF-1α (human) (Agonist, Full agonist) (3.98x10^-9^ -- 7.94x10^-9^ M) [@b576],[@b587]        --                   \[125I\]CXCL16 (Agonist, Full agonist)
  ---------------------------------- ---------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- -------------------- ------------------------------------------

  ------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------- --------------------------------------------------------------------
  Nomenclature                    CX3CR1                                           XCR1                                                                                     DARC
  HGNC, UniProt                   CX3CR1, P49238                                   XCR1, P46094                                                                             DARC, Q16570
  Principal transduction          G~i/o~                                           G~i/o~                                                                                   not defined
  Endogenous agonists (p*K*~i~)   CX3CL1 (Selective) (pIC~50~ 8.9) [@b578]         XCL1 (Selective), XCL2 (Selective)                                                       --
  Endogenous ligands              --                                               --                                                                                       CXCL5, CXCL6, CXCL8, CXCL11, CCL2, CCL5, CCL7, CCL11, CCL14, CCL17
  Selective agonists (p*K*~i~)    --                                               SEAP-XCL1                                                                                --
  Radioligands (*K*~d~)           \[125I\]CX3CL1 (human) (Agonist, Full agonist)   --                                                                                       --
  Comment                         --                                               When fused with secreted alkaline phophatase (SEAP), XCL1 functions as a probe at XCR1   --
  ------------------------------- ------------------------------------------------ ---------------------------------------------------------------------------------------- --------------------------------------------------------------------

  ------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------- --------------------------------------------
  Nomenclature                    ACKR2                                                                   ACKR3                                                  ACKR4                                                           CCRL2
  HGNC, UniProt                   ACKR2, O00590                                                           ACKR3, P25106                                          ACKR4, Q9NPB9                                                   CCRL2, O00421
  Principal transduction          arrestin                                                                arrestin                                               not defined                                                     not defined
  Endogenous agonists (p*K*~i~)   --                                                                      CXCL11, SDF-1α (pEC~50~ 7.52 -- 7.9) [@b581],[@b612]   CCL19 (8.4) [@b618], CCL25 (7.6) [@b618], CCL21 (6.9) [@b618]   --
  Endogenous ligands              CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL22   --                                                     --                                                              chemerin C-terminal peptide, CCL19 [@b567]
  ------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------- --------------------------------------------

Comments
--------

Mouse Cxcr binds iodinated mouse KC (CXCL1) and mouse MIP-2 (CXCL2) with high affinity (mouse KC and MIP-2 are homologues of human CXCL1 (CXCL1, P09341), CXCL2 (CXCL2, P19875) and CXCL3 (CXCL3, P19876)), but shows low affinity for human IL-8 (CXCL8 (IL8, P10145)).

Specific chemokine receptors facilitate cell entry by microbes, such as ACKR1 for *Plasmodium vivax*, and CCR5 for HIV-1. Virally encoded chemokine receptors are known (*e.g.* US28, a homologue of CCR1 from human cytomegalovirus and ORF74, which encodes a homolog of CXCR2 in *Herpesvirus saimiri* and Herpesvirus-68), but their role in viral life cycles is not established. Viruses can exploit or subvert the chemokine system by producing chemokine antagonists and scavengers.

The CC chemokine family (CCL1--28) includes I309 (CCL1 (CCL1, P22362)), MCP-1 (CCL2 (CCL2, P13500)), MIP-1*α* (CCL3 (CCL3, P10147)), MIP-1*β* (CCL4 (CCL4, P13236)), RANTES (CCL5 (CCL5, P13501)), MCP-3 (CCL7 (CCL7, P80098)), MCP-2 (CCL8 (CCL8, P80075)), eotaxin (CCL11 (CCL11, P51671)), MCP-4 (CCL13 (CCL13, Q99616)), HCC-1 (CCL14 (CCL14, Q16627)), Lkn-1/HCC-2 (CCL15 (CCL15, Q16663)), TARC (CCL17 (CCL17, Q92583)), ELC (CCL19 (CCL19, Q99731)), LARC (CCL20 (CCL20, P78556)), SLC (CCL21 (CCL21, O00585)), MDC (CCL22 (CCL22, O00626)), MPIF-1 (CCL23 (CCL23, P55773)), eotaxin-2 (CCL24 (CCL24, O00175)), TECK (CCL25 (CCL25, O15444)), eotaxin (CCL26 (CCL26, Q9Y258)), eskine/CTACK (CCL27 (CCL27, Q9Y4X3)) and MEC (CCL28 (CCL28, Q9NRJ3)). The CXC chemokine family (CXCL1--17) includes GROα (CXCL1 (CXCL1, P09341)), GROβ (CXCL2 (CXCL2, P19875)), GROγ (CXCL3 (CXCL3, P19876)), platelet factor 4 (CXCL4 (PF4, P02776)), ENA78 (CXCL5 (CXCL5, P42830)), GCP-2 (CXCL6 (CXCL6, P80162)), NAP-2 (CXCL7 (PPBP, P02775)), IL-8 (CXCL8 (IL8, P10145)), MIG (CXCL9 (CXCL9, Q07325)), IP10 (CXCL10 (CXCL10, P02778)), I-TAC (CXCL11 (CXCL11, O14625)), SDF-1 (CXCL12, *i.e.* SDF-1α (CXCL12, P48061) and SDF-1β (CXCL12, P48061)), BLC (CXCL13 (CXCL13, O43927)), BRAK (CXCL14 (CXCL14, O95715)), mouse lungkine (CXCL15) SR-PSOX (CXCL16 (CXCL16, Q9H2A7)) and CXCL17 (CXCL17, Q6UXB2). The CX~3~C chemokine (CX3CL1 (CX3CL1, P78423)) is also known as fractalkine (neurotactin in the mouse). Like CXCL16 (CXCL16, Q9H2A7), and unlike other chemokines, CX3CL1 (CX3CL1, P78423) is multimodular containing a chemokine domain, an elongated mucin-like stalk, a transmembrane domain and a cytoplasmic tail. Both plasma membrane-associated and shed forms have been identified. The C chemokine (XCL1 (XCL1, P47992)) is also known as lymphotactin. Two chemokine receptor antagonists have now been approved by the FDA: the CCR5 antagonist maraviroc (Pfizer) for treatment of HIV/AIDS in patients with CCR5-using strains; and the CXCR4 antagonist plerixafor (Plerixifor, from Sanofi) for hematopoietic stem cell mobilization with G-CSF (CSF3, P09919) in patients undergoing transplantation in the context of chemotherapy for lymphoma and multiple myeloma.

Cholecystokinin receptors
=========================

Overview
--------

Cholecystokinin receptors (nomenclature recommended by the NC-IUPHAR Subcommittee on CCK receptors, [@b644]) are activated by the endogenous peptides cholecystokinin-4 (CCK-4 (CCK, P06307)), CCK-8 (CCK, P06307), CCK-33 (CCK, P06307) and gastrin (gastrin-17 (GAST, P01350)). There are only two distinct subtypes of CCK receptors, CCK~1~ and CCK~2~ receptors, with some alternatively spliced forms most often identified in neoplastic cells. The CCK receptor subtypes are distinguished by their peptide selectivity, with the CCK~1~ receptor requiring the carboxyl-terminal heptapeptide-amide that includes a sulfated tyrosine for high affinity and potency, while the CCK~2~ receptor requires only the carboxyl-terminal tetrapeptide shared by both CCK and gastrin peptides. These receptors have characteristic and distinct distributions, with both present in both the central nervous system and peripheral tissues.

  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      CCK1 receptor                                                                                                                                                                                              CCK2 receptor
  HGNC, UniProt                     CCKAR, P32238                                                                                                                                                                                              CCKBR, P32239
  Principal transduction            G~q/11~/G~s~                                                                                                                                                                                               G~s~
  Rank order of potency             CCK-8 \>\> gastrin-17, CCK-8 (desulphated) \> CCK-4                                                                                                                                                        CCK-8 ≥ gastrin-17, CCK-8 (desulphated), CCK-4
  Endogenous agonists (p*K*~i~)     --                                                                                                                                                                                                         CCK-8 (desulphated) (pIC~50~ 8.3 -- 8.7) \[14\], CCK-4 (pIC~50~ 7.5) [@b636]
  Selective agonists (p*K*~i~)      A-71623 (pIC~50~ 8.4 - Rat) \[2\], JMV180 (pIC~50~ 8.3) [@b639], GW-5823 (pIC~50~ 7.6) [@b633]                                                                                                             RB-400 (9.1 - Rat) \[3\], PBC-264 (pIC~50~ 9.1 -- Rat) [@b638], gastrin-17 (pIC~50~ 8.3 - Mouse) [@b634]
  Selective antagonists (p*K*~i~)   devazepide (pIC~50~ 9.7 - Rat) \[8\], T-0632 (pIC~50~ 9.6 - Rat) [@b650], PD-140548 (pIC~50~ 8.6 - Rat) [@b647], lintitript (pIC~50~ 8.3) [@b632], lorglumide (pIC~50~ 6.7 -- 8.2 - Rat) [@b634],[@b637]   YF-476 (pIC~50~ 9.7) \[4,24\], GV150013 (pIC~50~ 9.4) [@b651], L-740093 (pIC~50~ 9.2) [@b643], YM-022 (pIC~50~ 9.2) [@b643], JNJ-26070109 (pIC~50~ 8.5) [@b642], L-365260 (pIC~50~ 8.4) [@b640], RP73870 (pIC~50~ 8.0 - Rat) [@b641], LY262691 (pIC~50~ 7.5 - Rat) [@b646]
  Radioligands(*K*~d~)              \[3H\]devazepide (Antagonist) (2x10^-10^ M) \[5\]                                                                                                                                                          \[3H\]L365260 (Antagonist) (2.9x10^-9^ -- 5.7x10^-9^ M) \[17\], \[3H\]PD140376 (Antagonist) (*K*~i~ 1x10^-10^ -- 2x10^-10^ M -- Guinea pig) [@b635], \[125I\]PD142308 (Antagonist) (*K*~i~ 2.5x10^-10^ M), \[125I\]-BDZ2 (Antagonist) (*K*~i~ 3.98x10^-9^ M) [@b631], \[125I\]DTyr-Gly-\[(Nle28,31)CCK-26-33 (Agonist, Full agonist) (IC~50~ 1x10^-9^ M) [@b645], \[125I\]gastrin (Agonist, Full agonist) (IC~50~ 1x10^-9^ M), \[3H\]gastrin (Agonist, Full agonist) (IC~50~ 1x10^-9^ M)
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

While a cancer-specific CCK receptor has been postulated to exist, which also might be responsive to incompletely processed forms of CCK (Gly-extended forms), this has never been isolated. An alternatively spliced form of the CCK~2~ receptor in which intron 4 is retained, adding 69 amino acids to the intracellular loop 3 (ICL3) region, has been described to be present particularly in certain neoplasms where mRNA mis-splicing has been commonly observed [@b648], but it is not clear that this receptor splice form plays a special role in carcinogenesis. Another alternative splicing event for the CCK~2~ receptor was reported [@b649], with alternative donor sites in exon 4 resulting in long (452 amino acids) and short (447 amino acids) forms of the receptor differing by five residues in ICL3, however, no clear functional differences have been observed.

Complement peptide receptors
============================

Formerly known as: Anaphylatoxin receptors
------------------------------------------

### Overview

Complement peptide receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Complement peptide receptors, see [@b665]) are activated by the endogenous ∼75 amino-acid anaphylatoxin polypeptides C3a (C3, P01024). C4a (C4A, P0C0L4) and C5a (C5, P01031), generated upon stimulation of the complement cascade.

  --------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  Nomenclature                      C3a receptor                                                          C5a1 receptor                                                                                                                                                           C5a2 receptor
  HGNC, UniProt                     C3AR1, Q16581                                                         C5AR1, P21730                                                                                                                                                           C5AR2, Q9P296
  Principal transduction            G~i/o~, G~z~                                                          G~i/o~, G~z~, G~16~ (Buhl *et al*., 1993)                                                                                                                               --
  Rank order of potency             C3a \> C5a [@b653]                                                    C5a, C5a des-Arg (C5) \> C3a [@b653]                                                                                                                                    --
  Endogenous agonists (p*K*~i~)     --                                                                    RP-S19 (RPS19, P39019) [@b675]                                                                                                                                          --
  Selective agonists (p*K*~i~)      E7 (pEC~50~ 8.7) [@b654]                                              N-methyl-Phe-Lys-Pro-D-Cha-Cha-D-Arg-CO2H (pIC~50~ 7.6) [@b664],[@b666]                                                                                                 --
  Selective antagonists (p*K*~i~)   SB290157 (pIC~50~ 7.6) [@b652]                                        CHIPS (p*K*~d~ 9.0) [@b670], W54011 (8.7) [@b672], AcPhe-Orn-Pro-D-Cha-Trp-Arg (pIC~50~ 7.9) [@b674], N-methyl-Phe-Lys-Pro-D-Cha-Trp-D-Arg-CO2H (pIC~50~ 7.2) [@b666]   --
  Radioligands (*K*~d~)             \[125I\]C3a (human) (Agonist, Full agonist) (3.85x10^-9^ M) [@b657]   \[125I\]C5a (human) (Agonist, Full agonist) (2x10^-9^ M) [@b661]                                                                                                        \[125I\]C5a (human) (Agonist, Full agonist)
  Comment                           --                                                                    --                                                                                                                                                                      Binds C5a complement factor, but appears to lack G protein signalling and has been termed a decoy receptor [@b671]
  --------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------

Comments
========

SB290157 has also been reported to have agonist properties at the C3a receptor [@b668]. The putative chemoattractant receptor termed C5a~2~ (also known as GPR77, C5L2) binds \[^125^I\]C5a with no clear signalling function, but has a putative role opposing inflammatory responses [@b656],[@b658],[@b659]. Binding to this site may be displaced with the rank order C5a des-Arg (C5)\> C5a (C5, P01031) [@b656],[@b669] while there is controversy over the ability of C3a (C3, P01024) and C3a des Arg (C3, P01024) to compete [@b660],[@b662],[@b663],[@b669]. C5a~2~ appears to lack G protein signalling and has been termed a decoy receptor [@b671]. However, C5a~2~ does recruit β-arrestin after ligand binding, which might provide a signaling pathway for this receptor [@b655],[@b673]. There are also reports of pro-inflammatory activity of C5a~2~, mediated by HMGB1, but the signaling pathway that underlies this is currently unclear (reviewed in [@b667]).

Corticotropin-releasing factor receptors
========================================

Overview
--------

Corticotropin-releasing factor (CRF, nomenclature as recommended by the NC-IUPHAR sub-committee on Corticotropin-releasing Factor Receptors, [@b682]) receptors are activated by the endogenous peptides CRF (CRH, P06850), a 41 amino-acid peptide, urocortin 1 (UCN, P55089), 40 amino-acids), urocortin 2 (UCN2, Q96RP3), 38 amino-acids) and urocortin 3 (UCN3, Q969E3), 38 amino-acids). CRF1 and CRF2 receptors are activated non-selectively by CRF (CRH, P06850) and urocortin 1 (UCN, P55089). Binding to CRF receptors can be conducted using \[^125^I\]Tyr^0^-CRF or \[125I\]Tyr0-sauvagine with *K*^d^ values of 0.1--0.4 nM. CRF1 and CRF2 receptors are non-selectively antagonized by α-helical CRF, D-Phe-CRF-(12-41) and astressin.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Nomenclature                      CRF1 receptor                                                                                                                                                                                                                                                                     CRF2 receptor
  HGNC, UniProt                     CRHR1, P34998                                                                                                                                                                                                                                                                     CRHR2, Q13324
  Principal transduction            G~s~                                                                                                                                                                                                                                                                              G~s~
  Endogenous agonists               --                                                                                                                                                                                                                                                                                urocortin 2 (Selective) (p*K*~d~ 8.5 -- 8.6) [@b679], urocortin 3 (Selective) (p*K*~d~ 7.9 -- 8.0) [@b679]
  Selective antagonists (p*K*~i~)   SSR125543A (8.7) [@b681], antalarmin (8.3 -- 9.0) [@b688], DMP696 (8.3 -- 9.0) [@b683], NBI27914 (8.3 -- 9.0) [@b677], R121919 (8.3 -- 9.0) [@b689], CP 154,526 (pIC~50~ 9.3 -- 10.4 - Rat) [@b685], CP376395 (pIC~50~ 8.3 - Rat) [@b678], CRA1000 (pIC~50~ 6.4 -- 7.1) [@b676]   antisauvagine (p*K*~d~ 8.8 -- 9.6) [@b680], K41498 (9.2) [@b684], K31440 (8.7 -- 8.8) [@b687]
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------

Comments
========

A CRF binding protein has been identified (CRHBP, P24387) to which both CRF and urocortin 1 bind with high affinities, which has been suggested to bind and inactivate circulating CRF [@b686].

Dopamine receptors
==================

Overview
--------

Dopamine receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Dopamine Receptors, [@b723]) are commonly divided into D~1~-like (D~1~ and D~5~) and D~2~-like (D~2~, D~3~ and D~4~) families, where the endogenous agonist is dopamine.

  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Nomenclature                                  D1 receptor                                                                                                                                                                                                                D5 receptor                                                                                                                                                                                                                D2 receptor                                                                                              D3 receptor                                                                                                                                                                D4 receptor
  HGNC, UniProt                                 DRD1, P21728                                                                                                                                                                                                               DRD5, P21918                                                                                                                                                                                                               DRD2, P14416                                                                                             DRD3, P35462                                                                                                                                                               DRD4, P21917
  Principal transduction                        G~s~, G~olf~                                                                                                                                                                                                               G~s~                                                                                                                                                                                                                       G~i/o~                                                                                                   G~i/o~                                                                                                                                                                     G~i/o~
  (Sub)family-selective agonists (p*K*~i~)      A68930 (pEC~50~ 6.82) [@b712]                                                                                                                                                                                              A68930 (pEC~50~ 6.6) [@b712]                                                                                                                                                                                               quinpirole (4.9--7.7) [@b693],[@b706],[@b713],[@b724],[@b725],[@b729]                                    quinpirole (6.4--8.0) [@b693],[@b706],[@b710],[@b713],[@b724],[@b725],[@b729]                                                                                              quinpirole (7.5) [@b709],[@b713],[@b729]
  Selective agonists (p*K*~i~)                  SKF-81297 (8.7 - Rat) [@b691], SKF-38393 (6.2--6.8) [@b726],[@b727]                                                                                                                                                        --                                                                                                                                                                                                                         sumanirole (8.1) [@b705]                                                                                 PD 128907 (7.6--7.7) [@b715],[@b720]                                                                                                                                       PD168,077 (Partial agonist) (8.8 - Rat) [@b700], A412997 (8.1 - Rat) [@b711]
  (Sub)family-selective antagonists (p*K*~i~)   SKF-83556 (9.5) [@b726], SCH-23390 (7.4--9.5) [@b726],[@b727], ecopipam (8.3) [@b728]                                                                                                                                      SKF-83556 (9.4) [@b726], SCH-23390 (7.5--9.5) [@b726], ecopipam (8.3) [@b726]                                                                                                                                              haloperidol (7.4--8.8) [@b695],[@b704],[@b706],[@b724],[@b728]                                           haloperidol (7.5--8.0) [@b695],[@b724],[@b728]                                                                                                                             haloperidol (8.7) [@b703],[@b728]
  Selective antagonists (p*K*~i~)               --                                                                                                                                                                                                                         --                                                                                                                                                                                                                         L-741,626 (7.9--8.5) [@b696],[@b701], domperidone (7.9--8.4) [@b695],[@b724], raclopride (8.0) [@b710]   S33084 (9.6) [@b708], nafadotride (9.52) [@b721], PG01037 (9.2) [@b697], NGB 2904 (8.8) [@b730], SB 277011-A (8.0) [@b716], (+)-S-14297 (7.9) [@b707]                      L745870 (9.4) [@b701], sonepiprazole (8.9) [@b722], L741742 (8.5) [@b719]
  (Sub)family-selective radioligands (*K*~d~)   \[3H\]SCH-23390 (Antagonist) (3x10^−10^ M) [@b732]                                                                                                                                                                         \[3H\]SCH-23390 (Antagonist) (5.8x10^−10^ M) [@b717]                                                                                                                                                                       \[3H\]spiperone (Antagonist) (5.7x10^−11^ M - Rat) [@b692],[@b699],[@b731]                               --                                                                                                                                                                         \[3H\]spiperone (Antagonist) (3x10^−10^ M) [@b698],[@b729]
  Radioligands (*K*~d~)                         \[125I\]SCH23982 (Antagonist) (3.5x10^−10^ M) [@b694]                                                                                                                                                                      \[125I\]SCH23982 (Antagonist) (8x10^−10^ M)                                                                                                                                                                                \[3H\]raclopride (Antagonist) (1.2x10^−9^ M - Rat) [@b702]                                               \[3H\]spiperone (Antagonist) (1.25x10^−10^ M - Rat) [@b699],[@b731], \[3H\]7-OH-DPAT (Agonist) (2.7x10^−10^ M) [@b718], \[3H\]PD128907 (Agonist) (9.9x10^−10^ M) [@b690]   \[125I\]L750667 (Antagonist) (1.6x10^−10^ M) [@b713], \[3H\]NGD941 (Antagonist) (5x10^−9^ M) [@b714]
  Comment                                       A68930 is an agonist with selectivity for D~1~-like receptors [@b712]., SCH-23390 (pKi 9.5) [@b726], SKF-83556 (pKi 9.3) [@b726] and ecopipam (pKi 8.3) [@b728] are antagonists with selectivity for D~1~-like receptors   A68930 is an agonist with selectivity for D~1~-like receptors [@b712]., SCH-23390 (pKi 9.5) [@b726], SKF-83556 (pKi 9.3) [@b726] and ecopipam (pKi 8.3) [@b728] are antagonists with selectivity for D~1~-like receptors   quinpirole is an agonist with selectivity for D~2~-like receptors [@b729]                                quinpirole is an agonist with selectivity for D~2~-like receptors [@b729]                                                                                                  quinpirole is an agonist with selectivity for D~2~-like receptors [@b729]
  --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------

Comments
========

The selectivity of many of these agents is less than two orders of magnitude. \[3H\]raclopride exhibits similar high affinity for D~2~ and D~3~ receptors (low affinity for D~4~), but has been used to label D~2~ receptors in the presence of a D~3~-selective antagonist. \[3H\]7-OH-DPAT has similar affinity for D~2~ and D~3~ receptors, but labels only D~3~ receptors in the absence of divalent cations. The pharmacological profile of the D~5~ receptor is similar to, yet distinct from, that of the D~1~ receptor. The splice variants of the D~2~ receptor are commonly termed D~2S~ and D~2L~ (short and long). The *DRD4* gene encoding the D~4~ receptor is highly polymorphic in humans, with allelic variations of the protein from amino acid 387 to 515.

Endothelin receptors
====================

Overview
--------

Endothelin receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on endothelin receptors, [@b736]) are activated by the endogenous 21 amino-acid peptides endothelins 1--3 (ET-1 (EDN1, P05305), ET-2 (EDN2, P20800) and ET-3 (EDN3, P14138)).

  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                  ETA receptor                                                                                                                                                                                                                    ETB receptor
  HGNC, UniProt                                 EDNRA, P25101                                                                                                                                                                                                                   EDNRB, P24530
  Principal transduction                        G~q/11~, G~s~                                                                                                                                                                                                                   G~q/11~, G~i/o~
  Family selective agonists                     ET-1 = ET-2 \> ET-3 [@b744]                                                                                                                                                                                                     ET-1 = ET-2, ET-3
  (Sub)family-selective antagonists (p*K*~i~)   TAK 044 (p*A*~2~ 8.4 - Rat) [@b755], bosentan (p*A*~2~ 7.2 - Rat) [@b735], SB209670 (p*K*~B~ 9.4 - Rat) [@b739]                                                                                                                 --
  Selective agonists (p*K*~i~)                  --                                                                                                                                                                                                                              sarafotoxin S6c (p*K*~d~ 8.8--9.8) [@b743],[@b752], \[Ala1,3,11,15\]ET-1 (p*K*~d~ 8.7--9.2) [@b747], BQ 3020 (9.7) [@b751], IRL 1620 (8.7) [@b754]
  (Sub)family-selective antagonists (p*K*~i~)   --                                                                                                                                                                                                                              TAK 044 (p*A*~2~ 8.4 - Rat) [@b755], bosentan (p*A*~2~ 6.0 - Rat) [@b735], SB209670 (p*K*~B~ 9.4 - Rat) [@b739]
  Selective antagonists (p*K*~i~)               A127722 (p*A*~2~ 9.2--10.5) [@b749], BQ123 (p*A*~2~ 6.9--7.4) [@b744], ambrisentan (p*A*~2~ 7.1) [@b733], PD-156707 (p*K*~d~ 9.0--9.8) [@b745], FR139317 (Inverse agonist) (pIC~50~ 7.3--7.9) [@b744]                           A192621 (p*K*~d~ 8.1) [@b753], BQ788 (p*K*~d~ 7.9--8.0) [@b752], IRL 2500 (p*K*~d~ 7.2) [@b752], RO4868443 (pIC~50~ 7.2) [@b734]
  Radioligands (*K*~d~)                         \[125I\]PD164333 (Antagonist) (1.58x10^−10^--2.5x10^−10^ M) [@b737], \[3H\]S0139 (Antagonist) (6x10^−10^ M), \[125I\]PD151242 (Antagonist) (7.9x10^−10^--1x10^−9^ M) [@b738], \[3H\]BQ123 (Antagonist) (3.2x10^−9^ M) [@b742]   \[125I\]IRL1620 (Agonist, Full agonist) (7.9x10^−11^--1.26x10^−10^ M) [@b748], \[125I\]\[Ala1,3,11,15\]ET-1 (Agonist, Full agonist) (2x10^−10^ M) [@b747], \[125I\]BQ3020 (Agonist, Full agonist) (1x10^−10^--5x10^−9^ M) [@b740],[@b747],[@b750]
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

Splice variants of the ETA receptor have been identified in rat pituitary cells; one of these, ET~A~R-C13, appeared to show loss of function with comparable plasma membrane expression [@b741]. Subtypes of the ET~B~ receptor have been proposed, although gene disruption studies in mice suggest that the heterogeneity results from a single gene product [@b746].

Estrogen (G protein-coupled) receptor
=====================================

Overview
--------

The G protein-coupled estrogen receptor (GPER, provisional nomenclature) was identified following observations of estrogen-evoked cAMP signalling in breast cancer cells [@b756], which mirrored the differential expression of an orphan 7-transmembrane receptor GPR30 [@b758]. There are observations of both cell-surface and intracellular expression of the GPER receptor [@b763],[@b764].

  -------------- --------------- ------------------------------ ------------------------------ ------------------------------------------------------------- --------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Principal transduction         Selective agonists (p*K*~i~)   Selective antagonists (p*K*~i~)                               Radioligands (*K*~d~)
  GPER           GPER1, Q99527   G~s~ [@b761], G~i/o~ [@b763]   G-1 (8.0) [@b757]              G36 (pIC~50~ 6.78--6.95) [@b760], G15 (pIC~50~ 6.7) [@b759]   \[3H\]17β-estradiol (Agonist, Full agonist) (2.7x10^−9^--3.3x10^−9^ M) [@b764]
  -------------- --------------- ------------------------------ ------------------------------ ------------------------------------------------------------- --------------------------------------------------------------------------------

Comments
========

Antagonists at the nuclear estrogen receptor, such as fulvestrant and tamoxifen [@b761], as well as the flavonoid 'phytoestrogens' genistein and quercetin [@b762], are agonists at GPER receptors.

Formylpeptide receptors
=======================

Overview
--------

The formylpeptide receptors, nomenclature agreed by NC-IUPHAR Subcommittee on the formyl peptide receptor family, [@b787]) respond to exogenous ligands such as the bacterial product fMet-Leu-Phe (fMLP) and endogenous ligands such as annexin I (ANXA1, P04083), cathepsin G (CTSG, P08311), amyloid β42, serum amyloid A and spinorphin, derived from β-haemoglobin (HBB, P68871).

  ---------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  Nomenclature                       FPR1                                                                                                  FPR2/ALX                                                                                                                                                                         FPR3
  HGNC, UniProt                      FPR1, P21462                                                                                          FPR2, P25090                                                                                                                                                                     FPR3, P25089
  Principal transduction             G~i/o~, G~z~                                                                                          G~i~ [@b778]                                                                                                                                                                     --
  Rank order of potency              fMet-Leu-Phe \> cathepsin G (CTSG, P08311) \> annexin I [@b776],[@b783]                               LXA4=aspirin triggered lipoxin A4=ATLa2\>LTC4=LTD4\>\>15-deoxy-LXA4\>\>fMet-Leu-Phe [@b765],[@b766],[@b768],[@b770],[@b784]                                                      --
  Selective agonists (p*K*~i~)       fMet-Leu-Phe (pEC~50~ 10.1--10.2) [@b769],[@b782]                                                     --                                                                                                                                                                               --
  Endogenous antagonists (p*K*~i~)   spinorphin (Selective) (pIC~50~ 4.3) [@b777],[@b780]                                                  aspirin triggered lipoxin A4 (Selective), LXA4 (Selective) (pEC~50~ ∼12.0) [@b775], resolvin D1 (Selective) (pEC~50~ ∼11.9) [@b775]                                              --
  Endogenous agonists(pKi)           F2L (HEBP1, Q9NRV9) (Selective) (pEC~50~ 8.0--8.2) [@b779]                                            --                                                                                                                                                                               --
  Selective antagonists (p*K*~i~)    cyclosporin H (6.1--7.1) [@b785],[@b786], t-Boc-FLFLF (6.0--6.5) [@b785]                              ATLa2 [@b771]                                                                                                                                                                    --
  Radioligands (*K*~d~)              \[3H\]fMet-Leu-Phe (Agonist, Full agonist) (5×10^−10^--2.51×10^−8^ M) [@b774]                         \[3H\]LXA4 (Agonist, Full agonist) (5×10^−10^--7×10^−10^ M) [@b766],[@b767]                                                                                                      --
  Comment                            A FITC-conjugated fMLP analogue has been used for binding to the mouse recombinant receptor [@b773]   The agonist activity of the lipid mediators described has been questioned [@b772],[@b781], which may derive from batch-to-batch differences, partial agonism or biased agonism   --
  ---------------------------------- ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------

Comments
========

Note that the data for FPR2ALX are also reproduced on the leukotriene receptor page.

Free fatty acid receptors
=========================

Overview
--------

Free fatty acid receptors (FFA, nomenclature as agreed by NC-IUPHAR Subcommittee on free fatty acid receptors, [@b792],[@b814]) are activated by free fatty acids. Long-chain saturated and unsaturated fatty acids (C14.0 (myristic acid), C16:0 (palmitic acid), C18:1 (oleic acid), C18:2 (linoleic acid), C18:3, (α-linolenic acid), C20:4 (arachidonic acid), C20:5,n-3 (EPA), C22:6,n-3 (docosahexaenoic acid)) activate FFA~1~ [@b789],[@b797],[@b799] and FFA4 receptors [@b793],[@b796],[@b807], while short chain fatty acids (C2 (acetic acid), C3 (propanoic acid), C4 (butyric acid) and C5 (pentanoic acid)) activate FFA~2~ [@b790],[@b801],[@b806] and FFA~3~ [@b790],[@b801] receptors. In addition, thiazolidinedione PPARγ agonists such as rosiglitazone activate FFA~1~ (pEC~50~ 5.2; [@b800],[@b811],[@b813]) and small molecule allosteric modulators, such as 4-CMTB, have recently been characterised for FFA~2~ [@b795],[@b802],[@b812].

  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                               FFA1 receptor                                                                                                                                                                                                                                                                                                                                                                                                                                          FFA2 receptor                                                                                                                                                                                                                                                                                                      FFA3 receptor                                                                                                                                                                                                                                                   FFA4 receptor
  HGNC, UniProt                              FFAR1, O14842                                                                                                                                                                                                                                                                                                                                                                                                                                          FFAR2, O15552                                                                                                                                                                                                                                                                                                      FFAR3, O14843                                                                                                                                                                                                                                                   FFAR4, Q5NUL3
  Principal transduction                     G~q/11~ [@b789],[@b797],[@b809],[@b813]                                                                                                                                                                                                                                                                                                                                                                                                                G~q/11~, G~i/o~ [@b790],[@b801],[@b806],[@b808]                                                                                                                                                                                                                                                                    G~i/o~ [@b790],[@b801],[@b808],[@b813]                                                                                                                                                                                                                          G~q/11~ [@b793],[@b807],[@b810],[@b819]
  Endogenous agonists (p*K*~i~)              docosahexaenoic acid (pEC~50~ 5.4--6.0) [@b789],[@b797]                                                                                                                                                                                                                                                                                                                                                                                                --                                                                                                                                                                                                                                                                                                                 --                                                                                                                                                                                                                                                              α-linolenic acid (pEC~50~ 5.5) [@b810]
  (Sub)family-selective agonists (p*K*~i~)   α-linolenic acid (pEC~50~ 4.6--5.7) [@b789],[@b797],[@b799], myristic acid (pEC~50~ 4.5--5.1) [@b789],[@b797],[@b799], oleic acid (pEC~50~ 3.9--5.7) [@b789],[@b797],[@b799]                                                                                                                                                                                                                                                                           propanoic acid (pEC~50~ 3.0--4.9) [@b790],[@b801],[@b806],[@b808], acetic acid (pEC~50~ 3.1--4.6) [@b790],[@b801],[@b806],[@b808], trans-2-methylcrotonic acid (pEC~50~ 3.8) [@b808], butyric acid (pEC~50~ 2.9--4.6) [@b790],[@b801],[@b806],[@b808], 1-methylcyclopropanecarboxylic acid (pEC~50~ 2.6) [@b808]   propanoic acid (pEC~50~ 3.9--5.7) [@b790],[@b801],[@b808],[@b820], butyric acid (pEC~50~ 3.8--4.9) [@b790],[@b801],[@b808],[@b820], 1-methylcyclopropanecarboxylic acid (pEC~50~ 3.9) [@b808], acetic acid (pEC~50~ 2.8--3.9) [@b790],[@b801],[@b808],[@b820]   myristic acid (pEC~50~ 5.2) [@b819], oleic acid (pEC~50~ 4.7) [@b819]
  Selective agonists (p*K*~i~)               AMG-837 (pEC~50~ 8.5) [@b804], TUG-770 (pEC~50~ 8.2) [@b791], GW9508 (pEC~50~ 7.3) [@b788], TAK-875 (pEC~50~ 7.1) [@b817], linoleic acid (pEC~50~ 4.4--5.7) [@b789],[@b797],[@b799]                                                                                                                                                                                                                                                                    3-benzyl-4-(cyclopropyl-(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid (pEC~50~ 7.1 - Rat) [@b794], (S)-4-CMTB (pEC~50~ 6.4) [@b795],[@b802]                                                                                                                                                        --                                                                                                                                                                                                                                                              TUG-891 (pEC~50~ 7.0) [@b810], NCG21 (pEC~50~ 5.92) [@b816]
  Selective antagonists (p*K*~i~)            GW1100 (pIC~50~ 6.0) [@b788]                                                                                                                                                                                                                                                                                                                                                                                                                           CATPB (pIC~50~ 6.5) [@b795]                                                                                                                                                                                                                                                                                        --                                                                                                                                                                                                                                                              --
  Comment                                    Antagonist GW1100 has been shown to reduce \[^35^S\]GTPγS binding in *FFAR1*-expressing cells [@b813]. GW1100 is also an oxytocin receptor antagonist [@b788]. TUG770 and GW9508 are both approximately 100 fold selective for FFA1 over FFA4 [@b788],[@b791]. AMG837 and the related analogue AM6331 have been suggested to have an allosteric mechanism of action at FFA1, with respect to the orthosteric fatty acid binding site [@b804],[@b821]   --                                                                                                                                                                                                                                                                                                                 Beta-hydroxybutyrate has been reported to antagonise FFA3 responses to short chain fatty acids [@b798]. trans-2-methylcrotonic acid is a weak agonist for FFA3, with a pEC of below 1 [@b808]                                                                   TUG891 exhibits 50--1000 fold selectivity for FFA4 over FFA1, dependent on the assay [@b810]. NGC21 exhibits approximately 15 fold selectivity for FFA4 over FFA1 [@b815]
  ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Short (361 amino acids) and long (377 amino acids) splice variants of human FFA4 have been reported [@b805], which differ by a 16 amino acid insertion in intracellular loop 3, and exhibit differences in intracellular signalling properties in recombinant systems [@b819]. The long FFA4 splice variant has not been identified in other primates or rodents to date [@b793],[@b805].

GPR42 was originally described as a pseudogene within the family (ENSFM00250000002583), but the recent discovery of several polymorphisms suggests that some versions of GPR42 may be functional [@b803]. GPR84 is a structurally-unrelated G protein-coupled receptor which has been found to respond to medium chain fatty acids [@b818].

Frizzled Class GPCRs
====================

Overview
--------

Receptors of the Class Frizzled (FZD, nomenclature as agreed by the NC-IUPHAR subcommittee [@b832]), are GPCRs originally identified in *Drosophila* [@b825], which are highly conserved across species. FZDs are activated by WNTs, which are cysteine-rich lipoglycoproteins with fundamental functions in ontogeny and tissue homeostatis. FZD signalling was initially divided into two pathways, being either dependent on the accumulation of the transcription regulator β-catenin (CTNNB1, P35222) or being β-catenin-independent (often referred to as canonical vs non-canonical WNT/FZD signalling, respectively). WNT stimulation of FZDs can, in cooperation with the low density lipoprotein receptors LRP5 (O75197) and LRP6 (O75581), lead to the inhibition of a constitutively active destruction complex, which results in the accumulation of β-catenin and subsequently its translocation to the nucleus. β-Catenin, in turn, modifies gene transcription by interacting with TCF/LEF transcription factors. β-Catenin-independent FZD signalling is far more complex with regard to the diversity of the activated pathways. WNT/FZD signalling can lead to the activation of pertussis toxin-sensitive heterotrimeric G proteins [@b830], the elevation of intracellular calcium [@b833], activation of cGMP-specific PDE6 [@b822] and elevation of cAMP as well as RAC-1, JNK, Rho and Rho kinase signalling [@b828]. Furthermore, the phosphoprotein Disheveled constitutes a key player in WNT/FZD signalling. As with other GPCRs, members of the Frizzled family are functionally dependent on the β-arrestin scaffolding protein for internalization [@b826], β-catenin-dependent [@b823] and -independent [@b824],[@b831] signalling. The pattern of cell signalling is complicated by the presence of additional ligands, which can enhance or inhibit FZD signalling (secreted Frizzled-related proteins (sFRP), Wnt-inhibitory factor (WIF1, Q9Y5W5) (WIF), Sclerostin (SOST (SOST, Q9BQB4)) or Dickkopf (DKK)), as well as modulatory (co)-receptors with positive Ryk, ROR1, ROR2 and Kremen, which may also function as independent signalling proteins.

  --------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------- -------------
  Nomenclature    FZD1           FZD2           FZD3           FZD4           FZD5           FZD6           FZD7           FZD8           FZD9           FZD10           SMO
  HGNC, UniProt   FZD1, Q9UP38   FZD2, Q14332   FZD3, Q9NPG1   FZD4, Q9ULV1   FZD5, Q13467   FZD6, O60353   FZD7, O75084   FZD8, Q9H461   FZD9, O00144   FZD10, Q9ULW2   SMO, Q99835
  --------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------- -------------

Comments
========

There is limited knowledge about WNT/FZD specificity and which molecular entities determine the signalling outcome of a specific WNT/FZD pair. Understanding of the coupling to G proteins is incomplete (see [@b827]). There is also a scarcity of information on basic pharmacological characteristics of FZDs, such as binding constants, ligand specificity or concentration--response relationships [@b829].

Ligands associated with FZD signalling
--------------------------------------

***WNTs***: Wnt-1 (WNT1, P04628), Wnt-2 (WNT2, P09544) (also known as Int-1-related protein), Wnt-2b (WNT2B, Q93097) (also known as WNT-13), Wnt-3 (WNT3, P56703), Wnt-3a (WNT3A, P56704), Wnt-4 (WNT4, P56705), Wnt-5a (WNT5A, P41221), Wnt-5b (WNT5B, Q9H1J7), Wnt-6 (WNT6, Q9Y6F9), Wnt-7a (WNT7A, O00755), Wnt-7b (WNT7B, P56706), Wnt-8a (WNT8A, Q9H1J5), Wnt-8b (WNT8B, Q93098), Wnt-9a (WNT9A, O14904) (also known as WNT-14), Wnt-9b (WNT9B, O14905) (also known as WNT-15 or WNT-14b), Wnt-10a (WNT10A, Q9GZT5), Wnt-10b (WNT10B, O00744) (also known as WNT-12), Wnt-11 (WNT11, O96014) and Wnt-16 (WNT16, Q9UBV4).

***Extracellular proteins that interact with FZDs*:** norrin (NDP, Q00604), R-spondin-1 (RSPO1, Q2MKA7), R-spondin-2 (RSPO2, Q6UXX9), R-spondin-3 (RSPO3, Q9BXY4), R-spondin-4 (RSPO4, Q2I0M5), sFRP-1 (SFRP1, Q8N474), sFRP-2 (SFRP2, Q96HF1), sFRP-3 (FRZB, Q92765), sFRP-4 (SFRP4, Q6FHJ7), sFRP-5 (SFRP5, Q6FHJ7).

***Extracellular proteins that interact with WNTs or LRPs:*** Dickkopf 1 (DKK1, O94907), WIF1 (Q9Y5W5), SOST (SOST, Q9BQB4), kremen 1 (KREMEN1, Q96MU8) and kremen 2 (KREMEN2, Q8NCW0)

***Small exogenous ligands:*** Foxy-5, Box-5, UM206, and XWnt8 also known as mini-Wnt8.

GABAB receptors
===============

Overview
--------

Functional GABA~B~ receptors (nomenclature agreed by NC-IUPHAR Subcommittee on GABA~B~ receptors, [@b839],[@b860]) are formed from the heterodimerization of two similar 7TM subunits termed GABA~B1~ (GABBR1, Q9UBS5) and GABA~B2~ (GABBR2, O75899) [@b839],[@b843],[@b859],[@b860],[@b866]. GABA~B~ receptors are widespread in the CNS and regulate both pre- and post-synaptic activity. The GABA~B1~ subunit, when expressed alone, binds both antagonists and agonists, but the affinity of the latter is generally 10--100-fold less than for the native receptor. The GABA~B1~ subunit when expressed alone is not transported to the cell membrane and is non-functional. Co-expression of GABA~B1~ and GABA~B2~ subunits allows transport of GABA~B1~ to the cell surface and generates a functional receptor that can couple to signal transduction pathways such as high-voltage-activated Ca^2+^ channels (Ca~v~2.1, Ca~v~2.2), or inwardly rectifying potassium channels (Kir3) [@b837],[@b839],[@b840]. The GABA~B2~ subunit also determines the rate of internalisation of the dimeric GABA~B~ receptor [@b850]. The GABA~B1~ subunit harbours the GABA (orthosteric)-binding site within an extracellular domain (ECD) venus flytrap module (VTM), whereas the GABA~B2~ subunit mediates G-protein-coupled signalling [@b839],[@b849],[@b859]. The two subunits interact by direct allosteric coupling [@b857], such that GABA~B2~ increases the affinity of GABA~B1~ for agonists and reciprocally GABA~B1~ facilitates the coupling of GABA~B2~ to G proteins [@b855],[@b859]. GABA~B1~ and GABA~B2~ subunits assemble in a 1:1 stoichiometry by means of a coiled-coil interaction between α-helices within their carboxy-termini that masks an endoplasmic reticulum retention motif (RXRR) within the GABA~B1~ subunit but other domains of the proteins also contribute to their heteromerization [@b837],[@b859]. Recent evidence indicates that higher order assemblies of GABA~B~ receptor comprising dimers of heterodimers occur in recombinant expression systems and *in vivo* and that such complexes exhibit negative functional cooperativity between heterodimers [@b841],[@b858]. Adding further complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16 associate as tetramers with the carboxy terminus of the GABA~B2~ subunit to impart altered signalling kinetics and agonist potency to the receptor complex [@b835],[@b864] and reviewed by [@b861]. Four isoforms of the human GABA~B1~ subunit have been cloned. The predominant GABA~B1(a)~ and GABA~B1(b)~ isoforms, which are most prevalent in neonatal and adult brain tissue respectively, differ in their ECD sequences as a result of the use of alternative transcription initiation sites. GABA~B1(a)~-containing heterodimers localise to distal axons and mediate inhibition of glutamate release in the CA3--CA1 terminals, and GABA release onto the layer 5 pyramidal neurons, whereas GABA~B1(b)~-containing receptors occur within dendritic spines and mediate slow postsynaptic inhibition [@b862],[@b868]. Isoforms generated by alternative splicing are GABA~B1(c)~ that differs in the ECD, and GABA~B1(e)~, which is a truncated protein that can heterodimerize with the GABA~B2~ subunit but does not constitute a functional receptor. Only the 1a and 1b variants are identified as components of native receptors [@b839]. Additional GABA~B1~ subunit isoforms have been described in rodents and humans [@b856] and reviewed by [@b837].

  ---------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature     Principal transduction   Selective agonists (p*K*~i~)                                                                                                        Selective antagonists (p*K*~i~)                                                                                                                                                Radioligands (*K*~d~)
  GABAB receptor   G~i/o~                   3-APPA (5.2--7.2) [@b851], 3-APMPA (5.1) [@b869], CGP 44532 (pIC~50~ 8.6 - Rat) [@b846], (-)-baclofen (pIC~50~ 8.5 - Rat) [@b846]   CGP 62349 (8.5--8.9) [@b851],[@b869], CGP 55845 (7.8) [@b869], SCH 50911 (5.5--6.0) [@b851],[@b869], CGP 35348 (4.4) [@b869], 2-hydroxy-saclofen (pIC~50~ 4.1 - Rat) [@b853]   \[3H\](R)-(-)-baclofen (Agonist), \[3H\]CGP 62349 (Antagonist) (9x10^-10^ M - Rat) [@b854], \[125I\]CGP 64213 (Antagonist) (1x10^-9^ M - Rat) [@b847], \[125I\]CGP 71872 (Antagonist) (1x10^-9^ M - Rat) [@b853], \[3H\]CGP 54626 (Antagonist) (*K*~i~ 7.9x10^-10^ M - Rat) [@b852]
  ---------------- ------------------------ ----------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

Potencies of agonists and antagonists listed in the table, quantified as IC~50~ values for the inhibition of \[3H\]CGP27492 binding to rat cerebral cortex membranes, are from [@b839],[@b845],[@b846]. Radioligand *K*~D~ values relate to binding to rat brain membranes. CGP 71872 is a photoaffinity ligand for the GABA~B1~ subunit [@b836]. CGP27492 (3-APPA), CGP35024 (3-APMPA) and CGP 44532 act as antagonists at human GABA~A~ ρ1 receptors, with potencies in the low micromolar range [@b845]. In addition to the ligands listed in the table, Ca2+ binds to the VTM of the GABA~B1~ subunit to act as a positive allosteric modulator of GABA [@b847]. In cerebellar Purkinje neurones, the interaction of Ca2+ with the GABA~B~ receptor enhances the activity of mGlu~1~, through functional cross-talk involving G-protein Gβγ subunits [@b863],[@b865]. Synthetic positive allosteric modulators with low, or no, intrinsic activity include CGP7930, GS39783, BHF-177 and (+)-BHFF [@b834],[@b837],[@b838],[@b845]. The site of action of CGP7930 and GS39783 appears to be on the heptahelical domain of the GABA~B2~ subunit [@b842],[@b859]. In the presence of CGP7930, or GS39783, CGP 35348 and 2-hydroxy-saclofen behave as partial agonists [@b845]. Knock-out of the GABA~B1~ subunit in C57B mice causes the development of severe tonic-clonic convulsions that prove fatal within a month of birth, whereas GABA~B1~^−/−^ BALB/c mice, although also displaying spontaneous epileptiform activity, are viable. The phenotype of the latter animals additionally includes hyperalgesia, hyperlocomotion (in a novel, but not familiar, environment), hyperdopaminergia, memory impairment and behaviours indicative of anxiety [@b844],[@b867]. A similar phenotype has been found for GABA~B2~^−/−^ BALB/c mice [@b848].

Galanin receptors
=================

Overview
--------

Galanin receptors (provisional nomenclature, [@b876]) are activated by the endogenous peptides galanin (GAL, P22466) and galanin-like peptide (GALP, Q9UBC7). Human galanin (GAL, P22466) is a 30 amino-acid non-amidated peptide [@b874]; in other species, it is 29 amino acids long and C-terminally amidated. Amino acids 1--14 of galanin are highly conserved in mammals, birds, reptiles, amphibia and fish. Shorter peptide species (*e.g*. human galanin-1--19 [@b872] and porcine galanin-5--29 [@b885] and N-terminally extended forms (*e.g.* N-terminally seven and nine residue elongated forms of porcine galanin [@b873],[@b885]) have been reported.

  --------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ -----------------------------------------
  Nomenclature                      GAL1 receptor                                                      GAL2 receptor                                                                                                            GAL3 receptor
  HGNC, UniProt                     GALR1, P47211                                                      GALR2, O43603                                                                                                            GALR3, O60755
  Principal transduction            G~i/o~                                                             G~i/o~, G~q/11~                                                                                                          G~i/o~
  Rank order of potency             galanin \> galanin-like peptide [@b881]                            galanin-like peptide ≥ galanin [@b881]                                                                                   galanin-like peptide \> galanin [@b878]
  Selective agonists (p*K*~i~)      --                                                                 \[D-Trp2\]galanin-(1--29) (8.15 - Rat) [@b887], galanin(2--29) (rat/mouse) (7.25--8.72 - Rat) [@b882],[@b891]--[@b893]   --
  Selective antagonists (p*K*~i~)   2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide (pIC~50~ 5.57) [@b884]   M871 (7.88) [@b889]                                                                                                      --
  --------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ -----------------------------------------

Comments
========

galanin-(1-11) is a high-affinity agonist at GAL~1~/GAL~2~ (p*K*~i~ 9), and galanin(2--11) is selective for GAL~2~ and GAL~3~ compared with GAL~1~ [@b880]. \[^125^I\]-\[Tyr^26^\]galanin binds to all three subtypes with *K*~d~ values ranging from 0.05 to 1 nM [@b875],[@b886]--[@b888],[@b892]. Porcine galanin-(3--29) does not bind to cloned GAL~1~, GAL~2~ or GAL~3~ receptors, but a receptor that is functionally activated by porcine galanin-(3--29) has been reported in pituitary and gastric smooth muscle cells [@b877],[@b895]. Additional galanin receptor subtypes are also suggested from studies with chimeric peptides (*e.g*. M15, M35 and M40), which act as antagonists in functional assays in the cardiovascular system [@b890], spinal cord [@b894], locus coeruleus, hippocampus [@b870] and hypothalamus [@b871],[@b879], but exhibit agonist activity at some peripheral sites [@b871],[@b877]. The chimeric peptides M15, M32, M35, M40 and C7 are agonists at GAL~1~ receptors expressed endogenously in Bowes human melanoma cells [@b881], and at heterologously expressed recombinant GAL~1~, GAL~2~ and GAL~3~ receptors [@b875],[@b887],[@b888]. Recent studies have described the synthesis of a series of novel, systemically-active, galanin analogues, with modest preferential binding at the GAL~2~ receptor. Specific chemical modifications to the galanin backbone increased brain levels of these peptides after *i.v.* injection and several of these peptides exerted a potent antidepressant-like effect in mouse models of depression [@b883].

Ghrelin receptor
================

Overview
--------

Ghrelin receptors (nomenclature approved by NC-IUPHAR, [@b898]) are activated by a 28 amino-acid peptide originally isolated from rat stomach, where it is cleaved from a 117 amino-acid precursor (GHRL, Q9UBU3). The human gene encoding the precursor peptide has 83% sequence homology to rat prepro-ghrelin, although the mature peptides from rat and human differ by only two amino acids [@b907]. Alternative splicing results in the formation of a second peptide, \[des-Gln14\]ghrelin (GHRL, Q9UBU3) with equipotent biological activity [@b904]. A unique post-translational modification (octanoylation of Ser^3^, catalysed by ghrelin Ο-acyltransferase (MBOAT4, Q96T53) [@b913] occurs in both peptides, essential for full activity in binding to the ghrelin receptors in the hypothalamus and pituitary; and the release of growth hormone release from the pituitary [@b906]. Structure activity studies showed the first five N-terminal amino acids to be the minimum required for binding [@b897], and receptor mutagenesis has indicated overlap of the ghrelin binding site with those for small molecule agonists and allosteric modulators of ghrelin (GHRL, Q9UBU3) function [@b902]. In cell systems, the ghrelin receptor is constitutively active [@b903], but this is abolished by a naturally occurring mutation (A204E) that results in decreased cell surface receptor expression and is associated with familial short stature [@b910].

  ------------------ --------------- ------------------------ ------------------------------------------------ -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature       HGNC, UniProt   Principal transduction   Rank order of potency                            Selective antagonists (p*K*~i~)                                                                          Radioligands (*K*~d~)
  ghrelin receptor   GHSR, Q92847    G~q/11~                  ghrelin = \[des-Gln14\]ghrelin [@b896],[@b907]   GSK1614343 (p*K*~B~ 8.0 - Rat) [@b911], YIL781 (p*K*~B~ 8.0) [@b899], GSK1614343 (pIC~50~ 8.4) [@b912]   \[125I\]\[His9\]ghrelin (human) (Agonist, Full agonist) (4x10^-10^ M) [@b905], \[125I\]\[Tyr4\]ghrelin (human) (Agonist, Full agonist) (4x10^-10^ M) [@b909]
  ------------------ --------------- ------------------------ ------------------------------------------------ -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

\[des-octanoyl\]ghrelin has been shown to bind (as \[125I\]Tyr4-des-octanoyl-ghrelin) and have effects in the cardiovascular system [@b896], which raises the possible existence of different receptor subtypes in peripheral tissues and the central nervous system. A potent inverse agonist has been identified (\[D-Arg1,D-Phe5,D-Trp7,9,Leu11\]substance P, p*D*~2~ 8.3; [@b901]). TZP101, described as a ghrelin receptor agonist (p*K*~i~ 7.8 and p*D*~2~ 7.5 at human recombinant ghrelin receptors), has been shown to stimulate ghrelin receptor mediated food intake and gastric emptying but not elicit release of growth hormone, or modify ghrelin stimulated growth hormone release, thus pharmacologically discriminating the orexigenic and gastrointestinal actions of ghrelin from the release of growth hormone [@b900]. A number of selective antagonists have been reported, including peptidomimetic [@b908] and non-peptide small molecules including GSK1614343 [@b911],[@b912].

Glucagon receptor family
========================

Overview
--------

The glucagon family of receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on the Glucagon receptor family, [@b926]) are activated by the endogenous peptide (27--44 aa) hormones glucagon, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), glucose-dependent insulinotropic polypeptide, also known as gastric inhibitory polypeptide or GIP (GIP, P09681), GHRH (GHRH, P01286) and secretin (SCT, P09683). One common precursor (GCG, P01275) generates glucagon, GLP-1 and GLP-2 peptides [@b922].

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------
  Nomenclature                      glucagon receptor                                                                                                                                   GLP-1 receptor                                                                                                                                                                                      GLP-2 receptor                            GIP receptor                                                        GHRH receptor                                                                                        secretin receptor
  HGNC, UniProt                     GCGR, P47871                                                                                                                                        GLP1R, P43220                                                                                                                                                                                       GLP2R, O95838                             GIPR, P48546                                                        GHRHR, Q02643                                                                                        SCTR, P47872
  Principal transduction            G~s~                                                                                                                                                G~s~                                                                                                                                                                                                G~s~                                      G~s~                                                                G~s~                                                                                                 G~s~
  Endogenous agonists (p*K*~i~)     glucagon (Selective) (pEC~50~ 9.0) [@b929]                                                                                                          glucagon-like peptide-1-(7-37) (Selective) [@b919], glucagon-like peptide 1-(7-36) amide (Selective) (9.2) [@b923]                                                                                  GLP-2 (Selective) (pIC~50~ 8.5) [@b932]   GIP (Selective) (p*K*~d~ 8.7) [@b938]                               --                                                                                                   secretin (Selective) (pEC~50~ 9.7) [@b916]
  Selective agonists (p*K*~i~)      --                                                                                                                                                  exendin-3 (P20394) [@b930], exendin-4 (8.7 -- 9.0) [@b923]                                                                                                                                          --                                        --                                                                  BIM28011 [@b918], JI-38 (Rat) [@b924]                                                                --
  Selective antagonists (p*K*~i~)   BAY27-9955 [@b928], des-His1-\[Glu9\]glucagon-NH2 (p*A*~2~ 7.2 - Rat) [@b934],[@b935], NNC 92-1687 (5.0) [@b925], L-168,049 (pIC~50~ 8.4) [@b915]   exendin-(9-39) (8.1) [@b923], GLP-1-(9-36) (pIC~50~ 6.91 - Rat) [@b927], T-0632 (pIC~50~ 4.7) [@b933]                                                                                               --                                        \[Pro3\]GIP                                                         JV-1-36 (10.1 -- 10.4 - Rat) [@b931],[@b936],[@b937], JV-1-38 (10.1 - Rat) [@b931],[@b936],[@b937]   \[(CH2NH)4,5\]secretin (5.3) [@b921]
  Radioligands (*K*~d~)             \[125I\]glucagon (human, mouse, rat) (Agonist, Full agonist)                                                                                        \[125I\]exendin, \[125I\]GLP-1-(7-37) (Agonist, Full agonist), \[125I\]GLP-1-(7-36)-amide (Agonist, Full agonist) (5x10^-10^ M) [@b923], \[125I\]exendin-(9-39) (Antagonist) (5x10^-9^ M) [@b923]   --                                        \[125I\]GIP (Agonist, Full agonist) (2.51x10^-9^ M - Rat) [@b920]   \[125I\]GHRH (human) (Agonist, Full agonist) (2.8x10^-8^ M - Rat) [@b914]                            \[125I\](Tyr10)secretin
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------------------------

Comments
========

The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), specifically RAMP2, in heterologous expression systems [@b917], although the physiological significance of this has yet to be established.

Glycoprotein hormone receptors
==============================

Overview
--------

Glycoprotein hormone receptors (provisional nomenclature) are activated by a non-covalent heterodimeric glycoprotein made up of a common α chain (glycoprotein hormone common alpha subunit (CGA, P01215) CGA, P01215), with a unique β chain that confers the biological specificity to FSH (CGA, FSHB, P01215, P01225), LH (LHB, CGA, P01229, P01215), hCG (CGA, CGB, P01233, P01215), CGB2/CGB or TSH (TSHB, CGA, P01222, P01215). There is binding cross-reactivity across the endogenous agonists for each of the glycoprotein hormone receptors. The deglycosylated hormones appear to exhibit reduced efficacy at these receptors [@b950].

  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                    FSH receptor                                                                                                                                                                                                                                                                                                                                      LH receptor                                                                                                                                                                                                                                                      TSH receptor
  HGNC, UniProt                   FSHR, P23945                                                                                                                                                                                                                                                                                                                                      LHCGR, P22888                                                                                                                                                                                                                                                    TSHR, P16473
  Principal transduction          G~s~                                                                                                                                                                                                                                                                                                                                              G~s~, G~q/11~ and G~i~                                                                                                                                                                                                                                           All four families of G proteins can be activated by this receptor
  Endogenous agonists (p*K*~i~)   FSH (Selective)                                                                                                                                                                                                                                                                                                                                   hCG (Selective) (p*K*~d~ 9.9 -- 11.8) [@b942],[@b946], LH (Selective) (pIC~50~ 9.9 -- 10.9) [@b942],[@b946]                                                                                                                                                      TSH (Selective)
  Radioligands (*K*~d~)           \[125I\]FSH (human) (Agonist, Full agonist)                                                                                                                                                                                                                                                                                                       \[125I\]CG (human) (Agonist, Full agonist), \[125I\]LH (Agonist, Full agonist)                                                                                                                                                                                   \[125I\]TSH (Agonist, Full agonist)
  Comment                         Animal follitropins are less potent than the human hormone as agonists at the human FSH receptor. Gain- and loss-of-function mutations of the FSH receptor are associated with human reproductive disorders [@b939]--[@b941],[@b953]. The rat FSH receptor also stimulates phosphoinositide turnover through an unidentified G protein [@b948].   Loss-of-function mutations of the LH receptor are associated with Leydig cell hypoplasia and gain-of-function mutations are associated with male-limited gonadotropin-independent precocious puberty (*e.g*. [@b944],[@b951]) and Leydig cell tumours [@b945].   Autoimmune antibodies that act as agonists of the TSH receptor are found in patients with Grave\'s disease (*e.g.* [@b949]). Mutations of the TSH receptor exhibiting constitutive activity underlie hyperfunctioning thyroid adenomas [@b947] and congenital hyperthyroidism [@b943]. TSH receptor loss-of-function mutations are associated with TSH resistance [@b952].
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Gonadotrophin-releasing hormone receptors
=========================================

Overview
--------

GnRH~1~ and GnRH~2~ receptors (provisonal nomenclature, also called Type I and Type II, respectively) have been cloned from numerous species (most of which express two or three types of GnRH receptor) and grouped phylogenetically [@b975]. Designated GnRH I (GNRH1, P01148) (to distinguish it from related peptides, such as GnRH II (GNRH2, O43555) (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH~2~, also known as chicken GnRH-II) is a hypothalamic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pr-Gly-NH~2~), also known as luteinising hormone-releasing hormone, gonadoliberin, luliberin, gonadorelin. Receptors for all three ligands exist in amphibians but only GnRH I (GNRH1, P01148) and GnRH II (GNRH2, O43555) (and their cognate receptors) have been found in mammals [@b969],[@b974]. GnRH~1~ receptors are expressed primarily by pituitary gonadotrophs in mammals and mediate central control of reproduction. They are selectively activated by GnRH I (GNRH1, P01148) and all lack the C-terminal tails found in other GPCR. GnRH~2~ receptors all possess C-terminal tails and (where tested) are selective for GnRH II (GNRH2, O43555) (over GnRH I (GNRH1, P01148)). An alternative phylogenetic classification [@b970] divided these receptors into three classes and includes both GnRH I-selective mammalian and GnRH II-selective non-mammalian receptors as GnRH~1~ receptors. Although thousands of peptide analogues of GnRH I (GNRH1, P01148) have been synthesised and several (agonists and antagonists) are used therapeutically [@b961], the potency of most of these peptides at GnRH~2~ receptors is unknown.

  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------
  Nomenclature                      GnRH receptor                                                                                                                      GnRH2 receptor
  HGNC, UniProt                     GNRHR, P30968                                                                                                                      GNRHR2, Q96P88
  Principal transduction            G~q/11~                                                                                                                            G~q/11~
  Rank order of potency             GnRH I \> GnRH II                                                                                                                  GnRH II \> GnRH I
  Selective agonists (p*K*~i~)      buserelin, goserelin, histrelin, nafarelin, triptorelin (9.3 -- 9.5) [@b954], leuprolide (8.5 -- 9.1) [@b976]                      --
  Selective antagonists (p*K*~i~)   ganirelix, abarelix (9.1 -- 9.5) [@b976], antide (9.0) [@b972], cetrorelix (8.8) [@b972]                                           trptorelix-1 [@b967]
  Radioligands (*K*~d~)             \[125I\]GnRH I (human, mouse, rat) (Agonist, Full agonist), \[125I\]buserelin (Agonist, Full agonist) (4x10^-8^ M - Rat) [@b964]   \[125I\]GnRH II (human) (Agonist, Full agonist)
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------

Comments
========

GnRH~1~ and GnRH~2~ receptors couple primarily to G~q/11~ [@b958] but coupling to G~s~ and G~i~ is evident in some systems [@b963]. GnRH~2~ receptors may also mediate (heterotrimeric) G protein-independent signalling to protein kinases [@b955]. There is increasing evidence for expression of GnRH receptors on hormone-dependent cancer cells where they can exert antiproliferative and/or proapoptotic effects and mediate effects of cytotoxins conjugated to GnRH analogues [@b956],[@b960],[@b966],[@b973]. In some human cancer cell models GnRH II (GNRH2, O43555) is more potent than GnRH I (GNRH1, P01148), implying mediation by GnRH2 receptors [@b959]. However, GnRH~2~ receptors that are expressed by some primates are probably not expressed in humans because the human GNRHR~2~ gene contains a frame shift and internal stop codon [@b971]. The possibility remains that this gene generates GnRH~2~ receptor-related proteins (other than the full-length receptor) that mediate responses to GnRH II (GNRH2, O43555) (see [@b972]). Alternatively, there is evidence for multiple active GnRH receptor conformations [@b955],[@b968],[@b970] raising the possibility that GnRH~1~ receptor-mediated proliferation inhibition in hormone-dependent cancer cells is dependent upon different conformations (with different ligand specificity) than effects on G~q/11~ in pituitary cells [@b968]. Loss-of-function mutations in the GnRH~1~ receptor and deficiency of GnRH I (GNRH1, P01148) are associated with hypogonadotropic hypogonadism although some 'loss of function' mutations may actually prevent trafficking of 'functional' GnRH~1~ receptors to the cell surface, as evidenced by recovery of function by nonpeptide antagonists [@b965]. GnRH receptor signalling may be dependent upon receptor oligomerisation [@b957],[@b962].

GPR18, GPR55 and GPR119
=======================

Overview
--------

GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB~1~ and CB~2~ cannabinoid receptors, respond to endogenous agents analogous to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [@b988].

  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                    GPR18                                                                                                                          GPR55                                                                                                                              GPR119
  HGNC, UniProt                   GPR18, Q14330                                                                                                                  GPR55, Q9Y2T6                                                                                                                      GPR119, Q8TDV5
  Principal transduction          G~i/o~ [@b982]                                                                                                                 G~12/13~ [@b989]                                                                                                                   G~s~ [@b984],[@b987]
  Rank order of potency           --                                                                                                                             --                                                                                                                                 N-oleoylethanolamide, N-palmitoylethanolamine \> SEA (anandamide is ineffective) [@b987]
  Endogenous agonists (p*K*~i~)   N-arachidonoylglycine [@b982]                                                                                                  2-arachidonoylglycerolphosphoinositol (Selective) [@b986], lysophosphatidylinositol (pEC~50~ 5.5 -- 7.3) [@b978],[@b985],[@b990]   N-palmitoylethanolamine (Selective), SEA (Selective), N-oleoylethanolamide (Selective) (pEC~50~ 5.4 -- 6.3) [@b977],[@b987],[@b990]
  Selective agonists (p*K*~i~)    --                                                                                                                             AM251 (pEC~50~ 6.2 -- 6.3) [@b978],[@b980]                                                                                         AS1269574 (pEC~50~ 5.6) [@b993], PSN632408 (pEC~50~ 5.3) [@b987], PSN375963 (pEC~50~ 5.1) [@b987]
  Comment                         The pairing of N-arachidonoylglycine with GPR18 was not replicated in two studies based on β-arrestin assays [@b990],[@b992]   --                                                                                                                                 --
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------

Comments
========

All listed endogenous agonists are remain currently as putative endogenous agonists.

GPR18 failed to respond to a variety of lipid-derived agents in an in vitro screen [@b992], but has been reported to be activated by Δ9-tetrahydrocannabinol [@b983]. GPR55 responds to AM251 and rimonabant at micromolar concentrations, compared to their nanomolar affinity as CB~1~ receptor antagonists/inverse agonists [@b988]. It has been reported lysophosphatidylinositol acts at other sites [@b991]. CID-16020046 has been described as a selective antagonist at GPR55 [@b979],[@b981], although it has not yet been fully characterized. It has also been suggested oleoyl-lysophosphatidylcholine acts, at least in part, through GPR119 [@b984]. Although PSN375963 and PSN632408 produce GPR119-dependent responses in heterologous expression systems, comparison with N-oleoylethanolamide-mediated responses suggests additional mechanisms of action [@b984].

Histamine receptors
===================

Overview
--------

Histamine receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Histamine Receptors, [@b1003]) are activated by the endogenous ligand histamine. Marked species differences exist between histamine receptor orthologues (see [@b1003]).

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      H1 receptor                                                                                                                                                                           H2 receptor                                                                                                                           H3 receptor                                                                                                                                                                                                                                                                                H4 receptor
  HGNC, UniProt                     HRH1, P35367                                                                                                                                                                          HRH2, P25021                                                                                                                          HRH3, Q9Y5N1                                                                                                                                                                                                                                                                               HRH4, Q9H3N8
  Principal transduction            G~q/11~                                                                                                                                                                               G~s~                                                                                                                                  G~i/o~                                                                                                                                                                                                                                                                                     G~i/o~
  Selective agonists (p*K*~i~)      methylhistaprodifen (6.4) [@b1025], histaprodifen (5.7) [@b1013]                                                                                                                      amthamine (pEC~50~ 6.4) [@b1008]                                                                                                      immethridine (9.1) [@b1007], methimepip (9.0) [@b1006]                                                                                                                                                                                                                                     clobenpropit (Partial agonist) (7.4 -- 8.3) [@b1000],[@b1013]--[@b1015],[@b1019], 4-methylhistamine (7.3 -- 8.2) [@b1001],[@b1013], VUF 8430 (7.5) [@b1012]
  Selective antagonists (p*K*~i~)   pyrilamine (Inverse agonist) (8.7 -- 9.0) [@b995],[@b1023], triprolidine (8.5 -- 9.0) [@b995],[@b1017]                                                                                tiotidine (7.5 - Rat) [@b994], ranitidine (7.1) [@b1010]                                                                              clobenpropit (8.4 -- 9.4) [@b997],[@b1000],[@b1011],[@b1014],[@b1016],[@b1028],[@b1029], A331440 (8.5) [@b1002], iodophenpropit (8.2 -- 8.7) [@b1028],[@b1029], thioperamide (7.1 -- 7.7) [@b997],[@b999],[@b1000],[@b1011],[@b1016],[@b1028],[@b1029]                                     JNJ 7777120 (7.8 -- 8.3) [@b1013],[@b1026],[@b1027]
  Radioligands (*K*~d~)             \[11C\]pyrilamine, \[11C\]doxepin (Antagonist) (1x10^-9^ M) [@b1004], \[3H\]pyrilamine (Antagonist, Inverse agonist) (7.9x10^-10^ -- 4x10^-9^ M) [@b998],[@b1017],[@b1024],[@b1025]   \[125I\]aminopotentidine (Antagonist) (2x10^-9^ M - Rat) [@b1009], \[3H\]tiotidine (Antagonist) (2.2x10^-9^ -- 2x10^-8^ M) [@b1018]   \[123I\]iodoproxyfan (Antagonist) (6.3x10^-11^ M) [@b1011], \[125I\]iodophenpropit (Antagonist) (6x10^-10^ M - Rat) [@b1005], \[3H\](R)-α-methylhistamine (Agonist, Full agonist) (6x10^-10^ M) [@b1014], N-\[3H\]α-methylhistamine (Agonist, Full agonist) (1x10^-9^ M - Mouse) [@b996]   \[3H\]JNJ 7777120 (Antagonist) (3.6x10^-9^ M) [@b1027]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

histaprodifen and methylhistaprodifen are reduced efficacy agonists. The H~4~ receptor appears to exhibit broadly similar pharmacology to the H~3~ receptor for imidazole-containing ligands, although (R)-α-methylhistamine and N-α-methylhistamine are less potent, while clobenpropit acts as a reduced efficacy agonist [@b1014],[@b1020]--[@b1022],[@b1030]. Moreover, 4-methylhistamine is identified as a high affinity, full agonist for the human H~4~ receptor [@b1013]. \[3H\]histamine has been used to label the H~4~ receptor in heterologous expression systems.

Hydroxycarboxylic acid receptors
================================

Formerly known as: Nicotinic acid receptor family
-------------------------------------------------

### Overview

The hydroxycarboxylic acid family of receptors (ENSFM00500000271913, nomenclature as agreed by NC-IUPHAR Subcommittee on Hydroxycarboxylic acid receptors, [@b1037]) respond to organic acids, including the endogenous hydroxy carboxylic acids 3-hydroxy butyric acid and L-lactic acid, as well as the lipid lowering agents nicotinic acid (niacin), acipimox and acifran [@b1040],[@b1044],[@b1045]. These receptors were provisionally described as nicotinic acid receptors, although nicotinic acid shows submicromolar potency at HCA~2~ receptors only and is unlikely to be the natural ligand [@b1044],[@b1045].

  ------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------
  Nomenclature                    HCA1 receptor                                                                         HCA2 receptor                                                                                                                                                                                                                  HCA3 receptor
  HGNC, UniProt                   HCAR1, Q9BXC0                                                                         HCAR2, Q8TDS4                                                                                                                                                                                                                  HCAR3, P49019
  Principal transduction          G~i/o~ [@b1031],[@b1034],[@b1036].                                                    G~i/o~ [@b1040],[@b1044],[@b1045]                                                                                                                                                                                              G~i/o~ [@b1040],[@b1045]
  Endogenous agonists (p*K*~i~)   L-lactic acid (Selective) (pEC~50~ 1.3 -- 2.89) [@b1032],[@b1034],[@b1036],[@b1041]   β-D-hydroxybutyric acid (pEC~50~ 3.1) [@b1042]                                                                                                                                                                                 3-hydroxyoctanoic acid (pEC~50~ 5.1) [@b1031]
  Selective agonists (p*K*~i~)    3,5-dihydroxybenzoic acid (pEC~50~ 3.72) [@b1035]                                     MK 6892 (pEC~50~ 7.8) [@b1039], MK 1903 (pEC~50~ 7.56) [@b1033], nicotinic acid (pEC~50~ 6.0 -- 7.2) [@b1040],[@b1044],[@b1045], acipimox (pEC~50~ 5.2 -- 5.6) [@b1040],[@b1045], monomethylfumarate (pEC~50~ 5.03) [@b1043]   1-isopropylbenzotriazole-5-carboxylic acid (pEC~50~ 6.4) [@b1038]
  Radioligands (*K*~d~)           --                                                                                    \[3H\]nicotinic acid (Agonist, Full agonist) (5.01x10^-8^ -- 1x10^-7^ M) [@b1040],[@b1044],[@b1045]                                                                                                                            --
  ------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------

Comments
========

Further closely-related GPCR include the 5-oxoeicosanoid receptor (OXER1, Q8TDS5) and GPR31 (O00270).

Kisspeptin receptors
====================

Overview
--------

The kisspeptin receptor (nomenclature agreed by NC-IUPHAR committee on kisspeptin receptors, Kirby *et al*., 2010 [@b1047]), like neuropeptide FF (NPFF), prolactin-releasing peptide (PrP) and QRFP receptors (provisional nomenclature) responds to endogenous peptides with an arginine-phenylalanine-amide (RFamide) motif. kisspeptin-54 (KISS1, Q15726) (KP54, originally named metastin), kisspeptin-13 (KISS1, Q15726) (KP13) and kisspeptin-10 (KISS1) (KP10) are biologically-active peptides cleaved from the KISS1 (Q15726) gene product.

  --------------------- ---------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature          HGNC, UniProt    Principal transduction      Endogenous agonists (p*K*~i~)                                                                                                                               Selective agonists (p*K*~i~)                                                                    Selective antagonists (p*K*~i~)   Radioligands (*K*~d~)
  kisspeptin receptor   KISS1R, Q969F8   G~q/11~ [@b1048],[@b1050]   kisspeptin-10 (Selective) (8.6--10.4) [@b1048],[@b1051], kisspeptin-54 (Selective) (8.8--9.5) [@b1048],[@b1051], kisspeptin-13 (Selective) (8.4) [@b1048]   4-fluorobenzoyl-FGLRW-NH2 (pEC~50~ 9.2) [@b1053], \[dY\]1KP-10 (pIC~50~ 8.4 - Mouse) [@b1046]   peptide 234 [@b1052]              \[125I\]kisspeptin-14 (human) [@b1049], \[125I\]Tyr45-kisspeptin-15 (Agonist, Full agonist) (1 × 10^−10^ M) [@b1051], \[125I\]kisspeptin-13 (human) (Agonist, Full agonist) (2 × 10^−10^ M) [@b1049], \[125I\]kisspeptin-10 (human) (Agonist, Full agonist) (1.9 × 10^−9^ M) [@b1048]
  --------------------- ---------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Leukotriene, lipoxin and oxoeicosanoid receptors
================================================

Overview
--------

Leukotriene receptors (nomenclature agreed by NC-IUPHAR subcommittee on Leukotriene Receptors, [@b1057]) are activated by the endogenous ligands leukotriene B~4~ (LTB4), LTC4, LTD4, LTE4, 12R-HETE and 12S-HETE. CysLT~1~ and CysLT~2~ are co-expressed by most myeloid cells. However, the function of CysLT~2~ remains unclear. CysLT~2~ has been demonstrated to exert a suppressive influence on CysLT~1~ expression, suggesting an autoregulatory function which is indicated by a reported up-regulation of CysLT-mediated responses in mice lacking CysLT~2~ receptors [@b1073].

Leukotrienes bind extensively to enzymes in their metabolic pathways (glutathione-S-transferase/LTC~4~ synthase, γ-glutamyltranspeptidase and several aminopeptidases) and can also bind to peroxisome proliferator-activated receptor *α* (PPAR*α*, [@b1076]) and the FPR2/ALX lipoxin receptor [@b1061], complicating the interpretation of radioligand binding and functional studies (*e.g.* LTC4 is rapidly converted in many systems to LTD4). Metabolic inhibitors (*e.g.* serine--borate complex) reduce this problem but can also have nonspecific effects.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------
  Nomenclature                      BLT1 receptor                                                                                                      BLT2 receptor                                                                                         CysLT1 receptor                                                                                                                                                                                  CysLT2 receptor
  HGNC, UniProt                     LTB4R, Q15722                                                                                                      LTB4R2, Q9NPC1                                                                                        CYSLTR1, Q9Y271                                                                                                                                                                                  CYSLTR2, Q9NS75
  Principal transduction            G~q/11~, G~i/o~                                                                                                    G~q/11~, G~i/o~                                                                                       G~q/11~                                                                                                                                                                                          G~q/11~
  Rank order of potency             LTB4 \>20-hydroxy-LTB4 \>\>12R-HETE [@b1103]                                                                       12-HHT \> LTB4 \> 12S-HETE = 12S-HPETE \> 15S-HETE \> 12R-HETE \> 20-hydroxy-LTB4 [@b1085],[@b1103]   LTD4 \> LTC4 \> LTE4 [@b1077],[@b1093]                                                                                                                                                           LTC4 ≥ LTD4 \>\> LTE4 [@b1068],[@b1082],[@b1099]
  Endogenous agonists (p*K*~i~)     --                                                                                                                 12S-HETE (Partial agonist) (pEC~50~\<7.52) [@b1103]                                                   --                                                                                                                                                                                               --
  Selective antagonists (p*K*~i~)   U75302 (6.4) [@b1055], CP105696 (pIC~50~ 8.1) [@b1095]                                                             LY255283 (pIC~50~ 6.0--7.1) [@b1069],[@b1103]                                                         ICI198615 (8.4--8.6), SR2640 (8.7), sulukast (8.3), zafirlukast (pIC~50~ 8.59--8.74) [@b1077],[@b1093], montelukast (pIC~50~ 8.31--8.64) [@b1077],[@b1093], pobilukast (pIC~50~ 7.52) [@b1093]   BAYu9773 (p*A*~2~ 6.8--7.7 - Rat) [@b1100]
  Radioligands (*K*~d~)             \[3H\]LTB4 (Agonist, Full agonist) (1.5×10^−10^ M) [@b1102], \[3H\]CGS23131 (Antagonist) (1.3×10^−8^ M) [@b1072]   \[3H\]LTB4 (2×10^−10^ -- 2.3×10^−8^ M)                                                                \[3H\]ICI-198615 (Antagonist, in human lung parenchyma) (2.5×10^−11^ M) [@b1092], \[3H\]LTD4 (Agonist) (2×10^−11^ -- 9.3×10^−9^ M)                                                               \[3H\]LTD4 (Agonist, Full agonist, K~d1~ and K~d-2~ in COS-7 cells) (3.98×10^−10^ -- 5.01×10^−8^ M) [@b1068]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------

  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  Nomenclature                      FPR2/ALX                                                                                                                                                                            OXE receptor
  HGNC, UniProt                     FPR2, P25090                                                                                                                                                                        OXER1, Q8TDS5
  Principal transduction            G~i~ [@b1078]                                                                                                                                                                       G~i/o~ [@b1070],[@b1071],[@b1074],[@b1083]
  Rank order of potency             LXA4=aspirin triggered lipoxin A4=ATLa2\>LTC4=LTD4\>\>15-deoxy-LXA4\>\>fMet-Leu-Phe [@b1060],[@b1061],[@b1063],[@b1065],[@b1098]                                                    5-oxo-ETE, 5-oxo-C20:3, 5-oxo-ODE \> 5-oxo-15-HETE \> 5S-HPETE \> 5S-HETE [@b1070],[@b1074],[@b1086]
  Endogenous agonists (p*K*~i~)     aspirin triggered lipoxin A4 (Selective), LXA4 (Selective) (pEC~50~ ∼12.0) [@b1075], resolvin D1 (Selective) (pEC~50~ ∼11.9) [@b1075]                                               5-oxo-ETE (Selective) (pEC~50~ 8.3--8.5) [@b1064],[@b1084],[@b1086],[@b1089],[@b1094]
  Selective antagonists (p*K*~i~)   ATLa2 [@b1066]                                                                                                                                                                      --
  Radioligands (*K*~d~)             \[3H\]LXA4 (Agonist, Full agonist) (5×10^−10^ -- 7×10^−10^ M) [@b1061],[@b1062]                                                                                                     \[3H\]5-oxo-ETE (Agonist) (3.8×10^−9^ M) [@b1084]
  Comment                           The agonist activity of the lipid mediators described has been questioned [@b1067],[@b1088], which may derive from batch-to-batch differences, partial agonism or biased agonism.   --
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------

Comments
========

BAYu9773 is an antagonist at CysLT~1~ (6.8--7.7) and a reduced efficacy agonist at CysLT~2~ receptors. The CysLT~1~ and CyLT~2~ receptors also respond to uracil nucleotides [@b1080],[@b1081]. GPR17 has been described as a 'dualistic' receptor responding to both uracil nucleotides and cysteinyl leukotrienes, responses which may be inhibited by antagonists of either P2 or CysLT receptors [@b1059].

Lipoxin A4 receptors (FPR2/ALX, nomenclature agreed by NC-IUPHAR on Leukotriene and Lipoxin Receptors; [@b1101]) are activated by the endogenous lipid-derived, anti-inflammatory ligands lipoxin A~4~ (LXA4) and 15-epi-LXA~4~ (aspirin triggered lipoxin A4, ATL). The FPR2/ALX receptor also interacts with endogenous peptide and protein ligands, such as MHC binding peptide [@b1058] as well as annexin I (ANXA1, P04083) (ANXA1) and its *N*-terminal peptides [@b1087]. In addition, a soluble hydrolytic product of protease action on the urokinase-type plasminogen activator receptor has been reported to activate the FPR2/ALX receptor [@b1090]. Furthermore, FPR2/ALX has been suggested to act as a receptor mediating proinflammatory actions of the acute-phase reactant, serum amyloid A [@b1096],[@b1097].

Oxoeicosanoid receptors (OXE, nomenclature agreed by NC-IUPHAR on Oxoeicosanoid Receptors; [@b1056]) are activated by endogenous chemotactic eicosanoid ligands oxidised at the C-5 position, with 5-oxo-ETE the most potent agonist identified for this receptor.

Note that the data for FPR2/ALX are also reproduced on the Formylpeptide receptor pages. A receptor selective for LXB4 has been suggested from functional studies [@b1054],[@b1079],[@b1091]. Initial characterization of the heterologously expressed OXE receptor suggested that polyunsaturated fatty acids, such as docosahexaenoic acid (DHA) and EPA, acted as receptor antagonists [@b1070].

Lysophospholipid (LPA) receptors
================================

Overview
--------

Lysophosphatidic acid (LPA) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Lysophospholipid Receptors; [@b1104]) are activated by the endogenous lipid derivative LPA. Originally identified as members of the endothelial differentiation gene (*edg*) family along with sphingosine 1-phosphate receptors, the gene names have recently been updated to *LPAR1*, etc. to reflect the receptor function of these proteins. The identified receptors can account for most, although not all, LPA-induced phenomena in the literature, indicating that a majority of LPA-dependent phenomena are receptor-mediated. Radioligand binding has been conducted in heterologous expression systems using \[3H\]LPA (*e.g.* [@b1107]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding, and therefore the relationship between recombinant and endogenously expressed receptors is unclear. Targeted deletion of LPA receptors has clarified signalling pathways and identified physiological and pathophysiological roles. Independent validation by multiple groups has been reported in the peer-reviewed literature for all six LPA receptors described in the tables, including further validation using a distinct read-out via a novel TGFα "shedding" assay [@b1111]. LPA has also been described to be an agonist at other orphan GPCRs (PSP24, GPR87 and GPR35), as well as at the nuclear hormone PPARγ receptors [@b1117],[@b1119], although the physiological significance of these observations remain unclear.

  --------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------ ---------------------------------- ----------------------------
  Nomenclature                      LPA1 receptor                  LPA2 receptor                                                                                                                   LPA3 receptor                                                   LPA4 receptor                              LPA5 receptor                      LPA6 receptor
  HGNC, UniProt                     LPAR1, Q92633                  LPAR2, Q9HBW0                                                                                                                   LPAR3, Q9UBY5                                                   LPAR4, Q99677                              LPAR5, Q9H1C0                      LPAR6, P43657
  Principal transduction            G~i/o~, G~q/11~, G~12/13~      G~i/o~, G~q/11~, G~12/13~                                                                                                       G~i/o~, G~q/11~, G~s~                                           G~i/o~, G~q/11~, G~s~, G~12/13~ [@b1115]   G~q~, G~12/13~ [@b1114],[@b1116]   G~12/13~ [@b1112],[@b1122]
  Selective agonists (p*K*~i~)      --                             dodecylphosphate (pEC~50~ 6.2) [@b1121], decyl dihydrogen phosphate (pEC~50~ 5.4) [@b1121], GRI977143 (pEC~50~ 4.48) [@b1113]   OMPT (pEC~50~ 7.17) [@b1108]                                    --                                         --                                 --
  Selective antagonists (p*K*~i~)   AM966 (pIC~50~ 7.8) [@b1120]   H2L5186303 (7.68) [@b1105]                                                                                                      dioctanoylglycerol pyrophosphate (5.5--7.0) [@b1106],[@b1118]   --                                         --                                 --
  --------------------------------- ------------------------------ ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------ ---------------------------------- ----------------------------

Comments
========

Ki16425 [@b1118], dodecylphosphate [@b1121], VPC12249 [@b1110] and VPC32179 [@b1109] have antagonist activity at LPA~1~ and LPA~3~ receptors. The selectivity of these antagonists is less than two orders of magnitude. None of the currently available chemical tools have validated specificity *in vivo*.

Lysophospholipid (S1P) receptors
================================

Overview
--------

Sphingosine 1-phosphate (S1P) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Lysophospholipid receptors; [@b1128]) are activated by the endogenous lipid derivatives sphingosine 1-phosphate (S1P) and with lower apparent affinity, sphingosylphosphorylcholine (SPC). Originally identified as members of the endothelial differentiation gene (*edg*) family along with lysophosphatidic acid receptors, the gene names have been updated to S1PR1, etc. to reflect the receptor function of these proteins. Most cellular phenomena ascribed to S1P can be explained by receptor-mediated mechanisms; S1P has also been described to act at intracellular sites [@b1142], still awaiting precise definition. Previously-proposed SPC (or lysophophosphatidylcholine) receptors -- G2A, TDAG8, OGR1 and GPR4 -- are lacking confirmation of these roles [@b1130]. The relationship between recombinant and endogenously expressed receptors is unclear. Radioligand binding has been conducted in heterologous expression systems using \[32P\]S1P (*e.g* [@b1137]). In native systems, analysis of binding data is complicated by metabolism and high levels of nonspecific binding. Targeted deletion of several S1P receptors and key enzymes involved in S1P biosynthesis or degradation has clarified signalling pathways and physiological roles. A crystal structure of an S1P~1~-T4 fusion protein has recently been described [@b1132].

  --------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  Nomenclature                      S1P1 receptor                                                                                                S1P2 receptor                                                                                                S1P3 receptor                                                                                       S1P4 receptor                                                                                       S1P5 receptor
  HGNC, UniProt                     S1PR1, P21453                                                                                                S1PR2, O95136                                                                                                S1PR3, Q99500                                                                                       S1PR4, O95977                                                                                       S1PR5, Q9H228
  Principal transduction            G~i/o~                                                                                                       G~q~, G~12/13~, G~s~                                                                                         G~q~, G~i/o~, G~s~                                                                                  G~i/o~, G~12/13~, G~s~                                                                              G~i/o~, G~12/13~
  Rank order of potency             sphingosine 1-phosphate \> dihydrosphingosine 1-phosphate \> sphingosylphosphorylcholine [@b1124],[@b1137]   sphingosine 1-phosphate \> dihydrosphingosine 1-phosphate \> sphingosylphosphorylcholine [@b1124],[@b1137]   sphingosine 1-phosphate \> dihydrosphingosine 1-phosphate \> sphingosylphosphorylcholine [@b1137]   sphingosine 1-phosphate \> dihydrosphingosine 1-phosphate \> sphingosylphosphorylcholine [@b1143]   sphingosine 1-phosphate \> dihydrosphingosine 1-phosphate \> sphingosylphosphorylcholine [@b1133]
  Selective agonists (p*K*~i~)      SEW2871 (5.5 -- 7.7) [@b1140], AUY954 (pEC~50~ 8.92) [@b1139]                                                --                                                                                                           --                                                                                                  --                                                                                                  --
  Selective antagonists (p*K*~i~)   W146 (7.7) [@b1141]                                                                                          JTE-013 (pIC~50~ 7.77) [@b1138]                                                                              --                                                                                                  --                                                                                                  --
  --------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------

Comments
========

The immunomodulator fingolimod (FTY720) can be phosphorylated *in vivo* [@b1123] to generate a relatively potent agonist with activity at S1P~1~, S1P~3~, S1P~4~ and S1P~5~ receptors [@b1125],[@b1134], although its biological activity appears to involve functional antagonism [@b1127],[@b1129],[@b1136]. This compound has received world-wide approval as the first oral therapy for relapsing forms of Multiple Sclerosis, with a novel mechanism of action involving modulation of S1P receptors in both the immune and nervous systems [@b1126],[@b1129],[@b1131]. VPC23019 and VPC44116 have antagonist activity at S1P~1~ and S1P~3~ receptors [@b1135].

Melanin-concentrating hormone receptors
=======================================

Overview
--------

Melanin-concentrating hormone (MCH) receptors (provisional nomenclature, [@b1148]) are activated by an endogenous nonadecameric cyclic peptide identical in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor (PMCH, P20382), which also produces neuropeptide EI and neuropeptide GE.

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Nomenclature                      MCH1 receptor                                                                                                                                                                                                  MCH2 receptor
  HGNC, UniProt                     MCHR1, Q99705                                                                                                                                                                                                  MCHR2, Q969V1
  Principal transduction            G~q/11~, G~i/o~                                                                                                                                                                                                G~q/11~ [@b1150]--[@b1152]
  Rank order of potency             melanin-concentrating hormone (human) \> MCH (salmon)                                                                                                                                                          melanin-concentrating hormone (human) = MCH (salmon) [@b1150]
  Selective antagonists (p*K*~i~)   SNAP-7941 (p*A*~2~ 9.2) [@b1145], GW803430 (pIC~50~ 9.3) [@b1149], T-226296 (pIC~50~ 8.3) [@b1153], ATC0175 (pIC~50~ 7.9--8.1) [@b1147]                                                                        --
  Radioligands (*K*~d~)             \[3H\]MCH (human, mouse, rat) (Agonist, Full agonist) [@b1146], \[125I\]S36057 (Antagonist) (3.2x10^−10^--6.3x10^−10^ M) [@b1144], \[125I\]\[Phe13,Tyr19\]MCH (Agonist, Full agonist) (7x10^−10^ M) [@b1146]   --
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------

Comments
========

The MCH~2~ receptor appears to be a non-functional pseudogene in rodents [@b1154].

Melanocortin receptors
======================

Overview
--------

Melanocortin receptors (provisional nomenclature, [@b1158]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH derived from a common precursor, pro-opiomelanocortin (POMC, P01189) forms; -- δ form is not found in mammals) and adrenocorticotrophin (ACTH (POMC, P01189)). Endogenous antagonists include agouti (ASIP, P42127) and agouti-related protein (AGRP (AGRP, O00253)).

  --------------------------------- ------------------------------------------------------------------ ---------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------
  Nomenclature                      MC1 receptor                                                       MC2 receptor           MC3 receptor                                                                                            MC4 receptor                                                                                                                              MC5 receptor
  HGNC, UniProt                     MC1R, Q01726                                                       MC2R, Q01718           MC3R, P41968                                                                                            MC4R, P32245                                                                                                                              MC5R, P33032
  Principal transduction            G~s~                                                               G~s~                   G~s~                                                                                                    G~s~                                                                                                                                      G~s~
  Rank order of potency             α-MSH \> β-MSH \> ACTH, γ-MSH                                      ACTH                   γ-MSH, β-MSH \> ACTH, α-MSH                                                                             β-MSH \> α-MSH, ACTH \> γ-MSH                                                                                                             α-MSH \> β-MSH \> ACTH \> γ-MSH
  Selective agonists (p*K*~i~)      --                                                                 --                     \[D-Trp8\]γ-MSH (pIC~50~ 8.2) [@b1159]                                                                  MK-0493 [@b1162], THIQ (pIC~50~ 8.9) [@b1166]                                                                                             --
  Selective antagonists (p*K*~i~)   --                                                                 --                     PG-106 (pIC~50~ 6.7) [@b1160]                                                                           HS014 (8.5) [@b1165], MBP10 (pIC~50~ 10.0) [@b1155]                                                                                       --
  Radioligands (*K*~d~)             \[125I\]NDP-MSH (Agonist, Full agonist) (3.3x10^-10^ M) [@b1161]   \[125I\]ACTH-(1--24)   \[125I\]SHU9119 (Antagonist) [@b1163], \[125I\]NDP-MSH (Agonist, Full agonist) (2x10^-10^ M) [@b1161]   \[125I\]SHU9119 (Antagonist) (7x10^-10^ M) [@b1163], \[125I\]NDP-MSH (Agonist, Full agonist) (1.2x10^-9^--4x10^-9^ M) [@b1161],[@b1164]   \[125I\]NDP-MSH (Agonist, Full agonist) (2.8x10^-9^ M) [@b1161]
  --------------------------------- ------------------------------------------------------------------ ---------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------

Comments
========

Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor have been linked to obesity [@b1156],[@b1157].

Melatonin receptors
===================

Overview
--------

Melatonin receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on melatonin receptors, [@b1170]) are activated by the endogenous ligands melatonin and N-acetylserotonin.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      MT1 receptor                                                                                                                                                              MT2 receptor
  HGNC, UniProt                     MTNR1A, P48039                                                                                                                                                            MTNR1B, P49286
  Principal transduction            G~i/o~                                                                                                                                                                    G~i/o~
  Selective agonists (p*K*~i~)      --                                                                                                                                                                        5-methoxy-luzindole (Partial agonist) (9.6) [@b1171], IIK7 (pIC~50~ 10.3) [@b1183]
  Selective antagonists (p*K*~i~)   --                                                                                                                                                                        K185 (9.3) [@b1175],[@b1183], 4P-PDOT (8.8--9.3) [@b1167],[@b1171], DH97 (8.0) [@b1184]
  Radioligands (*K*~d~)             2-\[125I\]MLT (Agonist, Full agonist) (2.13×10^−11^ -- 1.19×10^−10^ M) [@b1167],[@b1171], \[3H\]melatonin (Agonist, Full agonist) (1.3×10^−10^ -- 4×10^−10^ M) [@b1169]   2-\[125I\]MLT (Agonist, Full agonist) (1.07×10^−10^ -- 1.86×10^−10^ M) [@b1167],[@b1171], \[3H\]melatonin (Agonist, Full agonist) (2.8×10^−10^ -- 9.12×10^−10^ M) [@b1169]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

melatonin, 2-iodo-melatonin, S20098 (agomelatine), GR 196429, LY 156735 and ramelteon [@b1176] are nonselective agonists for MT~1~ and MT~2~ receptors. (-)-AMMTC displays an ∼400-fold greater agonist potency than (+)-AMMTC at rat MT~1~ receptors (see AMMTC for structure) [@b1185]. luzindole is an MT~1~/MT~2~ melatonin receptor-selective competitive antagonist with some selectivity for the MT2 receptor [@b1172]. MT~1~/MT~2~ heterodimers present different pharmacological profiles from MT~1~ and MT~2~ receptors [@b1168].

The *MT~3~* binding site of hamster brain and peripheral tissues such as kidney and testis, also termed the ML~2~ receptor, binds selectively 2-iodo-\[125I\]5MCA-NAT [@b1178]. Pharmacological investigations of MT~3~ binding sites have primarily been conducted in hamster tissues. At this site, N-acetylserotonin [@b1174],[@b1177],[@b1178],[@b1182] and 5MCA-NAT [@b1182] appear to function as agonists, while prazosin [@b1177] functions as an antagonist. A suggested physiological function of the MT~3~ receptor is in the control of intraocular pressure in rabbits [@b1181]. The *MT*~3~ binding site of hamster kidney was also identified as the hamster homologue of human quinone reductase 2 (NQO2, P16083 [@b1179],[@b1180]). *Xenopus* melanophores and chick brain express a distinct receptor (x420, P49219; c346, P49288, initially termed Mel~1C~) coupled to the G~i/o~ family of G proteins, for which GPR50 has recently been suggested to be a mammalian counterpart [@b1173] although melatonin does not bind to GPR50 receptors.

Metabotropic glutamate receptors
================================

Overview
--------

Metabotropic glutamate (mGlu) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on Metabotropic Glutamate Receptors, [@b1243]) are activated by the endogenous ligands L-glutamic acid, L-serine-O-phosphate (L-SOP), N-acetylaspartylglutamate (NAAG) and L-cysteine sulphinic acid. Examples of agonists selective for mGlu receptors compared with ionotropic glutamate receptors are (1S,3R)-ACPD and L-CCG-I, which show limited selectivity for Group II receptors. An example of an antagonist selective for mGlu receptors is LY341495, which blocks mGlu~2~ and mGlu~3~ at low nanomolar concentrations, mGlu~8~ at high nanomolar concentrations, and mGlu~3~, mGlu~4~, mGlu~5~ and mGlu~7~ in the micromolar range [@b1210]. Three groups of native receptors are distinguishable on the bases of similarities of agonist pharmacology, primary sequence and G-protein effector coupling: Group I (mGlu~1~ and mGlu~5~), Group II (mGlu~2~ and mGlu~3~) and Group III (mGlu~4~, mGlu~6~, mGlu~7~ and mGlu~8~) (see Further reading). Group I mGlu receptors may be activated by 3,5-DHPG and (S)-3HPG [@b1190] and antagonized by (S)-hexylhomoibotenic acid [@b1221]. Group II mGlu receptors may be activated by LY389795 [@b1229], LY379268 [@b1229], LY354740 [@b1244],[@b1254], DCG-IV and (2R,3R)-APDC [@b1245], and antagonised by eGlu (4.3, [@b1207] and LY307452 [@b1200],[@b1253]. Group III mGlu receptors may be activated by (R,S)-4-PPG [@b1203].

In addition to orthosteric ligands that directly interact with the glutamate recognition site directly, allosteric modulators have been described. Negative allosteric modulators are listed separately. The positive allosteric modulators most often act as 'potentiators' of an orthosteric agonist response, without significantly activating the receptor in the absence of agonist.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      mGlu1 receptor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      mGlu5 receptor
  HGNC, UniProt                     GRM1, Q13255                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        GRM5, P41594
  Principal transduction            G~q/11~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             G~q/11~
  Selective agonists (pKi)          --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  (S)-(+)-CBPG (Partial agonist) (pEC~50~ 4.3 - Rat) [@b1225], CHPG (pIC~50~ 3.4) [@b1232]
  Selective antagonists (pKi)       AIDA (p*A*~2~ 4.2) [@b1231], 3-MATIDA (pIC~50~ 5.2-Rat) [@b1230], LY367385 (pIC~50~ 5.1) [@b1196], (S)-(+)-CBPG (pIC~50~ 4.2-Rat) [@b1225], (S)-TBPG (pIC~50~ 4.2-Rat) [@b1197]                                                                                                                                                                                                                                                                                                                                                                                                                     ACDPP (pIC~50~ 6.9) [@b1188]
  Selective allosteric regulators   PHCCC (Positive), Ro67-7476 (Positive) (p*K*~i~ 7.5--7.9 - Rat) [@b1213], Ro01-6128 (Positive) (p*K*~i~ 7.5--7.7 - Rat) [@b1213], Ro67-4853 (Positive) (p*K*~i~ 5.1 - Rat) [@b1213], JNJ16259685 (Negative) (pIC~50~ 8.9) [@b1217], A-841720 (Negative) (pIC~50~ 8.0) [@b1255], 3,5-dimethyl PPP (Negative) (pIC~50~ 7.8-Rat) [@b1227], YM298198 (Negative) (pIC~50~ 7.8-Rat) [@b1214], BAY 367620 (Negative) (pIC~50~ 6.8--8.0-Rat) [@b1193],[@b1216], EM-TBPC (Negative) (pIC~50~ 6.9-Rat) [@b1223], LY456236 (Negative) (pIC~50~ 6.9) [@b1218], CPCCOEt (Negative) (pIC~50~ 5.2--5.8) [@b1220]   MTEP (Negative) (p*K*~i~ 7.8) [@b1191], VU-1545 (Positive) (pEC~50~ 8.0) [@b1198], CDPPB (Positive) (pEC~50~ 7.6--8.0) [@b1211],[@b1219], MPEP (Negative) (pIC~50~ 7.4--7.7) [@b1202],[@b1204], fenobam (Negative) (pIC~50~ 7.2) [@b1241], DFB (Positive) (pIC~50~ 5.6--8.5) [@b1236],[@b1237], CPPHA (Positive) (pIC~50~ 6.3) [@b1237], SIB-1757 (Negative) (pIC~50~ 6.0--6.4) [@b1202],[@b1252], SIB-1893 (Negative) (pIC~50~ 5.9--6.5) [@b1202],[@b1252]
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------
  Nomenclature                      mGlu2 receptor                                                                                                                                                                                                            mGlu3 receptor
  HGNC, UniProt                     GRM2, Q14416                                                                                                                                                                                                              GRM3, Q14832
  Principal transduction            G~i/o~                                                                                                                                                                                                                    G~i/o~
  Selective antagonists (pKi)       PCCG-4 (pIC~50~ 5.1 - Rat) [@b1239]                                                                                                                                                                                       --
  Selective allosteric regulators   biphenylindanone A (Positive) (pEC~50~ 7.0) [@b1189], CBiPES (Positive) (pEC~50~ 7.0) [@b1209], Ro64-5229 (Negative) (pIC~50~ 7.0 - Rat) [@b1215], 4-MPPTS (Positive) (pIC~50~ 5.8) [@b1187],[@b1208],[@b1209],[@b1242]   --
  Endogenous agonists (pKi)         --                                                                                                                                                                                                                        NAAG (Selective) (4.7) [@b1246]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------

  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- --------------------------------------------
  Nomenclature                          mGlu4 receptor                                                                                                                          mGlu6 receptor                                                                 mGlu7 receptor                                                mGlu8 receptor
  HGNC, UniProt                         GRM4, Q14833                                                                                                                            GRM6, O15303                                                                   GRM7, Q14831                                                  GRM8, O00222
  Principal transduction                G~i/o~                                                                                                                                  G~i/o~                                                                         G~i/o~                                                        G~i/o~
  Endogenous agonists (pKi)             --                                                                                                                                      --                                                                             --                                                            L-SOP (pIC~50~ 6.2--7.2) [@b1224],[@b1254]
  Non-selective agonists (pKi)          L-AP4 (pEC~50~ 6.5) [@b1254], L-SOP (pEC~50~ 5.9) [@b1254]                                                                              --                                                                             L-SOP (pEC~50~ 4.5) [@b1254], L-AP4 (pEC~50~ 3.8) [@b1254]    L-AP4 (pIC~50~ 7.0--7.2) [@b1224]
  Selective agonists (pKi)              LSP4-2022 [@b1205]                                                                                                                      1-benzyl-APDC (pEC~50~ 4.7 - Rat) [@b1250], homo-AMPA (pEC~50~ 4.1) [@b1192]   LSP4-2022 (pEC~50~ 4.96) [@b1205]                             (S)-3,4-DCPG (pEC~50~ 7.5) [@b1248]
  Non-selective antagonists (pKi)       MAP4 (4.6 - Rat) [@b1206]                                                                                                               MAP4 (pIC~50~ 3.5 - Rat) [@b1240]                                              --                                                            MPPG (pIC~50~ 4.33) [@b1254]
  Selective antagonists (pKi)           --                                                                                                                                      THPG [@b1249]                                                                  --                                                            --
  Non-selective allosteric regulators   SIB-1893 (Positive) (pEC~50~ 6.3--6.8) [@b1226], MPEP (Positive) (pEC~50~ 6.3--6.6) [@b1226], PHCCC (Positive) (pEC~50~ 4.5) [@b1222]   --                                                                             AMN082 (Positive) (pEC~50~ 6.5--6.8) [@b1228]                 --
  Selective allosteric regulators       VU0361737 (Positive) (pEC~50~ 6.6) [@b1199], VU0155041 (Positive) (pEC~50~ 6.1) [@b1235]                                                --                                                                             MMPIP (Negative) (pIC~50~ 6.1--7.6 - Rat) [@b1234],[@b1247]   --
  Comment                               pEC50 values for MPEP and SIB-1893 were obtained in the presence of L-AP4 [@b1226]                                                      --                                                                             --                                                            --
  ------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- --------------------------------------------

Comments
========

The activity of NAAG as an agonist at mGlu~3~ receptors was questioned on the basis of contamination with glutamate [@b1194],[@b1201], but this has been refuted [@b1233].

Radioligand binding using a variety of radioligands has been conducted on recombinant receptors (for example, \[3H\]R214127 [@b1216] and \[3H\]YM298198 [@b1214] at mGlu~1~ receptors and \[3H\]M-MPEP [@b1202] and \[3H\]methoxymethyl-MTEP [@b1186] at mGlu~5~ receptors. Although a number of radioligands have been used to examine binding using native tissues, correlation with individual subtypes is limited. Many pharmacological agents have not been fully tested across all known subtypes of mGlu receptors. Potential differences linked to the species (*e.g.* human *versus* rat or mouse) of the receptors and the receptor splice variants are generally not known. The influence of receptor expression level on pharmacology and selectivity has not been controlled for in most studies, particularly those involving functional assays of receptor coupling.

(S)-(+)-CBPG is an antagonist at mGlu~1~, but is an agonist (albeit of reduced efficacy) at mGlu~5~ receptors. DCG-IV also exhibits agonist activity at NMDA glutamate receptors [@b1251], and is an antagonist at all group-III mGluRs with an IC50 of 30μM. A potential novel metabotrophic glutamate receptor coupled to phosphoinositide turnover has been observed in rat brain; it is activated by 4-methylhomoibotenic acid (ineffective as an agonist at recombinant Group I metabotrophic glutamate receptors), but resistant to LY341495 [@b1195]. There are also reports of a distinct metabotrophic glutamate receptor coupled to phospholipase D in rat brain, which does not readily fit into the current classification [@b1212],[@b1238].

A related class C receptor composed of two distinct subunits, T1R1 +T1R3 is also activated by glutamate and is responsible for umùami taste detection.

All selective antagonists at metabotropic glutamate receptors are competitive.

Motilin receptor
================

Overview
--------

Motilin receptors (provisional nomenclature, [@b1261]) are activated by a 22 amino-acid peptide derived from a precursor (MLN, P12872), which may also generate a motilin-associated peptide (MLN, P12872). These receptors are also suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics (often called motilides; *e.g.* erythromycin), although for many of these molecules the evidence is sparse.

  ------------------ --------------- -------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature       HGNC, UniProt   Principal transduction     Endogenous agonists (p*K*~i~)                      Selective agonists (p*K*~i~)                                                                                                                                                                                                                                                  Selective antagonists (p*K*~i~)                                                                                               Radioligands (*K*~d~)                                                    Comment
  motilin receptor   MLNR, O43193    G~q/11~[@b1259],[@b1260]   motilin (8.4 -- 8.7) [@b1258],[@b1265]--[@b1267]   GSK962040 (pEC~50~ 7.9) [@b1275], mitemcinal (pEC~50~ 7.5 -- 7.8 - Rabbit) [@b1263],[@b1273], azithromycin (pEC~50~ 5.5) [@b1256], mitemcinal (pIC~50~ 8.1 -- 8.2 - Rabbit) [@b1257], ABT-229 (pIC~50~ 7.2) [@b1274], erythromycin-A (pIC~50~ 5.5 -- 6.5) [@b1260],[@b1274]   MA-2029 (p*A*~2~ 9.2) [@b1271], GM-109 (p*A*~2~ 7.2 -- 7.5 - Rabbit) [@b1257],[@b1272], GM-109 (pIC~50~ 8.0 - Pig) [@b1262]   \[125I\]motilin (human) (Agonist, Full agonist) (1x10^-10^ M) [@b1260]   Note that for the complex macrolide structures, selectivity of action has often not been rigorously examined and other actions are possible (*e.g.* P2X inhibition by erythromycin; [@b1277]). Small molecule motilin receptor agonists are now described [@b1264],[@b1270],[@b1276].
  ------------------ --------------- -------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

In laboratory rodents, the gene encoding the motilin percursor appears to be absent, while the receptor appears to be a pseudogene. Functions of motilin (MLN, P12872) are not usually detected in rodents, although brain and other responses to motilin (MLN, P12872) and the macrolide ABT-229 have been reported and the mechanism of these actions are obscure [@b1268],[@b1269].

Neuromedin U receptors
======================

Overview
--------

Neuromedin U receptors (provisional nomenclature, [@b1279]) are activated by the endogenous 25 amino acid peptide neuromedin U (NMU-25 (NMU, P48645), NMU), a peptide originally isolated from pig spinal cord [@b1285]. In humans, NMU-25 appears to be the sole product of a precursor gene (NMU, P48645) showing a broad tissue distribution, but which is expressed at highest levels in the upper gastrointestinal tract, CNS, bone marrow and fetal liver. Much shorter versions of NMU are found in some species, but not in human, and are derived at least in some instances from the proteolytic cleavage of the longer NMU. Despite species differences in NMU structure, the C-terminal region (particularly the C-terminal pentapeptide) is highly conserved and contains biological activity. Neuromedin S (NMS-33 (NMS, Q5H8A3)) has also been identified as an endogenous agonist [@b1286]. NMS-33 is, as its name suggests, a 33 amino-acid product of a precursor protein derived from a single gene and contains an amidated C-terminal heptapeptide identical to NMU. NMS-33 appears to activate NMU receptors with equivalent potency to NMU-25.

  --------------------------------- --------------------------- --------------------------------
  Nomenclature                      NMU1 receptor               NMU2 receptor
  HGNC, UniProt                     NMUR1, Q9HB89               NMUR2, Q9GZQ4
  Principal transduction            G~q/11~ [@b1278],[@b1280]   G~q/11~ [@b1278],[@b1281]
  Selective antagonists (p*K*~i~)   --                          R-PSOP (p*K*~B~ 7.04) [@b1283]
  --------------------------------- --------------------------- --------------------------------

Comments
========

NMU1 and NMU2 couple predominantly to G~q/11~ although there is evidence of good coupling to G~i/o~ [@b1278],[@b1281],[@b1282]. NMU1 and NMU2 can be labelled with \[^125^I\]-NMU and \[^125^I\]-NMS (of various species, *e.g.* [@b1284]), BODIPY® TMR-NMU or Cy3B-NMU-8 [@b1278]. A range of radiolabelled (^125^I-), fluorescently labelled (*e.g.* Cy3, Cy5, rhodamine and FAM) and biotin labelled versions of NMU-25 (NMU, P48645) and NMS-33 (NMS, Q5H8A3) are now commercially available.

Neuropeptide FF/neuropeptide AF receptors
=========================================

Overview
--------

A single propeptide precursor (NPFF, O15130) generates the octapeptides NPFF (FLFQPQRF-NH~2~, neuropeptide FF or F-8-F-amide) and NPSF (SLAAPQRF-NH~2~, neuropeptide SF) and the octadecapeptide NPAF (AGEGLSSPFWSLAAPQRF-NH~2~, neuropeptide AF or A-18-F-amide). NPFF and NPAF were originally isolated from bovine brain [@b1298].

  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      NPFF1 receptor                                                                                                                                                               NPFF2 receptor
  HGNC, UniProt                     NPFFR1, Q9GZQ6                                                                                                                                                               NPFFR2, Q9Y5X5
  Principal transduction            G~q/11~                                                                                                                                                                      G~i/o~ [@b1293]
  Rank order of potency             FMRF, NPFF \> NPAF \> NPSF, QRFP, PrRP-31 (PRLH) [@b1287]                                                                                                                    NPAF, NPFF \> PrRP-31 (PRLH) \> FMRF, QRFP (QRFP, P83859) \> NPSF [@b1287]
  Endogenous agonists (p*K*~i~)     RFRP-3 (NPVF, Q9HCQ7) (Selective) (9.2 -- 9.3) [@b1288],[@b1289],[@b1292], NPFF (NPFF, O15130) (Selective) (8.5 -- 9.9) [@b1287],[@b1288],[@b1292]                           NPFF (Selective) (9.7) [@b1288],[@b1291]
  Selective agonists (p*K*~i~)      --                                                                                                                                                                           dNPA (10.6) [@b1294],[@b1295], AC263093 (pEC~50~ 5.2 -- 5.9) [@b1290]
  Selective antagonists (p*K*~i~)   AC262620 (7.7 -- 8.1) [@b1290], AC262970 (7.4 -- 8.1) [@b1290], RF9 (7.2) [@b1296]                                                                                           --
  Radioligands (*K*~d~)             \[125I\]NPFF (Agonist, Full agonist) [@b1287], \[125I\]Y-RFRP-3 (Agonist, Full agonist) (8x10^-9^ M) [@b1288], \[3H\]NPVF (Agonist, Full agonist) (2.65x10^-9^ M) [@b1297]   \[125I\]NPFF (Agonist, Full agonist) [@b1287], \[125I\]EYF (Agonist, Full agonist) (6.3x10^-11^ M) [@b1292], \[3H\]EYF (Agonist, Full agonist) (5.4x10^-10^ M) [@b1297]
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

An orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF receptors, but does not distinguish between the NPFF1 and NPFF2 subtypes (p*K*~i~ 7.1 and 7.2, respectively, [@b1296]).

Neuropeptide S receptor
=======================

Overview
--------

The neuropeptide S receptor (NPS, provisional nomenclature, [@b1300]) responds to the 20 amino-acid peptide neuropeptide S derived from the precursor (NPS, P0C0P6).

  -------------- --------------- --------------------------------- ------------------------------- ---------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Principal transduction            Endogenous agonists (p*K*~i~)   Radioligands (*K*~d~)
  NPS receptor   NPSR1, Q6W5P4   G~s~, G~q/11~ [@b1301],[@b1302]   NPS (pEC~50~ 8.0) [@b1303]      \[125I\]Tyr10NPS (human) (Agonist, Full agonist) (3.3x10^−10^ M) [@b1303]
  -------------- --------------- --------------------------------- ------------------------------- ---------------------------------------------------------------------------

Comments
========

Polymorphisms in the NPS receptor have been suggested to be associated with asthma [@b1302] and irritable bowel syndrome [@b1299].

Neuropeptide W/neuropeptide B receptors
=======================================

Overview
--------

The neuropeptide BW receptor 1 (NPBW1) is activated by two 23-amino-acid peptides, neuropeptide W (NPW-23 (NPW, Q8N729)) and neuropeptide B (NPB-23 (NPB, Q8NG41)) [@b1305],[@b1309]. C-terminally extended forms of the peptides (NPW-30 (NPW, Q8N729) and NPB-29 (NPB, Q8NG41)) also activate NPBW1 [@b1304]. Unique to both forms of NPB is the N-terminal bromination of the first tryptophan residue. des-Br-NPB-23 (NPB, Q8NG41) and des-Br-NPB-29 (NPB, Q8NG41) were not found to be major components of bovine hypothalamic tissue extracts. The NPBW2 receptor is activated by the short and C-terminal extended forms of NPB and NPW [@b1304].

  ------------------------------ ----------------------------------------------------------- -----------------------------------------------------------
  Nomenclature                   NPBW1 receptor                                              NPBW2 receptor
  HGNC, UniProt                  NPBWR1, P48145                                              NPBWR2, P48146
  Principal transduction         G~i/0~ [@b1307]                                             G~i/0~ [@b1307]
  Rank order of potency          NPB-29 \> NPB-23 \> NPW-23 \> NPW-30 [@b1304]               NPW-23 \> NPW-30 \> NPB-29 \> NPB-23 [@b1304]
  Selective agonists (p*K*~i~)   Ava3 (9.37--9.43) [@b1306], Ava5 (8.8--9.0) [@b1306]        --
  Radioligands (*K*~d~)          \[125I\]NPW-23 (human) (Agonist) (4.4x10^−10^ M) [@b1310]   \[125I\]NPW-23 (human) (Agonist) (1.99x10^−8^ M) [@b1309]
  ------------------------------ ----------------------------------------------------------- -----------------------------------------------------------

Comments
========

Potency measurements were conducted with heterologously-expressed receptors with a range of 0.14--0.57 nM (NPBW1) and 0.98--21 nM (NPBW2).

NPBW1^-/-^ mice show changes in social behavior, suggesting that the NPBW1 pathway may have an important role in the emotional responses of social interaction [@b1308].

Neuropeptide Y receptors
========================

Overview
--------

Neuropeptide Y (NPY) receptors (nomenclature agreed by NC-IUPHAR on Neuropeptide Y Receptors, [@b1325]) are activated by the endogenous peptides NPY (NPY, P01303), NPY 3--36 (NPY, P01303), peptide YY (PYY (PYY, P10082)), PYY-(3--36) (PYY, P10082) and pancreatic polypeptide (PP (PPY, P01298)). The receptor originally identified as the Y3 receptor has been identified as the CXCR4 chemokine recepter (originally named LESTR, [@b1323]). The y6 receptor is a functional gene product in mouse, absent in rat, but contains a frame-shift mutation in primates producing a truncated non-functional gene [@b1321]. Many of the agonists exhibit differing degrees of selectivity dependent on the species examined. For example, the relative potency of PP (PPY, P01298) is greater at the rat Y~4~ receptor than at the human receptor [@b1317]. In addition, many agonists lack selectivity for individual subtypes, but can exhibit comparable potency against pairs of NPY receptor subtypes, or have not been examined for activity at all subtypes. \[^125^I\]-PYY or \[^125^I\]-NPY can be used to label Y~1~, Y~2~, Y~5~ and Y~6~ subtypes non-selectively, while \[125I\]\[cPP(1--7), NPY(19--23), Ala31, Aib32, Gln34\]hPP may be used to label Y~5~ receptors preferentially.

  --------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -----------------
  Nomenclature                      Y1 receptor                                                                                                 Y2 receptor                                                                Y4 receptor                                          Y5 receptor                                                                                                     y6 receptor
  HGNC, UniProt                     NPY1R, P25929                                                                                               NPY2R, P49146                                                              NPY4R, P50391                                        NPY5R, Q15761                                                                                                   NPY6R, Q99463
  Principal transduction            G~i/o~                                                                                                      G~i/o~                                                                     G~i/o~                                               G~i/o~                                                                                                          G~i/o~
  Rank order of potency             NPY \> PYY \>\> PP                                                                                          NPY \> PYY \>\> PP                                                         PP \> NPY = PYY                                      NPY \> PYY \> PP                                                                                                NPY = PYY \> PP
  Endogenous agonists (p*K*~i~)     --                                                                                                          NPY 3--36 (Selective), PYY-(3--36) (9.2--9.7) [@b1318],[@b1320]            PP (8.7--10.9) [@b1311],[@b1324],[@b1327],[@b1329]   --                                                                                                              --
  Selective agonists (p*K*~i~)      \[Leu31,Pro34\]PYY (human), \[Pro34\]NPY, \[Pro34\]PYY (human), \[Leu31,Pro34\]NPY (pEC~50~ 7.1) [@b1314]   --                                                                         --                                                   \[Ala31,Aib32\]NPY (pig) (pIC~50~ 8.2) [@b1313]                                                                 --
  Selective antagonists (p*K*~i~)   BIBP3226 (8.1--8.2) [@b1319],[@b1326], BIBO3304 (pIC~50~ 9.5) [@b1328]                                      BIIE0246 (pIC~50~ 8.5) [@b1315], JNJ-5207787 (pIC~50~ 6.9--7.1) [@b1312]   --                                                   L-152,804 (7.6) [@b1322]                                                                                        --
  Radioligands (*K*~d~)             \[125I\]\[Leu31,Pro34\]NPY (Agonist, Full agonist), \[3H\]BIBP3226 (Antagonist) (2.1x10^−9^ M)              \[125I\]PYY-(3--36) (human) (Agonist, Full agonist)                        \[125I\]PP (human) (Agonist, Full agonist)           \[125I\]\[cPP(1--7), NPY(19--23), Ala31, Aib32, Gln34\]hPP (Agonist) (5x10^−10^--7x10^−10^ M -- Rat) [@b1316]   --
  --------------------------------- ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -----------------

Comments
========

The Y~1~ agonists indicated are selective relative to Y~2~ receptors. BIBP3226 is selective relative to Y~2~, Y~4~ and Y~5~ receptors [@b1319]. NPY-(13--36) is Y~2~ selective relative to Y~1~ and Y~5~ receptors. PYY-(3--36) (PYY, P10082) is Y~2~ selective relative to Y~1~ receptors.

Neurotensin receptors
=====================

Overview
--------

Neurotensin receptors (provisional nomenclature, [@b1330]) are activated by the endogenous tridecapeptide neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) derived from a precursor (NTS, P30990), which also generates neuromedin N, an agonist at the NTS~2~ receptor. A nonpeptide antagonist, SR142948A, shows high affinity (pK~i~∼9) at both NTS~1~ and NTS~2~ receptors [@b1331]. \[3H\]neurotensin (human, mouse, rat) and \[125I\]neurotensin (human, mouse, rat) may be used to label NTS~1~ and NTS~2~ receptors at 0.1--0.3 and 3--5 nM concentrations respectively.

  --------------------------------- ----------------------------------------------------------- ---------------------------------------
  Nomenclature                      NTS1 receptor                                               NTS2 receptor
  HGNC, UniProt                     NTSR1, P30989                                               NTSR2, O95665
  Principal transduction            G~q/11~                                                     G~q/11~
  Rank order of potency             neurotensin \> neuromedin N [@b1332]                        neurotensin = neuromedin N [@b1335]
  Selective agonists (p*K*~i~)      JMV449 [@b1338]                                             levocabastine (6.8) [@b1335],[@b1337]
  Selective antagonists (p*K*~i~)   SR48692 (pIC~50~ 7.5--8.2) [@b1331]                         --
  Radioligands (*K*~d~)             \[3H\]SR48692 (Antagonist) (3.2x10^−9^ M -- Rat) [@b1333]   --
  --------------------------------- ----------------------------------------------------------- ---------------------------------------

Comments
========

neurotensin (NTS, P30990) appears to be a low-efficacy agonist at the NTS~2~ receptor [@b1339], while the NTS~1~ receptor antagonist SR48692 is an agonist at NTS2 receptors [@b1339]. An additional protein, provisionally termed NTS3 (also known as NTR3, gp95 and sortilin; ENSG00000134243), has been suggested to bind lipoprotein lipase and mediate its degradation [@b1336]. It has been reported to interact with the NTS~1~ receptor [@b1334] and has been implicated in hormone trafficking and/or neurotensin uptake.

Opioid receptors
================

Overview
--------

Opioid and opioid-like receptors are activated by a variety of endogenous peptides including \[Met\]enkephalin (PENK, P01210) (met), \[Leu\]enkephalin (PENK, P01210) (leu), β-endorphin (POMC, P01189) (β-end), α-neodynorphin (PDYN, P01213), dynorphin A (PDYN, P01213) (dynA), dynorphin B (PDYN, P01213) (dynB), big dynorphin (PDYN, P01213) (Big dyn), nociceptin/orphanin FQ (N/OFQ (PNOC, Q13519)); endomorphin-1 and endomorphin-2 are also potential endogenous peptides. The Greek letter names for the opioid receptors, μ, δ and κ, are well established, and IUPHAR considers these names most appropriate [@b1352]. The human N/OFQ receptor is considered 'opioid-related' rather than opioid because while it exhibits a high degree of structural homology with the conventional opioid receptors [@b1368], it displays a distinct pharmacology.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Nomenclature                      δ receptor                                                                                                                                                      κ receptor                                                                                                                                                                                       μ receptor                                                                                NOP receptor
  HGNC, UniProt                     OPRD1, P41143                                                                                                                                                   OPRK1, P41145                                                                                                                                                                                    OPRM1, P35372                                                                             OPRL1, P41146
  Principal transduction            G~i/o~                                                                                                                                                          G~i/o~                                                                                                                                                                                           G~i/o~                                                                                    G~i/o~
  Rank order of potency             --                                                                                                                                                              --                                                                                                                                                                                               --                                                                                        N/OFQ \>\> dynorphin A
  Principal endogenous agonists     β-endorphin, \[Leu\]enkephalin, \[Met\]enkephalin                                                                                                               big dynorphin, dynorphin A                                                                                                                                                                       β-endorphin, \[Met\]enkephalin, \[Leu\]enkephalin, endomorphin-1, endomorphin-2           --
  Endogenous agonists (p*K*~i~)     --                                                                                                                                                              --                                                                                                                                                                                               endomorphin-2 (Selective) (8.5 -- Rat) [@b1388], endomorphin-1 (8.3) [@b1353],[@b1388]    N/OFQ (Selective) (9.7--10.4) [@b1341],[@b1365]--[@b1367],[@b1372]
  Selective agonists (p*K*~i~)      \[D-Ala2\]deltorphin I (p*K*~d~ 9.35) [@b1350],[@b1382], \[D-Ala2\]deltorphin II (8.8) [@b1351], DPDPE (8.8) [@b1369],[@b1384], SNC80 (7.2) [@b1345],[@b1376]   enadoline (9.6) [@b1357],[@b1370], U69593 (9.5) [@b1363],[@b1384], U50488 (7.8--9.7) [@b1348],[@b1373],[@b1379],[@b1384],[@b1386],[@b1392],[@b1393], salvinorin A (7.8--8.7) [@b1343],[@b1377]   sufentanil (9.9) [@b1385], DAMGO (9.3) [@b1355],[@b1384], PL017 (8.2) [@b1347],[@b1384]   N/OFQ-(1--13)-NH2 (10.1--10.4) [@b1341],[@b1354],[@b1365],[@b1372], Ro64-6198 (9.6) [@b1358]
  Selective antagonists (p*K*~i~)   naltriben (10.0) [@b1381],[@b1384], naltrindole (9.7) [@b1375],[@b1384], TIPPψ (Inverse agonist) (9.0) [@b1378],[@b1384]                                        nor-binaltorphimine (8.9--11.0) [@b1373],[@b1374],[@b1379],[@b1384],[@b1392],[@b1393], GNTI (9.74--9.9) [@b1359],[@b1373],[@b1383]                                                               CTAP (8.6) [@b1347],[@b1384]                                                              UFP-101 (10.2) [@b1346], SB 612111 (9.5) [@b1391], J-113397 (pIC~50~ 8.3) [@b1361]
  Radioligands (*K*~d~)             \[3H\]deltorphin II [@b1344], \[3H\]DPDPE [@b1340], \[3H\]naltriben (Antagonist) [@b1364], \[3H\]naltrindole (Antagonist) [@b1387]                              \[3H\]CI977 [@b1380], \[3H\]U69593 (Agonist, Full agonist) (2x10^−9^--1.6x10^−9^ M) [@b1363],[@b1373],[@b1379]                                                                                   \[3H\]DAMGO (Agonist, Full agonist) [@b1390], \[3H\]PL017 (Agonist) [@b1356]              \[3H\]N/OFQ (Agonist, Full agonist) (6.3x10^-11^ M) [@b1349],[@b1367]
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------

Comments
========

Subtypes of μ (μ1, μ2), δ (δ1, δ2) and κ (κ1, κ2, κ3) receptor have been proposed based primarily on binding studies with poorly selective ligands or results from *in vivo* studies. Only three naloxone-sensitive opioid receptors have been cloned, and while the μ-receptor in particular may be subject to extensive alternative splicing, these putative isoforms have not been definitively correlated with any of the proposed subtypes. Opioid receptor subtypes may reflect heterodimerization of opioid receptors with each other or with other GPCR [@b1360], but evidence for heterodimers in native cells is equivocal. A distinct met-enkephalin receptor lacking structural resemblance to the opioid receptors listed has been identified (OGFR, 9NZT2) and termed an opioid growth factor receptor [@b1389]. Opioid receptor subtypes may reflect heterodimerization of opioid receptors with each other or with other GPCR, and while there is increasing evidence for heterodimers in native cells, the consequences this heterodimerization has for signalling remains largely unknown. For μ-opioid receptors at least, dimerization does not seem to be required for signalling [@b1362].

endomorphin-1 and endomorphin-2 have been identified as highly selective, putative endogenous agonists for the μ-opioid receptor. At present, however, the mechanisms for endomorphin synthesis *in vivo* have not been established, and there is no gene identified that encodes for either. Thus, the status of these peptides as endogenous ligands remains unproven.

Two areas of increasing importance in defining opioid receptor function are the presence of functionally relevant single nucleotide polymorphisms in human μ-receptors [@b1371] and the identification of biased signalling by opioid receptor ligands, in particular, compounds previously characterized as antagonists [@b1342]. Pathway bias for agonists makes general rank orders of potency and efficacy somewhat obsolete, and they have, therefore, been removed from the table. As ever, the mechanisms underlying the acute and long term regulation of opiod receptor function are the subject of intense investigation and debate.

Orexin receptors
================

Overview
--------

Orexin receptors (nomenclature as agreed by NC-IUPHAR, see [@b1395]**)** are activated by the endogenous polypeptides orexin-A (HCRT, O43612) and orexin-B (HCRT, O43612) (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage [@b1407]. Binding to both receptors may be accomplished with \[125I\]orexin A (human, mouse, rat) [@b1397].

  --------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      OX1 receptor                                                                         OX2 receptor
  HGNC, UniProt                     HCRTR1, O43613                                                                       HCRTR2, O43614
  Principal transduction            G~q/11~                                                                              G~q/11~
  Rank order of potency             orexin-A \> orexin-B                                                                 orexin-A = orexin-B
  Selective agonists (p*K*~i~)      --                                                                                   \[Ala11, D-Leu15\]orexin-B (pEC~50~ 9.9) [@b1394]
  Selective antagonists (p*K*~i~)   SB-334867 (7.4 -- 7.5) [@b1402],[@b1404], SB-408124 (7.2 -- 7.6) [@b1399],[@b1402]   N-ethyl-2-\[(6-methoxy-pyridin-3-yl)-(toluene-2-sulphonyl)-amino\]-N-pyridin-3-ylmethyl-acetamide (9.0) [@b1401], 1-(2,4-dibromo-phenyl)-3-((4S,5S)-2,2-dimethyl-4-phenyl-\[1394,1396\]dioxan-5-yl)-urea (7.9 -- 8.6) [@b1403], TCS-OX2-29 (7.4) [@b1396]
  --------------------------------- ------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

The primary coupling of orexin receptors to G~q/11~ proteins is rather speculative and based on the strong activation of phospholipase C. Coupling of both receptors to G~i/o~ and G~s~ has also been reported [@b1398],[@b1406]; for most cellular responses observed, the G protein pathway is unknown. The rank order of endogenous agonist potency may depend on the cellular signal transduction machinery. The synthetic \[Ala11, D-Leu15\]orexin-B may show poor OX~2~ receptor selectivity [@b1405].

Loss-of-function mutations in the gene encoding the OX~2~ receptor underlie canine hereditary narcolepsy [@b1400].

Oxoglutarate receptor
=====================

Overview
--------

the oxoglutarate receptor (NC-IUPHAR recommended nomenclature, see Davenport et al., 2004) has been suggested to respond to one of the intermediates of the citric acid cycle [@b1408].

  ----------------------- ------------------ -------------- ------------------------ -------------------------------------------------------------
  Nomenclature            HGNC gene symbol   UniProtKB AC   Principal transduction   Endogenous agonists (p*K*~i~)
  oxoglutarate receptor   OXGR1              Q96P68         G~q~ [@b1408]            α-ketoglutaric acid (pEC~50~ 3.3 -- 4.49) [@b1408],[@b1409]
  ----------------------- ------------------ -------------- ------------------------ -------------------------------------------------------------

P2Y receptors
=============

Overview
--------

P2Y receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on P2Y Receptors, [@b1410],[@b1411]) are activated by the endogenous ligands ATP, ADP, UTP, UDP and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'UTP-preferring (or ATP-, *etc*.) P2Y receptor' or 'P2Y~1~-like', *etc*., until further, as yet undefined, corroborative criteria can be applied.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Nomenclature                      P2Y1 receptor                                                                                                                                           P2Y2 receptor                                                                                                                                                          P2Y4 receptor                                        P2Y6 receptor
  HGNC, UniProt                     P2RY1, P47900                                                                                                                                           P2RY2, P41231                                                                                                                                                          P2RY4, P51582                                        P2RY6, Q15077
  Principal transduction            G~q/11~                                                                                                                                                 G~q/11~                                                                                                                                                                G~q/11~                                              G~q/11~
  Rank order of potency             ADP\>ATP                                                                                                                                                UTP=ATP                                                                                                                                                                UTP\>ATP (at rat recombinant receptors, UTP = ATP)   UDP\>\>UTP\>ATP
  Endogenous agonists (p*K*~i~)     --                                                                                                                                                      --                                                                                                                                                                     --                                                   UDP (pEC~50~ 6.5) [@b1423]
  Selective agonists (p*K*~i~)      MRS2365 (pEC~50~ 9.4) [@b1421], ADPβS (pEC~50~ 7.3) [@b1459], 2MeSADP (pIC~50~ 5.4 -- 7.0) [@b1458],[@b1461]                                            2-thioUTP (pEC~50~ 7.3) [@b1426], PSB1114 (pEC~50~ 6.9) [@b1427], Ap4A (pEC~50~ 6.1) [@b1419],[@b1457], UTPγS (pEC~50~ 5.8) [@b1443], MRS2768 (pEC~50~ 5.7) [@b1441]   UTPγS [@b1444], MRS4062 (pEC~50~ 7.6) [@b1448]       MRS2957 (pEC~50~ 7.9) [@b1447], 5-iodoUDP (pEC~50~ 7.82) [@b1416], 3-phenacyl-UDP (pEC~50~ 7.2) [@b1426]
  Selective antagonists (p*K*~i~)   MRS2500 (8.8 -- 9.1) [@b1420],[@b1438], MRS2279 (7.9) [@b1461], MRS2179 (7.0 -- 7.1) [@b1418],[@b1461], 2,2\'-pyridylisatogen tosylate (6.8) [@b1429]   AR-C118925XX (pIC~50~ ∼6.0) [@b1436]                                                                                                                                   ATP (p*K*~d~ 6.2) [@b1437]                           MRS2578 (pIC~50~ 7.4) [@b1445]
  Radioligands (*K*~d~)             \[35S\]ADPβS (Agonist), \[3H\]2MeSADP (Agonist), \[3H\]MRS2279 (Antagonist) (8x10^-9^ M) [@b1461]                                                       --                                                                                                                                                                     --                                                   --
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------

  --------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------------
  Nomenclature                      P2Y11 receptor                                                                                            P2Y12 receptor                                                                                                                                                       P2Y13 receptor                    P2Y14 receptor
  HGNC, UniProt                     P2RY11, Q96G91                                                                                            P2RY12, Q9H244                                                                                                                                                       P2RY13, Q9BPV8                    P2RY14, Q15391
  Principal transduction            G~s~, G~q/11~                                                                                             G~i/o~                                                                                                                                                               G~i/o~                            G~q/11~
  Rank order of potency             ATP\>UTP                                                                                                  ADP\>\>ATP                                                                                                                                                           ADP\>\>ATP                        UDP-glucose
  Endogenous agonists (p*K*~i~)     --                                                                                                        ADP (5.9) [@b1432], ATP (5.2) [@b1432]                                                                                                                               --                                --
  Selective agonists (p*K*~i~)      NAADP [@b1452], NAD [@b1453], AR-C67085 (pEC~50~ 8.52) [@b1413],[@b1424], NF546 (pEC~50~ 6.27) [@b1449]   2MeSADP (9.2) [@b1432]                                                                                                                                               --                                MRS2690 (pEC~50~ 6.64 -- 7.31) [@b1430],[@b1442]
  Selective antagonists (p*K*~i~)   NF157 (7.35) [@b1460], NF340 (pIC~50~ 6.4 -- 7.1) [@b1449]                                                PSB-0739 (7.6) [@b1414], ARL66096 (pIC~50~ 7.95) [@b1433],[@b1434]                                                                                                   MRS2211 (pIC~50~ 5.97) [@b1439]   --
  Radioligands (*K*~d~)             --                                                                                                        \[3H\]PSB-0413 (Antagonist) (3.16x10^-9^ -- 4.57x10^-9^ M) [@b1425],[@b1455], \[3H\]2MeSADP (Agonist, Full agonist) (IC~50~ 2.5x10^-10^ -- 3.16x10^-8^ M) [@b1459]   --                                --
  --------------------------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------------

Comments
========

AR-C69931MX (cangrelor) shows selectivity for P2Y~12~ and P2Y~13~ receptors compared with other P2Y receptors [@b1446],[@b1459]. NF157 also has antagonist activity at P2X~1~ receptors [@b1460]. UDP has been reported to be an antagonist at the P2Y~14~ receptor [@b1428].

An orphan GPCR suggested to be a 'P2Y~15~' receptor [@b1435] appears not to be a genuine nucleotide receptor [@b1411], but rather responds to dicarboxylic acids [@b1431]. Further P2Y-like receptors have been cloned from non-mammalian sources; a clone from chick brain, termed a p2y~3~ receptor (ENSGALG00000017327), couples to the G~q/11~ family of G proteins and shows the rank order of potency ADP \> UTP \> ATP = UDP [@b1462]. In addition, human sources have yielded a clone with a preliminary identification of p2y5 (LPAR6, P43657) and contradictory evidence of responses to ATP [@b1440],[@b1463]. This protein is now classified as LPA4, a receptor for lysophosphatidic acid (LPA) [@b1456],[@b1464]. The clone clone termed p2y9 (LPAR4, 99677, [@b1454]). The clone p2y7 (NOP9, Q86U38), originally suggested to be a P2Y receptor [@b1412], has been shown to encode a leukotriene receptor [@b1465]. A P2Y receptor that was initially termed a p2y8 receptor (P79928) has been cloned from *Xenopus* laevis; it shows the rank order of potency ADPβS \> ATP = UTP = GTP = CTP = TTP = ITP \> ATPγS and elicits a Ca^2+^-dependent Cl- current in Xenopus oocytes [@b1417]. The p2y10 clone (P2RY10, O00398) lacks functional data. Diadenosine polyphosphates also have effects on as yet uncloned P2Y-like receptors with the rank order of potency of Ap4A \> Ap5a \> Ap3a, coupling via G~q/11~ [@b1419]. P2Y-like receptors have recently been described on mitochondria [@b1415]. CysLT1 and CysLT2 leukotriene receptors respond to nanomolar concentrations of UDP, although they are activated principally by leukotrienes LTC4 and LTD4 [@b1450],[@b1451]; Human GPR17 (13304) and rat GPR17, which are structurally related to CysLT and P2Y receptors, are also activated by leukotrienes as well as UDP and UDP-glucose [@b1422]. Activity at the rat GPR17 is inhibited by submicromolar concentrations of MRS2179 and cangrelor [@b1422].

Parathyroid hormone receptors
=============================

Overview
--------

The parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH~1~ receptor) is activated by precursor-derived peptides: PTH (PTH, P01270) (84 amino acids), and PTHrP (PTHLH, P12272) (141 amino-acids) and related peptides (PTH-(1-34), PTHrP-(1-36)). The parathyroid hormone 2 receptor (PTH~2~ receptor) is activated by the precursor-derived peptide TIP39 (39 amino acids, PTH2, Q96A98). \[^125^I\]PTH may be used to label both PTH~1~ and PTH~2~ receptors.

  ------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------
  Nomenclature                    PTH1 receptor                                                                                 PTH2 receptor
  HGNC, UniProt                   PTH1R, Q03431                                                                                 PTH2R, P49190
  Principal transduction          G~s~, G~q/11~                                                                                 G~s~, G~q/11~
  Rank order of potency           PTH = PTHrP                                                                                   TIP39, PTH \>\> PTHrP
  Endogenous agonists (p*K*~i~)   --                                                                                            TIP39 (pIC~50~ 7.6 -- 9.2) [@b1468],[@b1469]
  Selective agonists (p*K*~i~)    PTHrP-(1-34) (pIC~50~ 7.8 -- 8.1 - Rat) [@b1467], PTH-(1-34) (human) (pIC~50~ 7.4) [@b1466]   --
  ------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------

Comments
========

Although PTH (PTH, P01270) is an agonist at human PTH~2~ receptors, it fails to activate the rodent orthologues. TIP39 (PTH2, Q96A98) is a weak antagonist at PTH~1~ receptors [@b1470].

Peptide P518 receptor
=====================

Overview
--------

The peptide P518 receptor is also known as the QRFP receptor and responds to the endogenous peptide agonist QRFP.

  --------------- --------------- -------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Nomenclature    HGNC, UniProt   Principal transduction     Endogenous agonists (p*K*~i~)                                                                              Radioligands (*K*~d~)
  QRFP receptor   QRFPR, Q96P65   G~q/11~, G~i/o~ [@b1471]   QRFP26 (QRFP) (pEC~50~ 8.15) [@b1472], QRFP (QRFP, P83859) (pIC~50~ 7.8 -- 9.28 − Rat) [@b1471],[@b1474]   \[125I\]QRFP (human) (Agonist, Full agonist) (5.01x10^-11^ -- 1.58x10^-8^ M) [@b1471],[@b1473],[@b1474]
  --------------- --------------- -------------------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------

Comments
========

The orphan receptor GPR83 (9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.

Platelet-activating factor receptor
===================================

Overview
--------

Platelet-activating factor (PAF, 1-*O*-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inflammatory roles. The PAF receptor (provisional nomenclature, see [@b1475]) is activated by PAF and other suggested endogenous ligands are oxidized phosphatidylcholine [@b1479] and lysophosphatidylcholine [@b1482]. It may also be activated by bacterial lipopolysaccharide [@b1481].

  -------------- --------------- ------------------------ ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Principal transduction   Selective agonists (p*K*~i~)   Selective antagonists (p*K*~i~)                                                                                                                       Radioligands (*K*~d~)
  PAF receptor   PTAFR, P25105   G~q/11~, G~i~, G~o~      mc-PAF                         SR 27417 (10.3) [@b1478], L659989 (8.1), ginkgolide B (6.4), apafant (5.2 -- 7.5) [@b1483],[@b1484], CV-6209 (pIC~50~ 8.1 -- 8.3) [@b1477],[@b1480]   \[3H\]PAF (Agonist, Full agonist) (1.6x10^-9^ -- 1.3x10^-9^ M) [@b1476],[@b1480]
  -------------- --------------- ------------------------ ------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------

Comments
========

Note that a previously recommended radioligand (\[3H\]apafant; K~d~ 44.6 nM) is currently unavailable.

Prokineticin receptors
======================

Overview
--------

Prokineticin receptors (provisional nomenclature, [@b1486]) respond to the cysteine-rich 81--86 amino-acid peptides prokineticin-1 (PROK1, Q9HC23) (also known as endocrine-gland-derived vascular endothelial growth factor, mambakine) and prokineticin-2 (PROK2, Q9HC23) (protein Bv8 homologue). An orthologue of PROK1 from black mamba (*Dendroaspis polylepi*s) venom, mamba intestinal toxin 1 (MIT1, [@b1491]) is a potent, non-selective agonist at prokineticin receptors [@b1488], while Bv8, an orthologue of PROK2 from amphibians (*Bombina sp*., [@b1489]), is equipotent at recombinant PK~1~ and PK~2~ receptors [@b1490], and has high potency in macrophage chemotaxis assays, which are lost in PK~1~-null mice [@b1485].

  ------------------------ ------------------------------------------------------------- -------------------------------------------------------------
  Nomenclature             PKR1                                                          PKR2
  HGNC, UniProt            PROKR1, Q8TCW9                                                PROKR2, Q8NFJ6
  Principal transduction   G~q/11~ [@b1487],[@b1488]                                     G~q/11~ [@b1487],[@b1488]
  Rank order of potency    prokineticin-2 \> prokineticin-1 [@b1487],[@b1488],[@b1492]   prokineticin-2 \> prokineticin-1 [@b1487],[@b1488],[@b1492]
  ------------------------ ------------------------------------------------------------- -------------------------------------------------------------

Prolactin-releasing peptide receptor
====================================

Overview
--------

The precursor (PRLH, P81277) for PrRP generates 31 and 20-amino-acid versions. QRFP (QRFP, P83859) (named after a pyroglutamylated arginine-phenylalanine-amide peptide) is a 43 amino acid peptide derived from QRFP (P83859) and is also known as P518 or 26RFa. RFRP is an RF amide-related peptide [@b1495] derived from a FMRFamide-related peptide precursor (NPVF, Q9HCQ7), which is cleaved to generate neuropeptide NPSF (NPFF, O15130), neuropeptide RFRP-1 (NPVF, Q9HCQ7), neuropeptide RFRP-2 (NPVF, Q9HCQ7) and neuropeptide RFRP-3 (NPVF, Q9HCQ7) (neuropeptide NPVF).

  --------------- --------------- ------------------------ --------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  Nomenclature    HGNC, UniProt   Principal transduction   Rank order of potency       Endogenous agonists (p*K*~i~)                                                                        Endogenous antagonists (p*K*~i~)               Radioligands (*K*~d~)
  PRRP receptor   PRLHR, P49683   G~q/11~ [@b1497]         PrRP-20, PrRP-31 [@b1497]   PrRP-20 (Selective) (9.0--9.6) [@b1494],[@b1497], PrRP-31 (Selective) (9.0--9.2) [@b1494],[@b1497]   NPY (NPY, P01303) (Selective) (5.4) [@b1496]   \[125I\]PrRP31 [@b1493], \[125I\]PrRP-20 (human) (Agonist, Full agonist) (2.6×10^−11^--5.7×10^−10^ M) [@b1497]
  --------------- --------------- ------------------------ --------------------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------

Comments
========

The orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.

Prostanoid receptors
====================

Overview
--------

Prostanoid receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors, [@b1512]) are activated by the endogenous ligands prostaglandins PGD2, PGE2, PGF2α, PGH2, prostacyclin \[PGI2\] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      DP1 receptor                                                                                                                                                                         DP2 receptor                                                                                                              FP receptor                                                                                                                                     IP1 receptor                                                                                   TP receptor
  HGNC, UniProt                     PTGDR, Q13258                                                                                                                                                                        PTGDR2, Q9Y5Y4                                                                                                            PTGFR, P43088                                                                                                                                   PTGIR, P43119                                                                                  TBXA2R, P21731
  Principal transduction            G~s~                                                                                                                                                                                 G~i/o~                                                                                                                    G~q/11~                                                                                                                                         --                                                                                             G~q/11~
  Rank order of potency             PGD2 \>\> PGE2 \> PGF2α \> PGI2, thromboxane A2                                                                                                                                      PGD2 \>\> PGF2α, PGE2 \> PGI2, thromboxane A2                                                                             PGF2α \> PGD2 \> PGE2 \> PGI2, thromboxane A2                                                                                                   PGI2 \>\> PGD2, PGE2, PGF2α \> thromboxane A2                                                  thromboxane A2 = PGH2 \>\> GD2, PGE2, PGF2α, PGI2
  Selective agonists (p*K*~i~)      L-644,698 (9.0--9.3) [@b1563],[@b1564], BW 245C (8.4--9.4) [@b1506],[@b1563],[@b1564], SQ-27986 (8.0) [@b1545], RS 93520 (Partial agonist) (7.5) [@b1545], ZK118182 (7.3) [@b1545]   15(R)-15-methyl-PGD2 (8.9) [@b1518],[@b1533],[@b1552], 13,14-dihydro-15-keto-PGD2 (7.4--8.5) [@b1518],[@b1544],[@b1552]   fluprostenol (8.6) [@b1498], latanoprost (free acid form) (8.6) [@b1498], AL12180 (pEC~50~ 7.7--7.9) [@b1547]                                   cicaprost (7.8) [@b1498], AFP-07 (pIC~50~ 8.5) [@b1508], BMY 45778 (pIC~50~ 8.0) [@b1520]      I-BOP (p*K*~d~ 8.94--9.32) [@b1532], U46619 (7.5) [@b1498], STA2 (pIC~50~ 6.38--7.06) [@b1502]
  Selective antagonists (p*K*~i~)   laropiprant (10.1) [@b1550], BWA868C (8.6--9.3) [@b1506],[@b1517],[@b1563], S-5751 (8.8) [@b1501]                                                                                    ramatroban (7.4) [@b1552], CAY 10471 (pIC~50~ 8.92) [@b1543],[@b1556]                                                     AS604872 (7.5) [@b1510]                                                                                                                         RO3244794 (p*A*~2~ 8.5) [@b1503], RO1138452 (8.7) [@b1503]                                     ifetroban (8.4--10.0) [@b1538], GR 32191 (8.3--9.4) [@b1502],[@b1528], SQ-29548 (8.1--9.1) [@b1498],[@b1554],[@b1559], ONO 3708 (7.4--8.9) [@b1522]
  Radioligands (*K*~d~)             \[3H\]PGD2 (Agonist, Full agonist) (1.3×10^−8^ -- 3×10^--10^ M) [@b1559],[@b1563]                                                                                                    \[3H\]PGD2 (Agonist, Full agonist) (1.6×10^--8^ -- 6×10^--9^ M) [@b1530],[@b1548]                                         \[3H\]PGF2α (Agonist, Full agonist) (7.9×10^--9^ -- 1×10^--9^ M) [@b1498],[@b1499],[@b1559], \[3H\](+)-fluprostenol (Agonist) (3.4×10^--8^ M)   \[3H\]iloprost (Agonist, Full agonist) (2×10^--8^ -- 1×10^--9^ M) [@b1498],[@b1505],[@b1559]   \[125I\]BOP (Agonist, Full agonist) (2×10^--9^ M) [@b1534], \[125I\]SAP (Antagonist) (2×10^--8^ -- 5×10^--10^ M) [@b1536], \[3H\]SQ-29548 (Antagonist) (4×10^--8^ -- 6.3×10^--9^ M) [@b1498],[@b1559]
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      EP1 receptor                                                                                 EP2 receptor                                                                                                                          EP3 receptor                                                                              EP4 receptor
  HGNC, UniProt                     PTGER1, P34995                                                                               PTGER2, P43116                                                                                                                        PTGER3, P43115                                                                            PTGER4, P35408
  Principal transduction            G~q/11~                                                                                      G~s~                                                                                                                                  G~i/o~                                                                                    G~s~
  Rank order of potency             PGE2 \> PGF2α, PGI2 \> PGD2, thromboxane A2                                                  PGE2 \> PGF2α, PGI2 \> PGD2, thromboxane A2                                                                                           PGE2 \> PGF2α, PGI2 \> PGD2, thromboxane A2                                               PGE2 \> PGF2α, PGI2 \> PGD2, thromboxane A2
  Selective agonists (p*K*~i~)      17-phenyl-ω-trinor-PGE2 (8.1) [@b1546], ONO-DI-004 (6.8 - Mouse) [@b1553]                    ONO-AE1-259 (8.5 - Mouse) [@b1553], butaprost (free acid form) (5.9--7.0) [@b1498],[@b1549], CP-533536 (pIC~50~ 7.3 - Rat) [@b1507]   SC46275 (pEC~50~ 8.74 - Rat) [@b1519], ONO-AE-248 (pEC~50~ 5.64--6.7) [@b1514],[@b1527]   L902688 (pEC~50~ 8.05--10.3) [@b1515],[@b1525], ONO-AE1-329 (pEC~50~ 7.66--7.8) [@b1514],[@b1515], CP734432 (pIC~50~ 8.7) [@b1540]
  Selective antagonists (p*K*~i~)   ONO-8711 (9.2) [@b1557], SC-51322 (7.9) [@b1498], GW848687X (pIC~50~ 8.6) [@b1516]           --                                                                                                                                    L-798,106 (9.52--9.62) [@b1521],[@b1551], ONO-AE3-240 (pIC~50~ 8.8 - Mouse) [@b1500]      MK-2894 (9.25) [@b1498],[@b1504],[@b1511], CP-533536 (8.6) [@b1535], ONO-AE3-208 (8.5), EP4A (7.6--8.5) [@b1529],[@b1565], BGC201531 (7.9) [@b1531], GW 627368 (7.0--7.1) [@b1559],[@b1560], ER819762 (pIC~50~ 7.15) [@b1509]
  Radioligands (*K*~d~)             \[3H\]PGE2 (Agonist, Full agonist) (1×10^--9^ -- 2.5×10^--8^ M) [@b1498],[@b1546],[@b1559]   \[3H\]PGE2 (Agonist, Full agonist) (1.25×10^--8^ -- 1.99×10^--8^ M) [@b1498],[@b1559]                                                 \[3H\]PGE2 (Agonist, Full agonist) (3×10^--10^ -- 7×10^--9^ M) [@b1498],[@b1559]          \[3H\]PGE2 (Agonist, Full agonist) (2.4×10^--8^ -- 3×10^--10^ M) [@b1498],[@b1513],[@b1558],[@b1559]
  --------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

ramatroban is also a TP receptor antagonist. cicaprost exhibits moderate EP~4~ receptor agonist potency [@b1498]. iloprost also binds to EP~1~ receptors. The TP receptor exists in α and β isoforms due to alternative splicing of the cytoplasmic tail [@b1542].

17-phenyl-ω-trinor-PGE2 also shows agonist activity at EP~3~ receptors. sulprostone also has affinity for EP~1~ receptors. butaprost and SC46275 may require de-esterification within tissues to attain full agonist potency. There is evidence for subtypes of FP [@b1526], IP [@b1555],[@b1561] and TP [@b1524] receptors. mRNA for the EP~1~ and EP~3~ receptors undergo alternative splicing to produce two [@b1539] and at least six variants, respectively, which can interfere with signalling [@b1539] or generate complex patterns of G-protein (G~i/o~, G~q/11~, G~s~ and G~12,13~) coupling (*e.g.* [@b1523],[@b1537]). The possibility of additional receptors for the isoprostanes has been suggested [@b1541]. Receptors (prostamide F, which as yet lack a molecular correlate) that preferentially recognize PGF2-1-ethanolamide and its analogues (*e.g.* bimatoprost) have been identified, together with moderate-potency antagonists (*e.g.* AGN 211334) [@b1562].

The free acid form of AL-12182, AL-12180, used in *in vitro* studies, has a EC~50~ value of 15nM which is the concentration of the compound giving half-maximal stimulation of IP turnover in HEK-293 cells expressing the human FP receptor [@b1547].

References given alongside the TP receptor agonists I-BOP [@b1532] and STA~2~ [@b1502] use human platelets as the source of TP receptors for competition radio-ligand binding assays to determine the indicated activity values.

Proteinase-activated receptors
==============================

Overview
--------

Proteinase-activated receptors (PARs, nomenclature as agreed by NC-IUPHAR Subcommittee on Protease-activated Receptors, [@b1574]) are unique members of the GPCR superfamily activated by proteolytic cleavage of their amino terminal exodomains. Agonist proteinase-induced hydrolysis unmasks a tethered ligand (TL) at the exposed amino terminus, which acts intramolecularly at the binding site in the body of the receptor to effect transmembrane signalling. TL sequences at human PAR1--4 are SFLLRN-NH2, SLIGKV-NH2, TFRGAP-NH2 and GYPGQV-NH2, respectively. With the exception of PAR3, these synthetic peptide sequences (as carboxyl terminal amides) are able to act as agonists at their respective receptors. Several proteinases, including neutrophil elastase, cathepsin G and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such that they cleave the exodomain of the receptor without inducing activation of Gαq-coupled calcium signaling, thereby preventing activation by activating proteinases but not by agonist peptides. Neutrophil elastase cleavage of PAR2 can however activate MAP kinase signaling by exposing a TL that is different from the one revealed by trypsin [@b1581]. The role of such an action *in vivo* is unclear.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------------------------
  Nomenclature                      PAR1                                                                                                                                                         PAR2                                                                                                                                                        PAR3                    PAR4
  HGNC, UniProt                     F2R, P25116                                                                                                                                                  F2RL1, P55085                                                                                                                                               F2RL2, O00254           F2RL3, Q96RI0
  Principal transduction            G~q/11~/G~i/o~/G~12/13~                                                                                                                                      G~q/11~/G~i/o~                                                                                                                                              Not known               G~q/11~/G~i/o~
  Agonist proteases                 thrombin (F2, P00734), activated protein C (PROC, P04070), matrix metalloproteinase 1 (MMP1, P45452), matrix metalloproteinase 13 (MMP13, P45452) [@b1569]   Trypsin, tryptase, TF/VIIa, Xa                                                                                                                              thrombin (F2, P00734)   thrombin (F2, P00734), trypsin, cathepsin G (CTSG, P08311)
  Selective agonists (p*K*~i~)      TFLLR-NH2 (pEC~50~ 5.41) [@b1573]                                                                                                                            SLIGKV-NH2 [@b1579], SLIGRL-NH2 [@b1579], 2-furoyl-LIGRLO-amide (5.4) [@b1580], GB 110 (pEC~50~ 6.55) [@b1570],                                             --                      AYPGKF-NH2, GYPGKF-NH2, GYPGQV-NH2
  Selective antagonists (p*K*~i~)   SCH530348 (8.09) [@b1572], atopaxar (pIC~50~ 7.72) [@b1578], RWJ-56110 (pIC~50~ 6.36) [@b1568]                                                               P2pal18s [@b1582], GB88 (pIC~50~ 5.7) [@b1583]                                                                                                              --                      --
  Radioligands (*K*~d~)             \[3H\]haTRAP (Agonist) (1.5x10^-8^ M) [@b1566]                                                                                                               2-furoyl-LIGRL\[N\[3H\]propionyl\]-O-NH2 [@b1575], \[3H\]2-furoyl-LIGRL-NH2 (Agonist) [@b1576], trans-cinnamoyl-LIGRLO \[N-\[3H\]propionyl\]-NH2 [@b1567]   --                      --
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------------------------

Comments
========

TFLLR-NH2 is selective relative to the PAR~2~ receptor [@b1571],[@b1577]. thrombin (F2, P00734) is inactive at the PAR~2~ receptor.

Endogenous serine proteases (EC 3.4.21.) active at the proteinase-activated receptors include: thrombin (F2, P00734), generated by the action of Factor X (F10, P00742) on liver-derived prothrombin (F2, P00734); trypsin, generated by the action of enterokinase (TMPRSS15, P98073) on pancreatic-derived trypsinogen (PRSS1, P07477); tryptase, a family of enzymes (α/β1 TPSAB1, Q15661; γ1 TPSG1, Q9NRR2; δ1 TPSD1, Q9BZJ3) secreted from mast cells; cathepsin G (CTSG, P08311) generated from leukocytes; liver- derived protein C (PROC, P04070) generated in plasma by thrombin (F2, P00734) and matrix metalloproteinase 1 (MMP1, P45452).

2-Furoyl-LIGRLO-NH~2~ activity was measured via calcium mobilisation in HEK 293 cells which constitutively coexpress human PAR~1~ and PAR~2~.

Relaxin family peptide receptors
================================

Overview
--------

Relaxin family peptide receptors (RXFP, nomenclature as recommended by the NC-IUPHAR committee on relaxin family peptide receptors, [@b1584]) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists at these receptors are a number of heterodimeric peptide hormones analogous to insulin: H1 relaxin (RLN1, P04808), H2 relaxin (RLN2, P04090), H3 relaxin (RLN3, Q8WXF3) (also known as INSL7), insulin-like peptide 3 (INSL3 (INSL3, P51460)) and INSL5 (INSL5, Q9Y5Q6).

Species homologues of relaxin have distinct pharmacology -- H2 relaxin (RLN2, P04090) interacts with RXFP1, RXFP2 and RXFP3, whereas mouse and rat relaxin selectively bind to and activate RXFP1 [@b1611] and porcine relaxin may have a higher efficacy than H2 relaxin (RLN2, P04090) [@b1591]. H3 relaxin (RLN3, Q8WXF3) has differential affinity for RXFP2 receptors between species; mouse and rat RXFP2 have a higher affinity for H3 relaxin (RLN3, Q8WXF3) [@b1610]. At least two binding sites have been identified on the RXFP1 and RXFP2 receptors: a high-affinity site in the leucine-rich repeat region of the ectodomain and a somewhat lower-affinity site located in the surface loops of the transmembrane domain [@b1591],[@b1618]. The unique N-terminal LDLa module of RXFP1 and RXFP2 is essential for receptor signalling [@b1612].

  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                       RXFP1 receptor                                                                                                                      RXFP2 receptor                                                                                                                                                    RXFP3 receptor                                                                                                                      RXFP4 receptor
  HGNC, UniProt                      RXFP1, Q9HBX9                                                                                                                       RXFP2, Q8WXD0                                                                                                                                                     RXFP3, Q9NSD7                                                                                                                       RXFP4, Q8TDU9
  Principal transduction             G~s~, G~αoB~, G~αι3~ [@b1590],[@b1595],[@b1599]                                                                                     G~s~, G~αoB~ [@b1590],[@b1601]                                                                                                                                    G~i/o~ [@b1606],[@b1620]                                                                                                            G~i/o~ [@b1604]
  Rank order of potency              H2 relaxin \> H3 relaxin \>\> INSL3 [@b1618]                                                                                        INSL3 \> H2 relaxin \>\> H3 relaxin [@b1601],[@b1618]                                                                                                             H3 relaxin \> H3 relaxin (B chain) [@b1604]                                                                                         INSL5 = H3 relaxin \> H3 relaxin (B chain) [@b1602],[@b1603]
  Endogenous antagonists (p*K*~i~)   --                                                                                                                                  --                                                                                                                                                                INSL5 (pIC~50~ 6.3) [@b1605]                                                                                                        --
  Selective antagonists (p*K*~i~)    LGR7-truncate [@b1612], B-R13/17K H2 relaxin (pEC~50~ 6.7) [@b1597],                                                                (des 1-8) A-chain INSL3 analogue [@b1586], INSL3 B-chain analogue [@b1587], INSL3 B chain dimer [@b1616],                                                         H3 relaxin analogue 3 [@b1613], R3(BΔ23-27)R/I5 chimeric peptide (pIC~50~ 9.2) [@b1600], R3-B1-22R (pIC~50~ 7.4) [@b1596]           R3(BΔ23-27)R/I5 chimeric peptide (pIC~50~ 8.64) [@b1600]
  Radioligands (*K*~d~)              \[125I\]H2 relaxin (Agonist, Full agonist), \[33P\]H2 relaxin (Agonist, Full agonist) (5x10^-10^--2x10^-10^ M) [@b1591],[@b1618],   \[125I\]INSL3 (human) (Agonist, Full agonist) (1x10^-10^ M) [@b1608], \[33P\]H2 relaxin (Agonist, Full agonist) (1.06x10^-9^--6.3x10^-10^ M) [@b1591],[@b1618],   \[125I\]H3 relaxin (Agonist, Full agonist) (3x10^-10^ M) [@b1604], \[125I\]H3-B/INSL5 A chimera (Agonist) (5x10^-10^ M) [@b1602],   \[125I\]H3 relaxin (Agonist, Full agonist) (2x10^-9^--2x10^-10^ M) [@b1603], \[125I\]H3-B/INSL5 A chimera (Agonist) (1.2x10^-9^ M) [@b1602],
  Comment                            europium-labelled H2 relaxin is a fluorescent ligand for this receptor (Kd=0.5 nM) [@b1614].                                        europium-labelled INSL3 is a fluorescent ligand for this receptor (Kd=1 nM) [@b1615].                                                                             europium-labelled H3-B/INSL5 A chimera is a fluorescent ligand for this receptor (Kd=5 nM) [@b1596].                                europium-labelled H3-B/INSL5 A chimera is a fluorescent probe at this receptor (Kd=5 nM) [@b1596], europium-labelled mouse INSL5 is a fluorescent ligand at this receptor (Kd=5 nM) [@b1585].
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

H2 relaxin has recently successfully completed a Phase III clinical trial for the treatment of acute heart failure. 48 hr infusion of H2 relaxin reduced dyspnoea and 180 day mortality [@b1607]. Small molecule agonists active at RXFP1 receptors have been developed [@b1617],[@b1622]. Mutations in *INSL3* and *LGR8* (RXFP2) have been reported in populations of patients with cryptorchidism [@b1588]. Numerous splice variants of the human RXFP1 and RXFP2 receptors have been identified, most of which do not bind relaxin family peptides [@b1608]. Splice variants of RXFP1 encoding the N-terminal LDLa module act as antagonists of RXFP1 signalling [@b1610],[@b1612]. cAMP elevation appears to be a major signalling pathway for RXFP1 and RXFP2 [@b1598],[@b1599], but RXFP1 also activates MAP kinases, nitric oxide signalling and interacts with tyrosine kinases and glucocorticoid receptors [@b1594]. RXFP1 signalling involves lipid rafts, residues in the C-terminus of the receptor and activation of phosphatidylinositol-3-kinase [@b1595]. More recent studies provide evidence that RXFP1 is pre-assembled in signalosomes with other signalling proteins including Gα~s~, Gβγ and adenyl cyclase 2 that display constitutive activity and are exquisitely sensitive to sub-picomolar concentrations of relaxin [@b1592]. The cAMP signalling pattern is highly dependent on the cell type in which RXFP1 is expressed [@b1593].

The receptor expression profiles suggest that RXFP3 is a neuropeptide receptor and RXFP4 a gut hormone receptor. The relaxin 3 RXFP3 system has roles in feeding and anxiety [@b1589],[@b1609]. H3 relaxin (RLN3, Q8WXF3) acts as an agonist at both RXFP3 and RXFP4 whereas INSL5 (INSL5, Q9Y5Q6) is an agonist at RXFP4 and a weak antagonist at RXFP3. Unlike RXFP1 and RXFP2 both RXFP3 and RXFP4 are encoded by a single exon and therefore no splice variants exist. The rat RXFP3 sequence has two potential start codons that encode RXFP3L and RXFP3S with the longer variant having an additional 7 amino-acids at the N-terminus. It is not known which variant is expressed. Rat and dog RXFP4 sequences are pseudogenes [@b1621]. RXFP3 couples to G~i/o~ and inhibits adenylyl cyclase [@b1604],[@b1619], and also causes Erk1/2 phosphorylation [@b1619]. Relatively little is known about RXFP4 signalling but like RXFP3 it couples to inhibitory G-proteins [@b1605]. Recent studies suggest that H2 relaxin (RLN2, P04090) also interacts with RXFP3 to cause a pattern of activation of signalling pathways that are a subset of those activated by H3 relaxin (RLN3, Q8WXF3). The two patterns of signaling observed in several cell types expressing RXFP3 are strong inhibition of forskolin-stimulated cAMP accumulation, ERK1/2 activation and nuclear factor NFκ-B reporter gene activation with H3 relaxin (RLN3, Q8WXF3), and weaker activity with H2 relaxin (RLN2, P04090), porcine relaxin, or insulin-like peptide 3 (INSL3 (INSL3, P51460)) and a strong stimulation of activator protein (AP)-1 reporter genes with H2 relaxin (RLN2, P04090), and weaker activation with H3 relaxin (RLN3, Q8WXF3) or porcine relaxin [@b1619]. Two pharmacologically distinct ligand binding sites were also identified on RXFP3-expressing cells using \[125I\]H3-B/INSL5 A chimera which binds with high affinity with competition by H3 relaxin (RLN3, Q8WXF3) or a H3 relaxin (B chain) (RLN3, Q8WXF3) peptide, and \[125I\]H2 relaxin which displays competition by H2 relaxin (RLN2, P04090), H3 relaxin (RLN3, Q8WXF3), or INSL3 (INSL3, P51460) and weakly by porcine relaxin. Thus at RXFP3, H2 relaxin (RLN2, P04090) is a biased ligand compared to the cognate ligand H3 relaxin (RLN3, Q8WXF3).

Somatostatin receptors
======================

Overview
--------

Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin receptor (sst~1~--sst~5~; **nomenclature approved by the NC-IUPHAR Subcommittee on Somatostatin Receptors,** [@b1628]). Activation of these receptors produces a wide range of physiological effects throughout the body including inhibiting the secretion of many hormones. The relationship of the cloned receptors to endogenously expressed receptors is not yet well established in some cases. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28 (SRIF-28 (SST, P61278)). Cortistatin (CST-14) has also been suggested to be an endogenous ligand for somatostatin receptors [@b1625].

  --------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Nomenclature                      sst1 receptor                                                                        sst2 receptor                                                                                                                                                                                              sst3 receptor               sst4 receptor                                        sst5 receptor
  HGNC, UniProt                     SSTR1, P30872                                                                        SSTR2, P30874                                                                                                                                                                                              SSTR3, P32745               SSTR4, P31391                                        SSTR5, P35346
  Principal transduction            G~i~                                                                                 G~i~                                                                                                                                                                                                       G~i~                        G~i~                                                 G~i~
  Selective agonists (p*K*~i~)      L-797,591 (8.8) [@b1635], Des-Ala1,2,5-\[D-Trp8,IAmp9\]SRIF (pIC~50~ 7.5) [@b1626]   L-054,522 (11.0) [@b1640], MK-678 (8.8 -- 10.3) [@b1623],[@b1634],[@b1636]--[@b1638],[@b1640], octreotide (8.7 -- 9.9) [@b1623],[@b1634],[@b1636]--[@b1638],[@b1640], BIM 23027 (pIC~50~ 10.85) [@b1624]   L-796,778 (7.6) [@b1635]    L-803,087 (9.2) [@b1635], NNC269100 (8.2) [@b1631]   L-817,818 (9.4) [@b1635], BIM 23268 (8.7) [@b1632], BIM 23052 (7.4 -- 9.6) [@b1632],[@b1636]--[@b1638]
  Selective antagonists (p*K*~i~)   SRA880 (p*K*~d~ 8.0 -- 8.1) [@b1629]                                                 \[D-Tyr8\]CYN 154806 (p*K*~d~ 8.1 -- 8.9) [@b1633]                                                                                                                                                         NVP ACQ090 (7.9) [@b1630]   --                                                   BIM 23627 (pIC~50~ 7.1) [@b1639]
  Radioligands (*K*~d~)             --                                                                                   \[125I\]Tyr3 SMS 201-995 (Agonist, Full agonist) (1.3x10^-10^ M) [@b1637],[@b1638], \[125I\]BIM23027 (Agonist, Full agonist) (IC~50~ 2.2x10^-10^ M - Rat) [@b1627]                                         --                          --                                                   \[125I\]Tyr3 SMS 201-995 (Agonist, Full agonist) (2.3x10^-10^ M) [@b1637],[@b1638]
  --------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------

Comments
========

\[125I\]Tyr11-SRIF-14, \[125I\]LTT-SRIF-28, \[125I\]CGP 23996 and \[125I\]Tyr10-CST14 may be used to label somatostatin receptors nonselectively; BIM 23052 is said to be selective in rat but not human receptor [@b1634]. A number of nonpeptide subtype-selective agonists have been synthesised [@b1635].

Succinate receptor
==================

Overview
--------

the succinate receptor (NC-IUPHAR recommended nomenclature, see Davenport et al., 2004) has been reported to respond to an intermediate of the citric acid cycle [@b1641].

  -------------------- ---------------- ------------------------ ----------------------------------------------------
  Nomenclature         HGNC, UniProt    Principal transduction   Endogenous agonists (p*K*~i~)
  succinate receptor   SUCNR1, Q9BXA5   --                       succinic acid (pEC~50~ 3.1--4.7) [@b1641],[@b1642]
  -------------------- ---------------- ------------------------ ----------------------------------------------------

Tachykinin receptors
====================

Overview
--------

Tachykinin receptors (provisional nomenclature, [@b1658]) are activated by the endogenous peptides substance P (TAC1, P20366) (SP), neurokinin A (TAC1, P20366) (NKA; previously known as substance K, neurokinin α, neuromedin L), neurokinin B (TAC3, Q9UHF0) (NKB; previously known as neurokinin β, neuromedin K), neuropeptide K (TAC1, P20366) and neuropeptide γ (TAC1, P20366) (N-terminally extended forms of neurokinin A). The neurokinins (A and B) are mammalian members of the tachykinin family, which includes peptides of mammalian and nonmammalian origin containing the consensus sequence: Phe-x-Gly-Leu-Met. Marked species differences in *in vitro* pharmacology exist for all three receptors, in the context of nonpeptide ligands.

  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      NK1 receptor                                                                                                                                                                                                                                                                                                 NK2 receptor                                                                                                                                                                                NK3 receptor
  HGNC, UniProt                     TACR1, P25103                                                                                                                                                                                                                                                                                                TACR2, P21452                                                                                                                                                                               TACR3, P29371
  Principal transduction            G~q/11~                                                                                                                                                                                                                                                                                                      G~q/11~                                                                                                                                                                                     G~q/11~
  Rank order of potency             substance P \> neurokinin A \> neurokinin B                                                                                                                                                                                                                                                                  neurokinin A \> neurokinin B \>\> substance P                                                                                                                                               neurokinin B \> neurokinin A \> substance P
  Selective agonists (p*K*~i~)      \[Pro9\]SP, septide (7.0--9.3) [@b1645],[@b1663], \[Sar9,Met(O2)11\]SP (pIC~50~ 9.7--9.9) [@b1673], substance P-OMe (pIC~50~ 7.4--7.5) [@b1673]                                                                                                                                                              \[βAla8\]neurokinin A-(4--10) (p*K*~d~ 6.0) [@b1656], GR64349 (pEC~50~ 8.4 -- Rat) [@b1653], \[Lys5,Me-Leu9,Nle10\]NKA-(4--10) (pIC~50~ 8.8--9.4 -- Rat) [@b1667]                           \[Phe(Me)7\]neurokinin B (8.7--9.6) [@b1670],[@b1671], senktide (7.1--8.6) [@b1670],[@b1671],[@b1673]
  Selective antagonists (p*K*~i~)   aprepitant (10.7) [@b1662], LY303870 (9.8--10.0) [@b1660], CP 99994 (9.3--9.7) [@b1643],[@b1671], LY303870 (pIC~50~ 9.82) [@b1664], SR 140,333 (pIC~50~ 8.9--9.0) [@b1673], RP67580 (pIC~50~ 7.7) [@b1657]                                                                                                   GR159897 (p*K*~d~ 7.8--9.5) [@b1647],[@b1656],[@b1672], GR94800 (9.8) [@b1649], saredutant (9.4--9.7) [@b1643],[@b1656],[@b1671], MEN10627 (9.2), nepadutant (8.5--8.7) [@b1650],[@b1652]   osanetant (8.4--9.7) [@b1643],[@b1644],[@b1651],[@b1655],[@b1665],[@b1668],[@b1670],[@b1671],[@b1673], SB 223412 (7.4--9.0) [@b1646],[@b1659],[@b1670],[@b1671], PD157672 (pIC~50~ 7.8) [@b1648]
  Radioligands (*K*~d~)             \[125I\]SP (human, mouse, rat) (Agonist, Full agonist), \[18F\]SPA-RQ (Antagonist), \[3H\]BH-\[Sar9,Met(O2)11\]SP, \[3H\]SP (human, mouse, rat) (Agonist, Full agonist), \[125I\]L703,606 (Antagonist) (3x10^−10^ M), \[125I\]BH-\[Sar9,Met(O2)11\]SP (Agonist, Full agonist) (1x10^−9^ M -- Rat) [@b1674]   \[125I\]NKA (human, mouse, rat), \[3H\]GR100679, \[3H\]SR48,968 (Antagonist) (2x10^−10^ M -- Rat) [@b1661]                                                                                  \[125I\]\[MePhe7\]NKB, \[3H\]senktide, \[3H\]SR142,801 (Antagonist) (1.3x10^−10^ M)
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

The NK~1~ receptor has also been described to couple to other G proteins [@b1669]. The hexapeptide agonist septide appears to bind to an overlapping but non-identical site to substance P (TAC1, P20366) on the NK~1~ receptor. There are suggestions for additional subtypes of tachykinin receptor; an orphan receptor (SwissProt P30098) with structural similarities to the NK~3~ receptor was found to respond to NKB when expressed in *Xenopus* oocytes or Chinese hamster ovary cells [@b1654],[@b1666].

Thyrotropin-releasing hormone receptors
=======================================

Overview
--------

Thyrotropin-releasing hormone (TRH) receptors (provisional nomenclature) are activated by the endogenous tripeptide TRH (TRH, P20396) (pGlu-His-ProNH2). TRH (TRH, P20396) and TRH analogues fail to distinguish TRH~1~ and TRH~2~ receptors [@b1677]. \[3H\]TRH (human, mouse, rat) is able to label both TRH~1~ and TRH~2~ receptors with K~d~ values of 13 and 9 nM respectively.

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Nomenclature                      TRH1 receptor                                                                                                                                      TRH2 receptor
  HGNC, UniProt                     TRHR, P34981                                                                                                                                       Trhr2, Q9ERT2
  Principal transduction            G~q~                                                                                                                                               G~q~
  Selective antagonists (p*K*~i~)   midazolam (5.49 - Rat) [@b1675], diazepam (5.15 - Rat) [@b1675], chlordiazepoxide (4.82 - Rat) [@b1675], chlordiazepoxide (4.7 - Mouse) [@b1676]   --
  Comment                           --                                                                                                                                                 A class A G protein-coupled receptor: not present in man
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------

Comments
========

The human orthologue of the rodent TRH~2~ receptor has yet to be identified.

Trace amine receptor
====================

Overview
--------

Trace amine-associated receptors (nomenclature as agreed by NC-IUPHAR for trace amine receptors, [@b1680]) were initially discovered as a result of a search for novel 5-HT receptors [@b1678], where 15 mammalian orthologues were identified and divided into two families. The TA~1~ receptor has been shown to have affinity for the endogenous trace amines tyramine, β-phenylethylamine and octopamine in addition to the classical amine dopamine [@b1678]. Emerging evidence suggests that TA~1~ is a modulator of monoaminergic activity in the brain [@b1683] with TA~1~ and dopamine D~2~ receptors shown to form constitutive heterodimers when co-expressed [@b1679].

  -------------- -------------------------------------------- ------------------------ ------------------------------------------------------------------ --------------------------------------------------------------
  Nomenclature   HGNC, UniProt                                Principal transduction   Rank order of potency                                              Radioligands (*K*~d~)
  TA1 receptor   TAAR1 (Hs), Taar1 (Mm), Taar1 (Rn), Q96RJ0   G~s~                     tyramine \> β-phenylethylamine \> octopamine = dopamine [@b1678]   \[3H\]tyramine (Agonist, Full agonist) (2x10^−8^ M) [@b1678]
  -------------- -------------------------------------------- ------------------------ ------------------------------------------------------------------ --------------------------------------------------------------

Comments
========

The product of the gene *TAAR2* (also known as GPR58) appears to respond to β-phenylethylamine \> tyramine and to couple through G~s~ [@b1678] See Orphan GPCR (Page 1462).

TAAR3, in some individuals, and TAAR4 are pseudogenes in man, although functional in rodents. The signalling characteristics and pharmacology of TAA5 (PNR, Putative Neurotransmitter Receptor: TAAR5, O14804), TAA6 (Trace amine receptor 4, TaR-4: TAAR6, 96RI8), TAA8 (Trace amine receptor 5, GPR102: TAAR8, Q969N4) and TAA9 (trace amine associated receptor 9: TAAR9, 96RI9) are lacking. The thyronamines, endogenous derivatives of thyroid hormone, have been shown to have affinity for rodent cloned trace amine receptors, including TA~1~ [@b1681]. An antagonist EPPTB has recently been described that has a pK~i~ of 9.1 at the mouse TA~1~ but less than 5.3 for human TA~1~ [@b1682].

Urotensin receptor
==================

Overview
--------

The urotensin-II (U-II) receptor (UT, nomenclature as agreed by NC-IUPHAR, [@b1691],[@b1694]) is activated by the endogenous dodecapeptide U-II (UTS2, O95399), originally isolated from the urophysis, the endocrine organ of the caudal neurosecretory system of teleost fish [@b1685]. Several structural forms of U-II exist in fish and amphibians. The Goby orthologue was used to identify U-II as the cognate ligand for the predicted receptor encoded by the rat gene *gpr14* [@b1689],[@b1700],[@b1702],[@b1703]. Human U-II (UTS2, O95399), an 11-amino-acid peptide [@b1689], retains the cyclohexapeptide sequence of goby U-II that is thought to be important in ligand binding [@b1686],[@b1696]. This sequence is also conserved in the deduced amino-acid sequence of rat U-II (14 amino-acids) and mouse U-II (14 amino-acids), although the N-terminal is more divergent from the human sequence [@b1688]. A second endogenous ligand for UT has been discovered in rat [@b1707]. The urotensin II-related peptide (URP (UTS2B, Q765I0)), an octapeptide, is derived from a different gene, but shares the C-terminal sequence (CFWKYCV) common to U-II from other species. Identical sequences to rat URP (UTS2B, Q765I0) are predicted for the mature mouse and human peptides.

  -------------- --------------- ------------------------ --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt   Principal transduction   Endogenous agonists (p*K*~i~)           Selective agonists (p*K*~i~)                                                                                                                                    Selective antagonists (p*K*~i~)                                                                                 Radioligands (*K*~d~)
  UT receptor    UTS2R, Q9UKP6   G~q/11~                  U-II (8.6) [@b1692],[@b1693],[@b1695]   \[Pen5\]-U (4--11) (human) (9.7) [@b1695], U-II-(4--11) (human) (9.6) [@b1695], AC-7954 (6.6) [@b1690],[@b1698], FL104 (pEC~50~ 5.8 -- 7.5) [@b1697],[@b1699]   urantide (8.3) [@b1704], SB-706375 (8.0) [@b1692], SB-611812 (6.6) [@b1705], palosuran (pIC~50~ 7.1) [@b1687]   \[125I\]U-II (human) (Agonist, Full agonist) (4x10^-10^ -- 2.4x10^-10^ M) [@b1684],[@b1701]
  -------------- --------------- ------------------------ --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------

Comments
========

In human vasculature, human U-II (UTS2, O95399) elicits both vasoconstrictor (p*D*~2~ 9.3--10.1, [@b1701]) and vasodilator (pIC~50~ 10.3--10.4, [@b1706]) responses.

Vasopressin and oxytocin receptors
==================================

Overview
--------

Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as agreed by NC-IUPHAR Subcommittee on vasopressin and oxytoxcin receptors) are activated by the endogenous cyclic nonapeptides AVP (AVP, P01178) and oxytocin (OXT, P01178) (OT). These peptides are derived from precursors which also produce neurophysins (neurophysin I for OT; neurophysin II for AVP).

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                      V1A receptor                                                                                                                                                                                                                                                                                                                     V1B receptor                                                                                                                                                                       V2 receptor                                                                                                                                                                                                                                                                                                                                                                                       OT receptor
  HGNC, UniProt                     AVPR1A, P37288                                                                                                                                                                                                                                                                                                                   AVPR1B, P47901                                                                                                                                                                     AVPR2, P30518                                                                                                                                                                                                                                                                                                                                                                                     OXTR, P30559
  Principal transduction            G~q/11~                                                                                                                                                                                                                                                                                                                          G~q/11~                                                                                                                                                                            G~s~                                                                                                                                                                                                                                                                                                                                                                                              G~q/11~, G~i/o~
  Rank order of potency             AVP \> oxytocin                                                                                                                                                                                                                                                                                                                  AVP \> oxytocin                                                                                                                                                                    AVP \> oxytocin                                                                                                                                                                                                                                                                                                                                                                                   oxytocin \> AVP
  Selective agonists (p*K*~i~)      F180 (p*K*~d~ 7.9 -- 8.3) [@b1711],[@b1719]                                                                                                                                                                                                                                                                                      d\[Leu4\]LVP (9.8) [@b1731], d\[Cha4\]AVP (9.0 -- 9.7) [@b1721],[@b1726], d\[D-Pal2\]AVP (7.9) [@b1715],[@b1721]                                                                   d\[Val4,DArg8\]VP, OPC-51803 (7.0) [@b1730], VNA932 (pIC~50~ 7.1) [@b1723]                                                                                                                                                                                                                                                                                                                        \[Thr4,Gly7\]OT (8.2 -- 8.4) [@b1718],[@b1722],[@b1727]
  Selective antagonists (p*K*~i~)   d(CH2)5\[Tyr(Me)2,Arg8\]VP (9.0), SR 49059 (8.1 -- 9.3) [@b1708],[@b1719],[@b1726],[@b1732],[@b1735],[@b1738],[@b1740]--[@b1742], conivaptan (8.2 -- 8.4) [@b1738],[@b1739]                                                                                                                                                      SSR149415 (8.4 -- 9.3) [@b1725],[@b1726],[@b1737]                                                                                                                                  tolvaptan (9.37) [@b1743], lixivaptan (Inverse agonist) (8.9 -- 9.2) [@b1710],[@b1735], SR 121463A (8.4 -- 9.3) [@b1708],[@b1719],[@b1720],[@b1734],[@b1735],[@b1738],[@b1742], d(CH2)5\[D-Ile2,Ile4\]AVP (6.9 -- 8.4) [@b1735], OPC-31260 (Inverse antagonist) (7.6) [@b1744]                                                                                                                    SSR126768A (8.82 -- 9.05) [@b1736], L-371,257 (8.8) [@b1726], desGlyNH2-d(CH2)5\[Tyr(Me)2,Thr4,Orn8\]OT (8.5), L-372662 (8.4) [@b1712]
  Radioligands (*K*~d~)             \[3H\]SR49059 (Antagonist), \[125I\]OH-LVA (Antagonist) (3.99x10^-11^ -- 5x10^-11^ M) [@b1717],[@b1719],[@b1732], \[3H\]AVP (Agonist, Full agonist) (2.51x10^-9^ -- 6.3x10^-11^ M) [@b1714],[@b1717],[@b1719],[@b1720],[@b1730],[@b1732],[@b1733],[@b1738]--[@b1743], \[3H\]d(CH2)5\[Tyr(Me)2\]AVP (Antagonist) (1.1x10^-9^ M)   \[3H\]SSR149415 (Antagonist), \[3H\]AVP (Agonist, Full agonist) (2.51x10^-9^ -- 2.5x10^-10^ M) [@b1714],[@b1717],[@b1719],[@b1720],[@b1730],[@b1732],[@b1733],[@b1738]--[@b1743]   \[3H\]AVP (Agonist, Full agonist) (3.98x10^-9^ -- 3.99x10^-10^ M) [@b1717],[@b1719],[@b1720],[@b1730],[@b1733],[@b1738],[@b1739],[@b1741]--[@b1743], \[3H\]SR 121463A (Antagonist, Inverse agonist) (4.1x10^-9^ -- 5x10^-10^ M) [@b1720],[@b1734], \[3H\]desGly-NH2\[D-Ile2,Ile4\]VP (2.8x10^-9^ M), \[3H\]dDAVP (Agonist, Full agonist) (6.3x10^-8^ -- 8x10^-10^ M) [@b1717],[@b1720],[@b1741]   \[35S\]non-peptide OT antagonist (Antagonist) (4.2x10^-11^ M) [@b1729], \[125I\]d(CH2)5\[Tyr(Me)2,Thr4,Orn8,Tyr-NH29\]OVT (Antagonist) (9x10^-11^ M), \[3H\]OT (human, mouse, rat) (Agonist, Full agonist) [@b1717],[@b1724],[@b1727],[@b1728], \[111In\]DOTA-dLVT (4.5x10^-9^ M) [@b1716]
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
========

The V~2~ receptor exhibits marked species differences, such that many ligands (d(CH2)5\[D-Ile2,Ile4\]AVP and \[3H\]desGly-NH2\[D-Ile2,Ile4\]VP) exhibit low affinity at human V~2~ receptors [@b1709]. Similarly, \[3H\]d\[D-Arg8\]VP is V~2~ selective in the rat, not in the human [@b1733]. The gene encoding the V~2~ receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [@b1713]. d\[Cha4\]AVP is selective only for the human and bovine V~1b~ receptors [@b1721], while d\[Leu4\]LVP has high affinity for the rat V~1b~ receptor [@b1731].

VIP and PACAP receptors
=======================

Overview
--------

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors (nomenclature recommended by the NC-IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors, [@b1749]) are activated by the endogenous peptides VIP (VIP, P01282), PACAP-38 (ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509), peptide histidine isoleucineamide (PHI), peptide histidine methionineamide (PHM (VIP, P01282)) and peptide histidine valine (PHV (VIP, P01282)). "PACAP type II receptors" (VPAC~1~ and VPAC~2~ receptors) display comparable affinity for PACAP and VIP (VIP, P01282), whereas PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509) are \>100 fold more potent than VIP (VIP, P01282) as agonists of most isoforms of the PAC~1~ receptor. However, one splice variant of the human PAC~1~ receptor has been reported to respond to PACAP-38 (ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509) and VIP (VIP, P01282) with comparable affinity [@b1745]. PG 99-465 [@b1752] has been used as a selective VPAC~2~ receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC~1~ and PAC~1~ receptors [@b1746]. The selective PAC~1~ receptor agonist maxadilan, was extracted from the salivary glands of sand flies (*Lutzomyia longipalpis*) and has no sequence homology to VIP (VIP, P01282) or PACAP [@b1753]. Two deletion variants of maxadilan, M65 [@b1758] and Max.d.4 [@b1754] have been reported to be PAC~1~ receptor antagonists, but these peptides have not been extensively characterised.

  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Nomenclature                      VPAC1 receptor                                                                                                                                                             VPAC2 receptor                                                                                                                                                                                             PAC1 receptor
  HGNC, UniProt                     VIPR1, P32241                                                                                                                                                              VIPR2, P41587                                                                                                                                                                                              ADCYAP1R1, P41586
  Principal transduction            G~s~                                                                                                                                                                       G~s~                                                                                                                                                                                                       G~s~
  Rank order of potency             VIP, PACAP-27, PACAP-38 \>\> GHRH (GHRH, P01286), PHI, secretin (SCT, P09683)                                                                                              VIP, PACAP-38, PACAP-27 \> PHI \>\> GHRH (GHRH, P01286), secretin (SCT, P09683)                                                                                                                            PACAP-27, PACAP-38 \>\> VIP
  Selective agonists (p*K*~i~)      \[Ala11,22,28\]VIP (8.1) [@b1755], \[Lys15,Arg16,Leu27\]VIP-(1--7)/GRF-(8--27)-NH2 (pEC~50~ 8.3) [@b1751]                                                                  Ro 25-1392 (8.0) [@b1760], Ro 25-1553 (pEC~50~ 8.7) [@b1751], Ro 25-1553 (pEC~50~ 8.3) [@b1750], Ro 25-1553 (pIC~50~ 9.5) [@b1748], Ro 25-1553 (pIC~50~ 8.8) [@b1750], Ro 25-1553 (pIC~50~ 7.8) [@b1751]   maxadilan (pEC~50~ 10.3) [@b1746], maxadilan (pEC~50~ 6.2) [@b1746]
  Selective antagonists (p*K*~i~)   PG 97-269 (pIC~50~ 8.7) [@b1747], PG 97-269 (pIC~50~ 8.7) [@b1750], PG 97-269 (pIC~50~ 8.7) [@b1750], PG 97-269 (pIC~50~ 8.0) [@b1746], PG 97-269 (pIC~50~ 7.1) [@b1746]   --                                                                                                                                                                                                         --
  Radioligands (*K*~d~)             \[125I\]PACAP-27 (Agonist), \[125I\]VIP (Agonist) (4x10^-10^ M) [@b1755]                                                                                                   \[125I\]PACAP-27 (Agonist), \[125I\]VIP (Agonist) (7x10^-10^ M) [@b1755]                                                                                                                                   \[125I\]PACAP-27 (Agonist) (8.7x10^-10^ M) [@b1756]
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------

Comments
========

Subtypes of PAC~1~ receptors have been proposed based on tissue differences in the potencies of PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509); these might result from differences in G protein coupling and second messenger mechanisms [@b1759], or from alternative splicing of PAC~1~ receptor mRNA [@b1757].
